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Investigation of the Assembly, Activity, and Lipid Dependence of Mitochondrial 
Respiratory Complex II via Model Membrane Systems 
 
Christine Therese Schwall 
University of Connecticut, 2014 
 
 Mitochondrial respiratory Complex II, also referred to as succinate dehydrogenase (SDH) 
and succinate: ubiquinone oxidoreductase (SQR), is a critical control point central to cellular 
energy metabolism as it links the Tricarboxylic Acid (TCA) Cycle and the electron transport 
chain (ETC).  Complex II oxidizes succinate to fumarate as part of the TCA Cycle and passes 
these electrons through a series of redox centers to a membrane-bound ubiquinone molecule as 
part of the OXPHOS system to generate cellular energy.  It is composed of four subunits, two of 
which form a soluble catalytic dimer (SdhA/SdhB) and two of which compose a membrane-
anchoring dimer (SdhC/SdhD).  As the smallest complex of the OXPHOS system, Complex II is 
often overlooked, but dysfunction of the complex has been implicated in various 
neurodegenerative diseases, tumorigenic states, and the aging process.  As Complex II is a 
membrane-bound enzyme, model membrane systems such as liposomes and discoidal bilayer 
nanoparticles (termed nanodiscs) are necessary to study the enzyme in solution.  The first part of 
this thesis investigates the relationship between Complex II and the characteristic mitochondrial 
membrane phospholipid, cardiolipin (CL) by substituting the lipids present in the nanodisc 
system.  The studies presented here support that CL is necessary for efficient Complex II activity 
and inter-dimer stability, also decreasing the reactive oxygen species formation by the complex.  
In addition, the presence of various types of CL in the membrane enhance to differing levels the  
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dehydration and packing in the interfacial region of the bilayer.  The second part of this thesis 
focuses on the assembly of holoenzyme Complex II.  First, Complex II membrane subunits can 
form dynamic interactions with each other as well as with homologs found in the mitochondrial 
inner membrane, possibly revealing a novel regulatory mechanism within the organelle.  Second, 
soluble Helix I of the SdhC membrane subunit is largely involved in modulating and recognizing 
the correct interaction between the membrane and catalytic dimers. Overall, Complex II 
assembly and activity prove to be dynamic processes that require regulation by the surrounding 
lipid, namely cardiolipin, and protein environments. 
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1.1. Mitochondria and mitochondrial membrane biology  
Mitochondria are the sites of many important metabolic processes within the eukaryotic 
cell, including oxidative phosphorylation (OXPHOS), the Tricarboxylic Acid (TCA) cycle, metal 
metabolism (synthesizing heme and Fe-S clusters), and calcium (Ca2+) regulation [1].  Given 
these essential roles, mitochondrial dysfunction underpins many characterized human diseases 
including myopathies, neurodegenerative disorders such as Huntington’s disease, cancers, and 
the aging process.  Based on the Endosymbiosis Theory, mitochondria are evolutionarily derived 
from an α-proteobacterium having been taken up, or engulfed, by a host cell [2].  This is 
supported by multiple lines of evidence, including, but not limited to, the lipid and protein 
composition of the mitochondrial double membrane and the existence of mitochondrial DNA 
that encodes various core subunits of some respiratory chain complexes [2]. 
1.1.1. Mitochondrial membrane composition 
Mitochondria have two distinct membranes, the outer membrane (OM) and the inner 
membrane (IM) that are separated by an aqueous intermembrane space and that enclose the 
innermost aqueous compartment, the matrix (Figure 1.1).  The lipid composition of both 
membranes is dominated by glycerophospholipids, including phosphatidylcholine (PC; ~40% of 
the total phospholipid in the membrane) and phosphatidylethanolamine (PE; ~30% of the total 
phospholipid) as the most abundant, with the remaining lipid composition including 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), and cardiolipin (CL, 
Figure 1.2, [2]).  The OM, as compared to the IM, has a relatively low protein to lipid ratio (1:1, 
by weight, respectively, which accounts for only ~4% of the total mitochondrial protein) and 
contains both α-helical and β-barrel transmembrane proteins [3].  The OM also contains multiple 
pore-forming proteins and complexes, including porins, that permit the free passage of small (< 3 
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kDa) molecules and equilibration with the cytosol.  In addition, the OM tends to have higher 
levels of PI and sterols as compared to the IM, with the exception of the yeast OM [4].  By 
contrast, the IM is an energy-conserving membrane that maintains an electrochemical proton 
potential (ΔµH+) to drive many vital processes such as OXPHOS.  In addition, the IM is much 
more protein rich as compared to the OM (3-4:1, by weight, protein-to-phospholipid ratio that 
accounts for approximately 21% of the total mitochondrial protein [3]) and contains only α-
helical membrane proteins.  The IM is also divided into two continuous, but morphologically 
distinct parts: the inner boundary membrane, which is in closer proximity to the OM, and the 
cristae membrane, which forms invaginations into the matrix, thereby providing a larger IM 
surface area that accommodates the complexes of the OXPHOS system [2].  In addition, the IM 
contains much higher amounts (between 10-30% of the total lipid content) of the signature 
mitochondrial phospholipid, CL, which will be explained further in Section 1.3. Lipids [4]. 
The IM cristae are enriched in many mitochondrial membrane proteins, including the 
components of the respiratory chain that generate a majority of the cellular energy as ATP 
(Figure 1.3, [5]).  In total, the complexes of the respiratory chain transport ten protons across the 
IM for every two electrons that are passed through the entire chain from NADH to oxygen [6].  
The OXPHOS system is composed of four major complexes that make up the respiratory chain: 
Complex I (NADH: ubiquinone oxidoreductase, which is replaced by multiple NADH 
dehydrogenases in yeast), Complex II (succinate: ubiquinone oxidoreductase), Complex III 
(ubiquinol: cytochrome c reductase or cytochrome bc1 complex), and Complex IV (cytochrome c 
oxidase) along with the F1FO-ATP Synthase (Complex V) as well as the ADP/ATP and 
phosphate carriers [7].  These complexes have historically been viewed as randomly distributed 
entities within the IM cristae that are functionally connected by freely-diffusing electron carriers 
7 
 
(ubiquinone and cytochrome c).  However, emerging evidence strongly suggests that some of the 
respiratory chain complexes assemble together into supercomplexes or respirasomes that support 
an overall higher stability of each individual complex as well as allow more efficient electron 
tunneling to occur between complexes (i.e. as a solid state electron transport mechanism) [2].  In 
addition, these supercomplexes are able to sequester the ubiquinone and cytochrome electron 
carriers, preventing them from leaking electrons that could cause ROS formation [6, 8].  The 
composition of these supercomplexes is dynamic, seemingly dependent on the physiological 
conditions of the cell, and various complex stoichiometries have been observed, including: 
supercomplex trimers III2IV1 and tetramers III2IV2 in yeast and trimers I-III2 and higher order 
oligomers of Complex IV in mammals [6, 9, 10].  Further, it has been shown that the ADP/ATP 
Carrier and the TIM23 translocon, both residing in the IM, may also interact with the respiratory 
complexes; in the case of TIM23 the interaction occurs through the Tim21 subunit to facilitate 
insertion of proteins into the IM [11, 12].  The existence of Complex II within supercomplex 
structures has been questioned [7, 9].  However, some groups have found evidence to support 
that a small population of Complex II may loosely interact with the other respiratory chain 
complexes to form fully functional respirasomes and also may form higher molecular weight 
species involving interactions with other Complex II enzymes as well as Complex V [13, 14]. 
The electron tunneling capacity of these respiratory chain supercomplexes and 
respirasomes is modulated by a mobile pool of ubiquinone (or coenzyme Q) molecules in the IM 
that act as electron carriers between Complexes I and II and Complex III [15].  The pool 
behavior is established when the rate of diffusion of both the oxidized ubiquinone and reduced 
ubiquinol molecules is faster than the oxidation-reduction reactions occurring at the respiratory 
chain enzymes within the IM [16, 17].  This pool comprises most of the ubiquinone found in the 
8 
 
IM with only a minority (between 10% and 32%) bound to mammalian proteins, but both of 
these ubiquinone species, pool and bound, exist in equilibrium [16].  It is thought that mainly 
Complex II pulls directly from the mobile pool as ubiquinone may primarily be directly shuttled 
between Complexes I and III as a result of supercomplex formation.  However, the pool also 
contributes to ubiquinone shuttling within supercomplexes in that it drives binding of ubiquinone 
molecules into the site between Complexes I and III and therefore acts as a reservoir for this 
bound ubiquinone [18].  In evidence of this phenomenon, when phospholipids are fused to 
mitochondrial membranes, diluting the ubiquinone pool, there is a decrease in respiratory chain 
activity most likely due to the decreased ability of the diluted pool to drive the binding of 
ubiquinone to Complexes I and III [17, 18]. 
1.1.2. Mitochondria and Reactive Oxygen Species 
The production and balance of reactive oxygen species (ROS) within the mitochondria 
are intimately linked to intracellular signaling and regulation as well as to apoptosis and cell 
death.  The typical type of ROS generated in mitochondria is the superoxide anion, O2-, which is 
a precursor to the majority of other ROS and is mostly formed during electron transport and 
cellular respiration in the IM [19].  Recently, it has been shown that not only are Complexes I 
and III of the respiratory chain major producers of ROS, but Complex II can contribute to the 
superoxide pool as well.  An estimated 1-2% of the electrons that enter the OXPHOS complexes 
are diverted to superoxide anion formation [20].  Being at the site of ROS production, 
mitochondrial proteins and lipids are especially subject to oxidative damage.  For example, the 
respiratory chain, among other protein complexes, as well as polyunsaturated fatty acids found 
within phospholipids and mitochondrial DNA are all major targets of ROS because of the highly 
oxidizable iron-sulfur centers, heme groups, and copper centers that many of the molecules 
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contain [19, 21].  In particular, it has been shown that the stability of Complex I and respiratory 
chain supercomplexes that contain Complex I are especially sensitive to ROS-induced oxidative 
damage [22].  Additionally, ROS sensitivity of the respiratory chain, especially at Complexes III 
and IV, is heightened when lipoperoxidative damage is incurred upon the unsaturated fatty acids 
of phospholipids, predominantly CL [21].  However, physiological or moderate levels of ROS 
are involved in intracellular signaling and can induce limited autophagy and mitophagy, the 
degradation of damaged proteins and mitochondria, respectively, which in turn can promote 
overall cell survival especially under conditions of cellular nutrient depletion.  On the other hand, 
if levels of ROS increase too far, full cell death can be triggered via autophagic or apoptotic 
processes [19]. 
 
1.2. Complex II structure, function, and biogenesis 
Complex II, also referred to as succinate dehydrogenase (SDH) and succinate: 
ubiquinone oxidoreductase (SQR), is located in the IM of the mitochondria bridging the TCA 
cycle and the ETC.  Complex II oxidizes succinate to fumarate as part of the TCA Cycle and 
then passes the resulting electrons and protons from succinate through multiple redox centers to 
the lipophilic electron carrier ubiquinone as part of the ETC.  As the linkage point between these 
two bioenergetic processes, Complex II has the potential to be a central control point critical to 
regulating basic metabolic processes within the cell. 
Complex II falls into the larger family of oxidoreductases that includes both succinate: 
quinone oxidoreductases (SQRs) and quinol: fumarate oxidoreductases (QFRs) that catalyze the 
opposite reaction and participate primarily in anaerobic respiration [23, 24].  In particular, 
Complex II is a Class I SQR, which is considered the most typical and catalyzes the energetically 
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favorable oxidation of succinate, passing the resulting electrons to the ubiquinone molecule in 
the membrane [25].  As a Class I SQR, mitochondrial Complex II contains a Type C membrane 
anchor, which is comprised of two subunits with three transmembrane helices each that 
coordinate a single heme molecule at the interface between them [26].  It is important to note that 
as a Type C enzyme, Complex II does not directly contribute to the generation of a membrane 
potential across the IM, as the other respiratory chain complexes do, because calculations from 
standard reduction potentials have revealed that the overall oxidation-reduction reaction 
catalyzed by Complex II is not sufficiently exergonic to support proton translocation (or 
generation of a membrane potential) across the IM [16].  In addition, the protons resulting from 
succinate oxidation are released to the same side of the membrane from which they are taken up 
for ubiquinone reduction, which does not allow them to contribute to gradient formation [26]. 
1.2.1. Complex II Structure and Function 
Complex II is a heterotetrameric enzyme that can be separated into two heterodimers: the 
soluble catalytic dimer that oxidizes succinate to fumarate and the integral membrane dimer that 
anchors the catalytic dimer and passes electrons to ubiquinone as part of the ETC (Figure 1.4).  
Crystal structures of Complex II and the related QFRs have been solved for various prokaryotic 
species including Escherichia coli and Wolinella succinogenes [27-31] as well as for the 
eukaryotic nematode, avian, and porcine species [32-36].  A homology model for the yeast 
Complex II has also been constructed that is based on the E. coli and W. succinogenes SQR and 
QFR structures [37, Figure 1.4].  These structures support an overall model of the enzyme in 
which the smaller of the two catalytic subunits (Fe-S protein Sdh2, Figure 1.4, blue) acts as the 
linkage point between the larger catalytic subunit (flavoprotein Sdh1, Figure 1.4, red) and the 
membrane dimer (Sdh3/4, Figure 1.4, yellow/green).  Within the complex, the membrane dimer 
11 
 
forms an antiparallel helix bundle within the membrane that stabilizes part of the binding pocket 
for ubiquinone [37].  Notably, whereas the catalytic subunits share a high degree of sequence 
conservation between prokaryotic and eukaryotic species (approximately 50% homology), there 
is higher variability among the sequences of each of the membrane subunits (approximately 20% 
homology).  However, the membrane subunits are similar in conformation among all known 
structures, which is especially pronounced in the high structural conservation of the heme-
binding pocket and the ubiquinone-binding site [36, 38, 39].  Further, as with other respiratory 
complexes [40, 41], many of the Complex II structures support tight binding interactions 
between lipid molecules and the membrane dimer. The E. coli SQR structure was shown to 
contain one each of tightly bound CL and PE molecules, while the porcine structure contained 
two PE molecules, which were interpreted to mediate interactions between the membrane 
subunits [6, 31, 36]. 
In eukaryotes, the catalytic dimer is often referred to as succinate dehydrogenase (SDH) 
and the two proteins are referred to as SdhA and SdhB in mammals or as Sdh1p and Sdh2p in 
yeast.  SdhA is an approximately 70 kDa flavoprotein that contains the FAD moiety covalently 
bound through a histidine linkage near the catalytic site of succinate oxidation.  The covalent 
linkage between FAD and SdhA increases the redox potential of FAD, which allows the 
oxidation of succinate by Complex II; when FAD is bound non-covalently, the enzyme is unable 
to complete SDH activity (i.e. succinate oxidation) [42, 43].  SdhB is approximately 27 kDa and 
contains three Fe-S centers, [2Fe-2S], [4Fe-4S], and [3Fe-4S] that constitute a linear path for 
electron flux from FAD to the ubiquinone in the membrane.  SdhB also confers overall structural 
stability to the holoenzyme as 40% of the total surface area of SdhB contributes to interactions 
with SdhA and the membrane dimer [36].  When the catalytic dimer is separated from the  
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membrane dimer, which can occur at low pH or in the presence of chaotropic reagents, it is 
considerably more unstable as compared to when it is securely interacting with the membrane 
dimer [44]. 
The holoenzyme is referred to as succinate: ubiquinone oxidoreductase (SQR) and 
includes both SdhA and SdhB as well as the membrane-bound SdhC and SdhD (in mammals, or 
Sdh3p and Sdh4p in yeast) [23, 37, 45].  SdhC and SdhD are each approximately 16 kDa with 
three transmembrane-spanning helices (six total transmembrane segments in the assembled 
enzyme), four of which form an antiparallel helix bundle and two of which act to stabilize the 
dimer within the membrane [46].  The membrane subunits also coordinate a low-spin, hexa-
coordinated b-type heme between them via a histidine residue in each subunit [47-54].  In yeast, 
the heme is bound by the traditional histidine residue in Sdh3p, but is thought to interact with a 
non-canonical cysteine residue in Sdh4p because there is no conserved histidine at this site; such 
atypical coordination has led some groups to question the presence or role of the heme moiety 
within Complex II [47, 50, 51].  The membrane subunits also contain a proximal ubiquinone-
binding site (QP) located close to the interface with SdhB and a putative distal site (QD) located 
on the opposite side of the heme molecule whose relevance is also disputed [29, 30, 35, 37, 38, 
55-58].  It has been postulated that both ubiquinone binding sites help in facilitating exchange of 
bound ubiquinone with the quinone pool within the membrane.  Dual sites may also be needed to 
balance efficient catalysis and decrease production of free radicals from the unstable 
ubisemiquinone intermediate that could damage the mitochondrial membrane and oxidative 
machinery [15, 37, 57]. 
Overall, electrons are passed a total distance of approximately 40 Å between succinate 
and ubiquinone within Complex II (Figure 1.5, [30]).  Electrons from succinate enter Complex 
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II at SdhA and are immediately passed to FAD, the first redox center in the linear electron chain 
within the complex.  Direct electron transfer is favored between redox centers of Complex II 
because there is less than 14 Å between each of the electron carriers, which enables electron 
tunneling [59].  These short distances are thought to overcome the unfavorable decrease in 
reduction potential of the [4Fe-4S] redox center as compared to the [2Fe-2S] center immediately 
preceding it (a drop of 260 mV in porcine Complex II).  Further, not only is the presence of 
heme in the yeast Complex II disputed, but the function of the heme in all species is inconclusive 
as its low reduction potential (-185 mV in porcine Complex II) poses a thermodynamic barrier to 
electron transfer from the [3Fe-4S] center.  The low reduction potential may not completely 
inhibit electron transfer, as it has been shown that even unfavorable free energy pathways can 
allow electron transfer if the centers are located in close proximity [59].  However, the heme is 
located farther away from the [3Fe-4S] center as compared to ubiquinone and this distance is at 
the edge of the 14 Å acceptable distance for such direct electron transfer (7.1 Å for ubiquinone 
compared to 13.3 Å for the heme in porcine) [26, 59]. 
Given that the role of the heme in Complex II electron transfer is disputed, other roles for 
this redox center have been proposed.  First, it is postulated that heme may play more of a 
structural role rather than taking part in electron transport through the complex.  When heme is 
not present, the holoenzyme is less stable and the ubiquinone binding site is disrupted, leading to 
loss of SQR activity [60, 61].  It has also been hypothesized that the heme can act as an excess 
electron acceptor that would prevent electrons that cannot be passed to a fully reduced ubiquinol 
from instead being passed to the surrounding environment and causing free radical damage to the 
mitochondria [62].  This hypothesis is further supported by the evidence that E. coli QFR that 
lacks a heme molecule but is otherwise structurally similar to Complex II and that catalyzes the 
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opposite reaction of SQR, is a higher producer of ROS as compared to Complex II.  This is 
thought to arise in QFR because without a high potential heme moiety electrons are kept at the 
flavin molecule where they are then passed or leaked to oxygen, forming ROS [15].  However, 
other studies by the Cecchini group did not find evidence to support that a loss of heme 
contributes to an increase in ROS formed by Complex II in E. coli [63, 64].  Further, the redox 
potential of the heme in eukaryotic Complex II (-185 mV in porcine) as compared to that of E. 
coli (+36 mV) is much lower, which would discourage even excess electrons from being passed 
to this moiety [31, 36, 65].  Hence, the role of the Complex II heme remains poorly understood 
and more work needs to be completed in order to determine its true function within Complex II. 
 The overall enzymatic activity of Complex II can be split into two separately observable 
activities in vitro: succinate dehydrogenase (SDH) activity that reflects the presence of an active 
catalytic dimer only and succinate: quinone oxidoreductase (SQR) activity that detects the 
presence of an active holoenzyme (Figure 1.6).  SDH activity requires that only the catalytic 
dimer be present so that electrons from succinate can be passed through FAD and all three [Fe-S] 
centers.  On the other hand, SQR activity requires that the catalytic dimer be docked to the 
membrane dimer so that electrons from the [3Fe-4S] center of SdhB can be passed to the 
ubiquinone located within the membrane between SdhC and SdhD.  In vitro, both of the assays 
utilize an artificial colorimetric electron acceptor, dichlorophenolindophenol (DCPIP), that 
undergoes an extinction in absorbance at 600 nm upon reduction [66].  
Complex II activity is regulated in vivo primarily by phosphorylation and acetylation of 
SdhA [67].  Specific chemical inhibitors have also been identified that bind to the catalytic site 
(Figure 1.7A) and the ubiquinone-binding site (Figure 1.7B).  Inhibitors that act at the succinate 
(or dicarboxylate) binding site tend to be competitive inhibitors that are also TCA Cycle 
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intermediates.  Examples include oxaloacetate and malate, which is oxidized by Complex II to 
enol-oxaloacetate that then is able to inhibit the enzyme [25, 67, 68].  Additionally, a toxin 
produced by certain plants and fungi that is similar structurally to succinate, known as 3-
nitropropionic acid (3-NP), has been found to act as a suicide inhibitor of the complex through 
the succinate-binding site [34].  Inhibitors of the quinone binding site include the metal chelator 
thenoyltrifluoroacetone (TTFA), atpenin A5 (a competitive ubiquinone analog that prevents 
electron transfer from the [3Fe-4S] cluster to ubiquinone), and carboxins, which are able to 
specifically inhibit SQR activity [25, 69, 70].  It has been shown that of these, the antifungal 
compound atpenin A5 is very specific and is also more effective than other Complex II inhibitors 
at hindering activity [71].  In addition, a molecule called HQNO is able to inhibit Complex II 
activity by binding at the quinone-binding site; however, HQNO is also able to bind and inhibit 
Complex III, making it a non-specific Complex II inhibitor.  Some inhibitors of Complex II are 
more recently being considered for, and developed into, anti-cancer therapeutics, such as 
MitoVES, which is a mitochondrially targeted vitamin E succinate molecule [72, 73]. 
Recently, our laboratory engaged in a collaborative effort with the Boelsterli laboratory 
in the Department of Pharmaceutical Sciences at the University of Connecticut aimed at 
understanding the mechanism of isoniazid-induced cell death and mitochondrial Complex I 
dysfunction [74].  Isoniazid is an antituberculosis drug that has been associated with drug-
induced liver injury in susceptible patients, but the lack of understanding regarding the 
mechanism by which this occurs has delayed development of screens to identify susceptibility.  
However, it had been known that a metabolite of isoniazid, called hydrazine, is able to interfere 
with mitochondrial energy production and function.  While we are still unclear of the mechanism 
by which this occurs, as increased succinate concentrations were unable to compete away the 
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inhibitory effects, hydrazine proved to be not only an inhibitor of Complex I, but also a potent 
Complex II inhibitor.  These results may shed light on the overall pathway by which hydrazine 
interferes with normal mitochondrial function and assist in developing assays to determine 
susceptibility to liver injury by isoniazid-based drugs. 
1.2.2. Complex II Biogenesis and Assembly 
Although the structure of Complex II is fairly well established, the process by which the 
holoenzyme is assembled is still uncertain.  Unlike the other respiratory chain complexes, all of 
the Complex II subunits are encoded by nuclear genes; therefore, all four subunits must first be 
targeted to the mitochondria with a cleavable amino-terminal presequence.  Such presequences, 
although lacking a consensus sequence, usually contain a 15-50 amino acid peptide sequence that 
forms an amphipathic α-helix with a hydrophobic face and a basic (positively charged, usually 
+3 to +6) hydrophilic face [12, 54].  Proteins targeted to the mitochondrion by presequences are 
transported across the OM via the TOM (Translocase of the Outer Mitochondrial Membrane) 
complex and across the IM via the TIM23 (Translocase of the Inner Mitochondrial Membrane) 
complex, which transports matrix-located proteins as well as single-spanning integral membrane 
proteins [2].  Upon entering the mitochondrial matrix, the presequences of both soluble, matrix-
directed proteins (for example, SdhA and SdhB) and membrane proteins (such as SdhC and 
SdhD) are cleaved by the mitochondrial-processing peptidase [75].   
Once in the matrix, cofactors are inserted into Complex II protein subunits.  FAD is 
covalently attached to SdhA through what is thought to be a self-catalytic process assisted and 
enhanced by chaperones, such as the eukaryotic Sdh5 (bacterial homolog SdhE), which are 
thought to deliver FAD to SdhA [76, 77].  This process is further stimulated by the presence of 
SdhB as well as succinate, malate, and fumarate.  In addition, the covalent attachment of FAD to 
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SdhA increases the redox potential of FAD and therefore the “oxidative power” of Complex II as 
a whole [78-80].  The assembly of the [Fe-S] centers into SdhB, where cysteine residues act as 
ligands, is now known to occur through a complex biosynthetic machinery, not simply 
spontaneously [25, 81].  Once the centers are formed through the help of molecular scaffolds 
(iron-sulfur clusters or ISCs) and chaperones, they are transferred to SdhB [81-83].  It has very 
recently been shown that the transfer process itself is modulated by two separate LYR motifs 
within SdhB that are able to interact with these chaperones, such as HSC20, Sdh6/SDHAF1, and 
Sdh7/SDHAF3 [84, 85].  It is postulated that FAD attachment to SdhA is promoted by the 
presence of SdhB, but also that both FAD and Fe-S cofactor attachment precede catalytic dimer 
assembly; therefore, SdhA and SdhB are likely to interact closely with each other once inside the 
matrix [15].  Further, a new SdhA assembly factor has recently been identified, Sdh8/SDHAF4, 
that binds preferably to flavinylated SdhA and facilitates the interaction of SdhA with SdhB to 
form the catalytic dimer while also preventing spurious ROS formation by SdhA [86]. 
Once the complementary membrane subunits have been inserted into the IM and 
assembled together, possibly through the addition of the heme moiety, the catalytic dimer will 
then attach to the membrane dimer via SdhB, forming the holoenzyme [87, 88].  This interaction 
between the catalytic and membrane dimers is mainly hydrophobic in nature and can be 
disrupted by the presence of chaotropic reagents, but is also mediated by a number of conserved 
polar contacts [89, 90].  It has also been observed in past studies that the catalytic dimer will not 
assemble with the membrane dimer if heme is not present, that the [3Fe-4S] cluster of SdhB 
must be protected from reduction and oxidation for catalytic dimer re-attachment, and that both 
membrane subunits in E. coli are required for heme to ligate the complex [25, 91].  These results 
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also provide several independent lines of evidence supporting the assertion that heme plays more 
of a structural, rather than catalytic, role within Complex II [91, 92]. 
The general chaperones that facilitate the overall subunit assembly of Complex II are 
poorly understood as well, but various studies have provided evidence supporting important roles 
for the following proteins.  One group identified Tcm62p, a member of the hsp60 protein family 
that is found in yeast and which is thought to form a complex with at least three Sdh subunits, as 
a potential stabilizer of Sdh2p until it is able to bind Sdh1p [93].  In addition, Abc1p, previously 
thought to be involved solely in Complex III biogenesis, is believed to be involved in 
modifications to the final structures of Complexes II and IV as well [46].   Further, the Flx1 
mitochondrial transporter, likely to transport flavin into the mitochondria, has been implicated in 
Complex II assembly as well [67]. 
This complex assembly process became even more complicated recently when multiple 
homologs to Sdh4p were identified in yeast (Figure 1.8).  These include Tim18p (39.5% 
identical to Sdh4p), which is a subunit of the TIM22 Complex, another translocase of the IM, 
that transports integral IM proteins with multiple membrane-spanning helices that do not contain 
cleavable presequences, and an open reading frame of unknown function in yeast, YLR164w 
(52.6% identity with Sdh4p) [94, 95].  Tim18p has previously been shown to be critical for the 
assembly of the Tim54p subunit into the TIM22 Complex [96].  It has further been found that 
Sdh3p interacts with Tim18p and is necessary for the assembly of the TIM22 Complex; in 
addition, when Sdh3p is knocked out in yeast, the levels of Tim18p, along with Sdh4p, are 
significantly decreased [96].  Moreover, YLR164w (Shh4p) and a paralog of Sdh3p, YMR118c 
(Shh3p), are able to complement Sdh4p and Sdh3p knockouts, respectively, and are thought to 
change Complex II catalytic activity under non-optimal growth conditions [97].  These 
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observations suggest that Complex II membrane subunits are part of a complex interactive 
network, or interactome, with other membrane proteins and complexes [94, 96] and that the 
assembly of Complex II may be more intricate and more highly regulated than previously 
thought.   
Complex II subunits have also been implicated in the operation of other membrane 
complexes.  For example, it has been demonstrated that fumarate reductase, which catalyzes the 
reverse reaction of reducing fumarate to succinate, is involved in the assembly and function of 
the bacterial flagellar switch complex [98].  Further, it has been proposed that succinate 
dehydrogenase, namely SdhA, is a component of the mitochondrial ATP-sensitive potassium 
channel as some of the functions and inhibitor-sensitivities of these complexes overlap [99, 100]. 
Overall, Complex II and its homologous counterparts are influential in more processes than 
simply respiration and energy production within the cell. 
1.2.3. Complex II and Disease 
As the linkage point between the TCA Cycle and the ETC and as a potential critical 
control point for cellular energy metabolism, it is no surprise that Complex II dysfunction is 
associated with a multitude of different disease types.  Mutations in Complex II have been 
implicated in various tumorigenic diseases [67, 101], most notably paraganglioma and a 
derivative of this phenotype, pheochromocytoma [45, 101-106].  Abnormal activity of Complex 
II has also been linked to general mitochondrial dysfunction that involves the loss of membrane 
potential, increased calcium concentrations and the production of reactive oxygen species (ROS), 
which not only affect the mitochondria but can also be exported to the cytoplasm causing further 
damage [107, 108]. 
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Complex II mutation has also been linked to the potential development of Huntington’s 
Disease and other neurological disorders, including Leigh Syndrome [15, 109, 110]. Mutations in 
the SDHA gene of Complex II are predominantly associated with the development of Leigh 
Syndrome and are linked with compromised SDH activity and lowered energy production [103].  
Leigh Syndrome is a very rare early onset degenerative neurological condition that affects the 
central nervous system [67, 111].  It is associated with disorders in movement such as seizures as 
well as general weakness.    
Mutations in SDHB, SDHC, and SDHD, on the other hand, have been extensively linked 
to autosomal dominant hereditary paraganglioma and its subtype pheochromocytoma.  
Paraganglioma is characterized by benign, highly vascularized tumors in the head and neck 
regions of the body that derive from the neural crest paraganglial system, which includes the 
adrenal medulla [42, 112-117].  The most common site for this type of tumor formation is the 
carotid body, which acts as an important oxygen sensor.  Pheochromocytoma is a hormonally 
active form of paraganglioma and is characterized by catechol-secreting tumors that tend to 
develop in the non-head and neck regions of the body [105, 118].  More recently, mutations in 
SDHA have also even been linked to the development of paraganglioma [119] and mutations in 
the cofactor required for SdhA flavinylation, Sdh5, have also been linked to paraganglioma and 
pheochromocytoma development [104, 118, 120].   
Of note, mutations in SDHC are more rare compared to mutations in SDHB and SDHD 
[121].  Further, mutations of SDHB tend to be associated with non-head and neck 
paragangliomas and have a higher frequency of being malignant (as high as 50%) and of leading 
to a poorer prognosis, as compared to mutations of SDHD; however, twenty percent of the amino 
acids in SdhD have been implicated in tumor formation [91, 102, 105, 118].  In addition, the 
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largest number of diseases associated with Complex II have been linked to mutations in SDHD 
and other diseases stemming from complications with Complex II include renal cell carcinoma 
[115, 122], certain types of colon and gastric cancers [45, 111, 123], and childhood T cell 
leukemias [124, 125].  SDHB, SDHC and SDHD are classified as tumor suppressor genes 
because loss of heterozygosity results in loss of protein function [42, 105, 126-129].  The best 
characterized heritable pathogenic missense mutations include L130P in SdhC and R35G, P46L, 
D57Y, L60P, H67L, Y79C, and L104P in SdhD (Figure 1.9).  
Complex II has also been implicated in the aging process because of its ability to produce 
free radicals in the form of ROS [45, 68, 73, 130, 131].  Mutations in the counterpart to yeast 
SDHC in C. elegans, known as mev-1, lead to a decreased lifespan and rapid aging [42, 132, 
133].  This is relevant in light of accumulating evidence that Complex II with key SdhC or SdhB 
mutations, particularly those within or near the [3Fe-4S] center and the proximal quinone 
binding site, generates ROS that may lead to oxidative stress resulting in a shortened lifespan 
[45, 132, 134]. 
Complex II-associated tumorigenesis has been suggested to occur by multiple different 
mechanisms.  First, a pseudo-hypoxic cellular response can be caused by increased succinate 
levels, which result from certain mutations in Complex II.  Within the cell there is a 
heterodimeric hypoxia-inducible transcription factor (HIF1α, β) that is induced under conditions 
of low oxygen (hypoxia) in order to promote glycolysis when the oxidative phosphorylation 
system is less efficient.  HIF1α also induces the growth of blood vessels to help transport oxygen 
to cells suffering from hypoxia [106].  Under normoxic (normal oxygen levels) conditions, 
HIF1α is hydroxylated by a prolyl hydroxylase (PHD) enzyme and inactivated or degraded.  
When Complex II is mutated, succinate may build up in the cell and inhibit PHD as succinate is 
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also a natural product of the hydroxylase, preventing PHD from hydroxylating HIF1α and 
effectively preventing HIF1α from undergoing the degradative processes [135].  Under these so-
called pseudo-hypoxic conditions, with the cell unable to degrade HIF1α, the transcription factor 
is able to activate genes that are involved with angiogenesis, cell proliferation and survival, and 
glycolysis, likely promoting tumorigenesis and paraganglioma formation [45, 105, 135].  It has 
also been suggested that higher levels of ROS can inhibit PHD as well, leading to this pseudo-
hypoxic response [106].  In addition, it has more recently been hypothesized that the production 
of ROS by Complex II may also have implications in the tumorigenic disease states linked 
directly with the complex [45, 105, 106, 127, 136]. 
Current work indicates that Complex II may also be a key mediator of apoptosis. The 
Grimm group has recently shown that decreased pH (intracellular acidification), which is 
generally an early apoptotic signal, triggers a separation between the catalytic and membrane 
dimers of Complex II [131, 137].  The separation of the heterodimers introduces a disconnect in 
the electron transfer pathway within the enzyme, separating the SDH and SQR activities and 
preventing electrons from succinate from completely passing to the final intracomplex acceptor, 
ubiquinone (Figure 1.10).  Electrons are instead passed from the FAD molecule or the [Fe-S] 
centers to surrounding oxygen molecules, leading to the formation of ROS, which can then 
contribute to the induction of cellular apoptosis.  This overall process, triggered by the sensitivity 
of Complex II to its surrounding pH, identifies the enzyme as an important apoptotic sensor and 
is consistent with previous findings that SDHB, SDHC, and SDHD act as tumor suppressor genes 
[131].  It is important to note, however, that if both enzymatic activities are blocked (SDH and 
SQR activities) increased levels of succinate would result due to lack of overall Complex II 
activity.  Succinate can then be transported to the cytosol where it can influence the development 
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of a pseudo-hypoxic state that promotes glycolysis, which would allow total dysfunction of 
Complex II to contribute to tumor formation rather than apoptosis [138]. 
Even more recently, it has been proposed that ROS formation by Complex II is not only a 
major contributor to the overall ROS creation within mitochondria, but also “antithetically” 
depends on the concentration of succinate present in the cell [69].  First, succinate is necessary to 
begin the reduction of redox centers within Complex II that can then pass electrons to oxygen, 
forming ROS.  In this way, an increase in succinate concentration would favor higher ROS 
production.  On the other hand, succinate bound to the active site of Complex II prevents oxygen 
from accessing the FAD moiety that is thought to be the primary center of ROS formation, 
although the [Fe-S] centers and ubiquinone molecule are not excluded from contributing to ROS 
as well.  In this respect, increasing succinate concentration would decrease the formation of 
ROS.  Therefore, there exists an optimal succinate concentration for maximal ROS production 
by Complex II that would lead to apoptosis. 
 
1.3.  Lipids 
As an integral component of biological membranes, phospholipids are intricately linked 
to the proper structure and function of membrane protein complexes and as such can be divided 
into categories based on location and function in relation to these complexes.  The complement 
of lipids within the bilayer that are not in immediate contact with a particular membrane protein 
or complex are referred to as bulk lipids.  Annular lipids are found at the surface of a membrane 
protein and provide a layer between the protein and the bulk bilayer lipids.  They are thought to 
be important for inserting the protein within the bilayer and keeping it positioned correctly.  
Non-annular lipids, on the other hand, mediate the interaction and interfaces between subunits or 
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proteins making up a larger complex and can also act as cofactors to activate enzymes.  They are 
able to seal spaces and gaps that could be caused by such interactions, maintaining electrical and 
other gradients across a particular bilayer [139]. 
In addition, lipids serve specific roles in the proper functioning of the mitochondria as a 
whole as well as its individual membrane proteins and complexes.  As some examples, lipids 
influence respiratory chain complex activity, transport processes across the mitochondrial 
membranes including import and assembly of newly synthesized proteins, and osmotic and phase 
behaviors of mitochondrial membranes [4, 140].  It has even been found that PE is critical to the 
correct later-stage folding of the E. coli membrane protein lactose permease [141], as well as to 
the correct functioning of the translocase complex of the mitochondrial OM, the TOM complex 
[142].  Further, anionic phospholipids can act as organization sites for both soluble and integral 
membrane proteins and complexes [143].  In particular, the signature phospholipid of energy 
conserving membranes, CL, supports many, if not all, of the above listed mitochondrial protein 
complex functions.   These include supporting OXPHOS, supporting the formation of cristae as 
well as allowing mitochondrial fission and fusion to occur, and acting as a mitochondrial 
membrane identifier, which is important for integrating various mitochondrial and cellular extra-
mitochondrial processes [144, 145].   
1.3.1.  Cardiolipin Structure 
CL is unique to energy-conserving membranes, including the IM of the mitochondria and 
bacterial plasma membranes.  This lipid has a distinctive structure that includes two 
phosphatidylglycerol backbone fragments esterified to a central glycerol moiety, thus giving it 
four acyl chains and a double headgroup, in comparison with typical glycerophospholipids, 
which have two acyl chains and a single headgroup (Figure 1.11).  Despite the fact that each 
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phosphate of CL has a titratable group, it has been supported that CL in fact has two pKa values, 
with pKa1 < 4.0 and pKa2 > 8.0, the second of which is a conformational pKa and is able to shift 
when titrated [146].  The shifting pKa2 results from the intramolecular hydrogen bonding 
between the hydroxyl group of the central glycerol  moiety and the phosphates from the 
surrounding headgroups, forming a bicyclic structure with both headgroup phosphates and the 
glycerol [147, 148].  This causes the headgroup to contain a single anionic charge at 
physiological pH due to a resonance effect that allows the anionic charge to be shared between 
both headgroups (Figure 1.12, left).  CL is therefore referred to as an acid-anion at physiological 
pH because of this tight bicyclic headgroup structure.  The resonance acid-anion structure is 
thought to allow CL to act as a proton buffer or proton sink that can then facilitate proton transfer 
from the bulk matrix to respiratory chain complexes, namely Complex III [40, 149].  Under 
certain conditions, it is even thought that acid-anion structures can occur between adjacent CL 
molecules as well, further facilitating the capacity of CL to act as a proton buffer [146].  In 
contrast, if the central glycerol hydroxyl group is removed, as in deoxyCL, or if the CL molecule 
contains asymmetrical acyl chains or is lacking one acyl chain, as in lysoCL, the resonance-
stabilized headgroup is unable to form and CL displays two pKa values that are much closer 
together, pKa1 = 1.8 and pKa2 = 4.0 [148, 150], and more typical of phosphates within a 
glycerophospholipid.  This view has been recently questioned, however, and it has been 
postulated that the acid-anion structure and divergent pKas of CL are an artifact of experimental 
design and CL does in fact contain two anionic charges at neutral pH, reopening the question of 
how CL truly exists at physiological pH [151]. 
It has also been demonstrated that CL is essential to the structure and function of various 
proteins and complexes within mammalian IMs [152, 153].  It is implicated in stabilizing the 
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structure of various respiratory chain complexes, has been crystallized with Complexes III and 
IV, and recent molecular dynamics simulations support  the location of CL binding sites within 
Complex III and Complex IV as well [41, 139, 154, 155].  While it has traditionally never been 
shown to be important for eukaryotic Complex II, it has been crystallized with the E. coli SQR 
where it occupies space at the interface of the membrane subunits and is stabilized by hydrogen 
bonds with the enzyme [6]; it is common for CL to be located at such an interface between 
monomer subunits of a protein complex [156].  In addition, I have shown that reconstituted 
Complex II requires CL for stability and functionality (Chapter 3, [157]); therefore, CL may be 
more important for Complex II structural stability and activity than previously thought.  Even 
more, CL has been implicated in the stability of respiratory chain supercomplexes, where it is 
again thought to stabilize the interaction between Complexes III and IV [10, 158-160].   These 
supercomplexes (respirasomes) constitute multiple respiratory chain complexes organized into a 
single larger complex to enhance efficiency of electron transport via substrate channeling [9, 18, 
161, 162].  Further, CL is critical to the proper functionality of the ADP/ATP carrier as well as 
recruiting this protein carrier to regions of the IM where OXPHOS complexes are located in 
order to increase the efficiency of energy metabolism [163-165]. 
Due to its four acyl chains forming a bulky hydrophobic region, CL is referred to as an 
inverted conical lipid whose acyl chain cross-sectional area is larger than that of its headgroup 
region.  This causes CL to be classified as an inverted-micellar or non-bilayer preferring lipid 
and to adapt a hexagonal (HII) phase in the presence of divalent cations and low pH [166].  The 
preference for a HII phase is in contrast to a major component of the IM, PC, which is a 
cylindrical phospholipid that favors a bilayer or lamellar conformation.  The proportions of 
bilayer and non-bilayer lipids within a membrane are tightly controlled and it has even been 
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shown that non-bilayer lipids can alter the lateral pressure of the membrane and induce packing 
defects that may enable the insertion of membrane proteins [167].  CL tends to be found in areas 
of the mitochondrial membrane that are highly curved, such as the cristae membrane of the IM or 
membrane regions susceptible to fusion events [168, 169].  When there are mutations in any of 
the enzymes involved in the CL synthesis pathway, either eliminating CL or causing changes in 
the acyl-chain composition of the lipid, there are large changes in the ultrastructure of the IM, 
underscoring the importance of the non-bilayer propensity of CL in relation to overall 
mitochondrial structure.  These results are further supported by findings that the acyl chain 
composition of CL affects HII structure formation; longer acyl chains that are unsaturated are 
more likely to favor formation of the HII phase [170, 171].   
1.3.2.  Cardiolipin and Divalent Cations 
The propensity of CL to form a HII phase is especially apparent in the presence of 
divalent cations, which are able to reduce the charge repulsion between negatively charged CL 
headgroups and further reduce the headgroup cross-sectional area [172].  Additionally, because 
the headgroup of CL is so small, it is unable to use conformational or orientation-based changes 
in this region to compensate for the added charge of the divalent cations [173].  In particular, CL 
is known to have a higher affinity for calcium (Ca2+) ions as compared to magnesium (Mg2+) and 
other divalent cations, making the presence of Ca2+ particularly effective at inducing the HII 
phase of CL and therefore membrane structural alterations, which can allow membrane fusion 
[143, 172].  It has been shown that Ca2+ is able to induce these changes by effectively 
dehydrating and neutralizing CL headgroups, allowing them to pack more closely together, 
resulting in formation of a HII structure.  In contrast, Mg2+ and even barium (Ba2+) are less able 
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to dehydrate CL structures and are more likely to form mixed lamellar and HII structures of CL 
when present in solution [174]. 
1.3.3. Cardiolipin Biosynthesis 
Due to its highly specialized structure, CL is synthesized by a unique biosynthetic 
pathway in the IM (Figure 1.13) [175].  First of all, CL is synthesized within the mitochondria, 
similar to phosphatidylethanolamine (PE) and phosphatidylglycerol (PG), other phospholipids 
found within both the OM and IM.  Briefly, PG, an immediate precursor of CL, is synthesized 
from PA, cytidine-triphosphate (CTP), and glycerol-3-phosphate through a number of 
enzymatically catalyzed steps.  Cardiolipin synthase (Crd1) then catalyzes a condensation 
reaction with PG and CDP-diacylglycerol to produce an immature form of CL.  This form of CL 
is considered immature because it does not contain the canonical acyl chains that would be found 
within a typical CL molecule located in the IM.  Instead, this immature version of CL typically 
contains four shorter (14 carbon), saturated acyl chains. 
Immature CL then enters a remodeling cycle that begins with the removal, by a 
deacylase, of one of its acyl chains to produce monolysocardiolipin (MLCL).  MLCL is then re-
acylated by taffazin (Taz1) to produce a CL species with four acyl chains [176].  After multiple 
rounds through this remodeling cycle, mature CL with four longer (typically 16 or 18 carbons), 
unsaturated acyl chains that are symmetric about its chiral centers is produced and ready for full 
incorporation into the membrane.  Of note, the final mature type of CL that is produced is both 
species and tissue specific, but is always symmetrical and structurally uniform [177].  The 
symmetrical nature fosters the ability of CL to exist as an acid-anion at physiological pH; it has 
been hypothesized that MLCL, which is asymmetrical due to having only three acyl chains, is 
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unable to produce the usual resonance-stabilized mature CL structure found at near neutral pH 
[150].   
In addition, CL synthesis is linked with the synthesis of other phospholipids, such as its 
precursor PG, and when CL is not present OXPHOS function under stress conditions, such as 
high temperature, is greatly reduced [178-180].   In this way, CL behaves as a “stabilizer” of 
mitochondrial function [181].  While the essential activities of CL can be compensated by PG or 
PE (another non-bilayer favoring lipid) in some circumstances, they cannot entirely replace the 
function of CL, and if any combination of these lipids is not synthesized, more dire effects are 
seen, such as reduced mitochondrial membrane potential, which affects a number of 
mitochondrial processes including protein import [182-186].  It has also been shown that lack of 
either PE or CL has different effects on the respiratory chain, supporting the limited 
complementarity of these HII-favoring phospholipids [187].  Further, when the Taz1 gene is 
mutated leading to alterations in the biosynthesis and metabolism of CL, the X-linked disease 
Barth syndrome often results, which is characterized by defects in OXPHOS assembly and 
function, among others [188, 189]. 
 
1.4. Model membrane systems 
Membrane proteins constitute roughly one third of any given proteome and are involved in 
a number of processes including transport, signal transduction, adhesion, and cell-to-cell 
communication, and are therefore popular candidates for therapeutic drug targets [190, 191].  
Despite the importance of membrane proteins, they are poorly understood as compared to soluble 
membrane proteins.  This is due to the fact that the use of traditional biochemical and 
biophysical experimental methods to study them is hindered because of their low expression 
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yields, insolubility (they tend to aggregate in aqueous solution), and formation of non-native 
structures after purification [190].  The development of model membrane systems has been 
instrumental in such experimentation by providing a near-native environment in which to study 
membrane proteins. 
1.4.1.  Detergents 
Traditionally, detergents have been utilized to maintain membrane protein solubility in 
aqueous solutions or dispersions as they are similar in amphipathicity to phospholipids: both 
have polar and nonpolar regions.  However, detergents generally have a more hydrophilic 
character than phospholipids, which allows them to be more soluble within aqueous solutions as 
compared to phospholipids alone [192].  In order for a detergent to shield a membrane protein 
from the aqueous phase and remove the protein from its native membrane bilayer, the 
concentration of detergent molecules in solution generally needs to be greater than the critical 
micelle concentration (CMC) of that particular detergent.  The CMC is the concentration at 
which a detergent will spontaneously form micelles, or monolayer vesicles, in which the 
detergent hydrophobic tails are shielded within the core of the micelle and the more hydrophilic 
heads face the aqueous environment.  The CMCs of ionic detergents can be up to 100 times 
greater than those for nonionic detergents because of the electrostatic repulsion between ionized 
headgroups that disfavors micellar formation [192].  In addition, ionic detergents tend to be more 
effective in breaking protein-protein or intra-protein interactions, whereas nonionic detergents 
tend to be used for disrupting lipid-protein interactions and solubilizing intact membrane proteins 
from their native bilayer [193].  At concentrations of detergent higher than the CMC, the 
detergent molecules are able to bind and incorporate into the bilayer and induce a lamellar-to-
micellar phase transition as well as saturate and replace the lipid binding sites of the membrane 
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proteins so that they are solubilized by the detergent as opposed to being bound by the lipid 
membrane [192]. 
Detergent molecules are likely to form micelles, as opposed to the inverted hexagonal phase 
favored by many inverted cone-shaped lipids, due to the larger cross-sectional area of the 
detergent headgroup as opposed to the hydrophobic tail region.  Detergents generally have one 
hydrophobic chain per headgroup in contrast to the two or four chains per headgroup that 
phospholipids generally contain.  The increased number of tails per headgroup for phospholipids 
causes them to prefer a bilayer (if they are cylindrical in shape) or inverted hexagonal phase (if 
they are cone shaped), rather than a micellar phase (preferred by inverted cone-shaped detergents 
or lysophospholipids).  In addition to forming structures dissimilar from phospholipid bilayers, 
monolayer detergent micelles tend to be irregular in shape as they are disorganized and can be 
compacted [194]; for these reasons, systems that more closely mimic native biological 
membranes as compared to detergents were developed to solubilize membrane proteins. 
1.4.2.  Bicelles 
Bicelles, which are lipid bilayer discs that are “belted” by detergents or short-chain lipids, 
are one way in which membrane proteins can be studied in solution  [195].  Bicelles are 
advantageous because they are amenable to spectroscopic approaches and are monodisperse, 
similar to detergent micelles, but they contain a much smaller amount of detergent and are 
bilayer-like in nature, providing them with characteristics more similar to bilayer vesicles [196].  
Because short-chain lipids are required for bicelle structure, there is a limit on the type and 
variety of lipids that can be incorporated.  In addition, even though it is presumed that limited 
short-chain lipids are incorporated into the planar bilayer of the bicelle, they may in fact partially 
localize there and affect activity or stability of incorporated proteins [196].  While suitable for 
32 
 
certain NMR studies, other model membrane systems may be more appropriate for different 
biochemical and biophysical studies.   
1.4.3.  Amphipols 
Another way in which to solubilize membrane proteins is to use amphipathic polymers, 
known as amphipols, that have a variable number of hydrophobic and hydrophilic pendant 
groups that are able to wrap around membrane proteins and keep them soluble within solution by 
protecting their hydrophobic transmembrane regions [197].  Some groups believe that the 
polymers, such as styrene maleic acid (SMA), are able to destabilize membranes and form discs 
that encapsulate a membrane protein as well as surrounding lipids (Figure 1.14, [198-200]).  
They have comparable stability to liposomes and are favorable because they solubilize 
membrane proteins away from their native membranes without the use of detergents [199, 201].  
In addition, amphipols are thought to stabilize and support native protein-protein folds and 
protein-lipid interactions to a better extent as compared to detergents [197].   
Our group in collaboration with the Albert Laboratory at the University of Connecticut and 
the Watts Laboratory at the University of Oxford has used the SMA copolymer to show that it is 
capable not only of solubilizing membrane proteins, but of removing fully functional protein 
complexes directly from intact mitochondrial membranes [202].  We demonstrated that SMA is 
able to disrupt the membrane potential across the IM and remove not only membrane proteins 
and entire complexes, but also select lipids that are presumably tightly bound to the membrane 
proteins and required for function.  A downside of using amphipathic polymers is that the lipid 
composition is restricted to that of the originating membrane used for membrane protein 
extraction and they are therefore not optimal systems in which to study protein-lipid interactions 
through direct experimental alteration of the lipid environment.  In addition, the size of the discs 
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cannot be adjusted to regulate the formation of oligomeric states of the membrane protein of 
interest. 
1.4.4. Liposomes 
A predominant model membrane system used extensively by our laboratory and others is 
the liposome, which allows usually challenging membrane proteins to be studied in a more 
native and functional state [203].  Liposomes, vesicles of phospholipid bilayers that are formed 
through hydration of lipid mixtures and subsequent agitation or addition of energy (e.g. through 
sonication followed by an extrusion process), have been successfully used to study a wide range 
of membrane proteins including bacteriorhodopsin, respiratory cytochromes, and various 
ATPases [190, 204-207].   Liposomes have also been added to cell-free translation systems in 
order to provide a lipid bilayer environment in which translated membrane proteins, such as 
human stearoyl-CoA desaturase complex, connexin-43, and the ADP/ATP Carrier, can fold 
correctly [203, 208-213].  One benefit of using liposomes as a model membrane is their 
versatility in regards to lipid composition and size [214].  Liposomes are also advantageous 
because they contain distinct inner and outer compartments that can maintain ion gradients and 
encapsulate certain molecules on a single side to mimic the native state of a membrane protein 
[214].  However, in some cases, technical problems such as sample heterogeneity and light-
scattering can plague spectroscopic-based approaches when working with liposomes, which led 
our laboratory to utilize a second model-membrane system in our studies as well. 
1.4.5.  Nanodiscs 
More recently, a novel model membrane system, the nanodisc, has been developed that 
allows membrane proteins to be reconstituted in a native-like environment as homogeneous and 
monodisperse samples.  Nanodiscs are discoidal phospholipid bilayers bound by a belt of 
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membrane scaffold proteins (MSPs) that self-assemble upon the removal of detergent from a 
solution of phospholipid and MSP [215-218].  They are beneficial not only because of their 
monodispersity as compared to liposomes, micelles, and polymer-stabilized bilayers, but also 
due to their stability over a wide range of temperatures, decreased light scattering, and better 
representation of lipid phase transitions within native membranes as compared to liposomes 
[190, 219].  In addition, they allow experimental access to both sides of the membrane bilayer, 
which can be beneficial in ligand-binding studies [215]. 
The membrane scaffolding protein (MSP) used to belt the nanodiscs was developed by the 
Sligar Laboratory through specific engineering of the human apolipoprotein, apoA-I, which is a 
high density lipoprotein (HDL) found in humans [220].  HDLs naturally bind free lipids and 
cholesterol throughout the body and transport them to the liver, a process known as reverse 
cholesterol transport [221].  It has been shown that lipid-bound apoA-I assumes not only a higher 
α-helical content, but also allows (or samples) only a limited number of conformations [190].  A 
pair of apoA-I proteins binds around the outside of the HDL particles in an antiparallel 
arrangement stabilized by salt bridges and proline stacking interactions [221].  When the lipid-to-
apoA-I ratio is approximately 100-to-1, discoidal HDL particles tend to form, whereas when the 
ratio is higher, the particles tend to be more spheroidal in shape [190].  During nanodisc 
assembly it has been observed that altering the lipid-to-MSP ratio in the final assembly reactions 
influences the final size and shape of nanodisc particles as well [222].  When the amino-terminal 
globular domain comprised of 43 amino acids is removed from apoA-I it tends to have a higher 
α-helical content and adapt a more discoidal structure in solution, similar to how it would behave 
in the presence of lipids [215].  For this reason, the simplest MSP is structurally equivalent to the 
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remaining 200 carboxy-terminal amino acids of apoA-I once the 43 amino-terminal residues 
have been removed [190]. 
By engineering the MSP in this way, it is likely to form an amphipathic α-helical discoidal 
belt around phospholipids in solution, protecting the hydrophobic acyl chains from the 
surrounding aqueous solution.  The 11- or 22-mer helices are broken up by proline and glycine 
residues in order to allow more flexibility and enable the MSP to form the belt-like discoidal 
shape [220].  Further, additional α-helices can be inserted into the MSP sequence to form 
scaffolding proteins of a particular length, which alter the diameter of the nanodiscs that are 
formed (Figure 1.15).  For example, MSP1 is the smallest MSP construct, forming nanodiscs of 
approximately 9.5 nm in diameter, whereas MSP1E3 has three additional 22-amino acid α-
helices inserted, forming a nanodisc of approximately 12.1 nm in diameter [223].  In addition, 
removing the most amino-terminal 11 residues on the MSP construct does not change the size of 
the nanodisc formed and they have been removed in many constructs; this is denoted as –D1; for 
example, as in MSP1D1 or MSP1E3D1 in the case of a construct with additional helices [217].  
Based on extensive characterization (chemical crosslinking analyses, mass spectrometry, 
scintillation counting), it is postulated that two MSPs wrap around the circumference of each 
nanodisc, one above the other, protecting the hydrophobic chains of each monolayer within the 
bilayer, in what is termed the “belt” model (Figure 1.15, [216-218]).  The MSPs are thought to 
be flexible both in solution and within the nanodisc structure causing the discs to be more 
dynamic, rather than static, structures [224]. 
A variety of membrane proteins and complexes of varying size have been reconstituted into 
nanodiscs, including bacteriorhodopsin, proteorhodopsin (a study on which our laboratory 
collaborated with the Birge group in the University of Connecticut Department of Chemistry), 
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cytochrome P450s, G-protein-coupled receptors, bacterial chemoreceptors, the mitochondrial 
voltage-dependent anion channel (VDAC-1), and the SecYEG complex [190, 223, 225-234].  
While certain cytochrome c oxidases have also been incorporated into nanodiscs, our group was 
the first to incorporate a respiratory chain complex, Complex II, into nanodiscs directly from 
solubilized mitochondrial membranes ([235], Chapter 3).  Our study, as well as a few other 
studies, including one focusing on phosphoinositide and another on bacterial chemoreceptor-PE 
dependence, have utilized the nanodisc platform to study protein-lipid interactions in more detail 
as the exact lipid content of the discs can be easily manipulated [236, 237].  Recently, nanodiscs 
have also been physisorbed to silicon surfaces and used in arrays to screen the interaction of 
soluble proteins or ligands with membrane proteins and are even being developed as drug 
delivery systems and in immune-protective responses [238-240]. 
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1.5. Figures and Tables 
 
 
Figure 1.1.  Schematic of mitochondrial compartments and membranes.  Mitochondria are 
surrounded by two membranes, the outer and inner membranes (OM and IM, respectively), that 
enclose an aqueous matrix and are separated by an aqueous intermembrane space.  The IM is the 
location of the respiratory chain complexes, including Complex II (green), which oxidizes 
succinate to fumarate within the matrix and passes the resulting electrons to the lipophilic 
electron carrier molecule, ubiquinone, located within the IM.  
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Figure 1.2.  Comparison of yeast and mammalian mitochondrial OM and IM phospholipid 
compositions.  PC and PE are the most prominent lipids in both the OM and IM bilayers of yeast 
and mammals, whereas CL is significantly more abundant in the IM of mitochondria from all 
eukaryotes [2]. 
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Figure 1.3.  Schematic of the Tricarboxylic Acid Cycle and Electron Transport Chain 
within the Mitochondria.  The Tricarboxylic Acid (TCA) Cycle within the matrix and the 
electron transport chain (ETC) within the IM are connected through Complex II activity, which 
couples succinate oxidation with the reduction of membrane-bound ubiquinone (Ub).  In 
addition, NADH from the TCA Cycle is shuttled to Complex I (or NADH dehydrogenases in 
yeast) and these electrons are passed to Ub as well.  Electrons from Ub are passed through 
Complex III to the intermembrane space-located cytochrome c (Cyt c), which then transports 
electrons to Complex IV, where oxygen is reduced to water.  The energy generated from electron 
transport allows Complexes I, III, and IV to pump protons into the intermembrane space from 
the matrix, building up a proton gradient.  The energy stored within this gradient is utilized by 
Complex V (ATP Synthase) in order to synthesize ATP from ADP and Pi in the matrix.  
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Figure 1.4.  Homology model of yeast Complex II.  The soluble catalytic dimer (succinate 
dehydrogenase subunit) consists of Sdh1p (red) and Sdh2p (blue).  The membrane-embedded 
dimer is composed of Sdh3p (yellow) and Sdh4p (green).  The model was developed using the 
Modeler6v2 program with templates from E. coli succinate dehydrogenase (PDB Structure 
1NEK), E. coli fumarate reductase (PDB Structure 1LOV), and W. succinogenes fumarate 
reductase (PDB Structure 1QLA). Figure derived from PDB Structure 1PB4 in Swiss-PdbViewer 
4.0.1 and [37]. 
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Figure 1.5.  Crystal structure of porcine Complex II.  The soluble catalytic dimer is 
represented by SdhA (Fp, blue) and SdhB (Ip, pale yellow) and the membrane-embedded dimer 
is composed of SdhC (CybL, magenta) and SdhD (CybS, orange), which are shown here within 
the IM (gray box).  Redox centers are represented within the structure and are also aligned at the 
right side of the figure in order to more accurately portray the edge-to-edge distances (no more 
than 14 Å) between each of the redox centers within the linear chain.  Figure adapted from [36]. 
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Figure 1.6.  Schematic of separable in vitro Complex II activities.  Succinate dehydrogenase 
(SDH) activity reflects the presence of an active catalytic dimer only.  The electron pathway 
begins with succinate passing electrons to FAD as it is oxidized, which then passes these 
electrons through three [Fe-S] centers.  Instead of making their way to the ubiquinone (Q) within 
the membrane, the in vitro assay includes the redox mediator phenazine methosulfate (PMS), 
which takes electrons from the [Fe-S] clusters and then passes them to the artificial electron 
acceptor, DCPIP.  Succinate: ubiquinone oxidoreductase (SQR) activity reflects the presence of a 
functional holoenzyme.  Electrons from succinate are passed through FAD, the three [Fe-S] 
centers, then to a ubiquinone analog (decylubiquinone, DB), and finally to the artificial electron 
acceptor, DCPIP.  DCPIP reduction in both assays is monitored spectroscopically as an 
extinction in absorbance at 600 nm. Figure adapted from [157]. 
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Figure 1.7.  Chemical structures of Complex II inhibitors and native substrates.  A selection 
of examples of Complex II inhibitors and structural comparison to those of native Complex II 
substrates. (A) Substrates and inhibitors of the SdhA catalytic site. From left to right, succinate, 
its substrate, malate, a TCA Cycle intermediate that also acts as an inhibitor, and 3-
nitropropionic acid (3-NP), another inhibitor.  (B) Substrates and inhibitors of the membrane 
subunit ubiquinone binding site.  From left to right, ubiquinone, its natural substrate, and two 
inhibitors, atpenin A5 and thenoyltrifluoroacetone (TTFA).  Figure adapted from [68, 71]. 
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1.8. Experimentally determined and hypothesized interactions of Complex II membrane 
subunits and their homologs.  It has been found in yeast that the Sdh4p membrane subunit of 
Complex II has multiple homologs, including Tim18p, part of the TIM22 (Translocase of the 
Inner Mitochondrial Membrane) Complex, and YLR164w, an open reading frame of unknown 
function.  Recent experimental evidence supports that Sdh3p is able to interact with Tim18p and 
is necessary for the proper integration of Tim18p into the TIM22 Complex.  Figure adapted from 
[96]. 
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Figure 1.9.  Clinically identified mutations within the membrane subunits of Complex II.  
On the left, a schematic of the porcine membrane subunits, SdhC and SdhD, with homologous 
residues to the clinically identified mutations in humans noted by the yellow highlighted circles.  
On the right, a comparison table of these mutations and the homologous residues among human, 
porcine, and yeast membrane subunits. 
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Figure 1.10.  Schematic of the detachment of the catalytic dimer from the membrane dimer 
and the resulting potential for ROS production.  When a decrease in the pH of the 
surrounding environment occurs, the soluble catalytic dimer (SDH) can detach from the 
membrane dimer of Complex II, causing a dissociation of the SDH and SQR activities.  
Electrons from the oxidation of succinate can no longer be passed through the entire redox chain 
within Complex II to membrane-bound ubiquinone and instead are passed to matrix oxygen 
species, forming ROS. Figure adapted from [131, 157]. 
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Figure 1.11.  Chemical structure of 1’,3’-bis[1,2-dioleoyl-sn-glycero-3-phospho]-sn-glycerol 
or tetraoleoylcardiolipin (TOCL).  This particular form of CL is termed tetraoleoyl-CL, which 
has four acyl chains that are each 18:1(9Z).  Figure adapted from [157]. 
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Figure 1.12.  Resonance effect of CL compared to its deoxy-analog.  When the hydroxyl 
group is removed from the central glycerol moiety of CL, the ability to form an acid anion 
structure due to resonance is abolished.  In this way, deoxyCL has two similar pKas, while CL 
has two disparate ones, the second of which is a shifting pKa that causes CL to hold a single 
anionic charge at physiological pH.  Figure adapted from [148]. 
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Figure 1.13.  CL biosynthesis pathway.  CL is synthesized from phosphatidic acid (PA) 
through multiple enzymatically-catalyzed steps within the IM of the mitochondria.  After 
synthesis from its immediate precursor, phosphatidylglycerol (PG), CL undergoes a cyclic 
remodeling process consisting of multiple deacylation and reacylation reactions, finally resulting 
in a mature CL with four symmetrical, unsaturated acyl chains. Figure adapted from [2]. 
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Figure 1.14.  SMA copolymer structure.  The SMA copolymer is composed of styrene 
(hydrophobic) and maleic acid (hydrophilic) groups, which lends it an amphipathic nature 
allowing it to shield lipid bilayers from aqueous environments.  Figure adapted from [202]. 
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Figure 1.15.  Membrane scaffolding protein (MSP) design and structure within nanodiscs.  
MSP1 is the simplest design for MSP, with a hexa-histidine tag separated by a TEV cleavage site 
linker from the N-terminus of MSP.  If an increasing number of 22-amino acid amphipathic α-
helical segments are added into the MSP1 sequence to increase its length (MSP1E1-E3), the 
diameter of the nanodiscs formed is increased.  Two copies of the MSP act as belts, one above 
the other, encircling the circumference of the discoidal lipid bilayer to form a nanodisc particle 
(inset). 
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Chapter 2 
 
Materials and Methods 
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2.1. Materials 
Chemicals were obtained from Sigma Aldrich (St. Louis, MO) or Thermo Fisher 
Scientific, Inc. (Pittsburg, PA).  All lipids were purchased from Avanti Polar Lipids (Alabaster, 
AL) as stocks in chloroform.  Fluorescent probes, 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-
s-indacene-3-propionic acid (BODIPY-FL); 6-((4,4-difluoro-1,3-dimethyl-5-(4-methoxyphenyl)-
4-bora-3a,4a-diaza-s-indacene-2-propionyl)amino)hexanoic acid (BODIPY-TMR); 1,6-diphenyl-
1,3,5-hexatriene (DPH); 6-dodecanoyl-2-dimethylaminonaphthalene (Laurdan); and 7-nitrobenz-
2-oxa-1,3-diazole (NBD) were obtained from Molecular Probes, Inc. (Eugene, OR).   
 
2.2 Methods 
2.2.1. Mitochondria Solubilization  
Mitochondria isolated from Saccharomyces cerevisiae (strain D273-10B) as previously 
described [241] were solubilized in buffer (50 mM potassium phosphate [pH 7.4], 50 mM KCl) 
with DDM at a final detergent : mitochondrial protein ratio of 1.5g : 1.0g (~3% [w/v] DDM). 
Mitochondria were incubated at RT for 25 min and then subjected to a clarifying centrifugation 
step to remove non-solubilized membranes. Supernatant containing solubilized mitochondrial IM 
proteins was taken for use in Nanodisc (ND) assemblies. 
2.2.2. Lipid Preparation 
Lipid stocks (DMPC or POPC), POPC/POPE lipid mix (50:50 mol%; 70:30 mol%), 
POPC/POPE/DMPC (40:40:20 mol%), POPC/POPE/POPG lipid mix (40:40:20 mol%), 
biomimetic lipid mix (POPC, POPE, and CL in 40:40:20 mol%), or CL-derivative lipid mix 
(POPC, POPE, and dTOCL or MLCL in 40:40:20 mol%) in chloroform were dried under a N2 
stream and desiccated under vacuum overnight to remove all traces of organic solvent, as 
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described [230]. For use in liposome preparation, lipid was reconstituted in Hydration Buffer (10 
mM Tris-HCl [pH 7.5], 100 mM NaCl) at RT (above Tm) and allowed to sit with intermittent 
vortexing for approximately 15 min at RT.  For pH-alteration experiments Glycine Hydration 
Buffer (50 mM Glycine [pH 3.0 or pH 9.0], 100 mM NaCl) was used in place of Hydration 
Buffer; for membrane subunit assembly experiments, Hydration Buffer with 2 mM MgCl2 was 
used.  Lipids were then extruded through either 0.1 µm or 0.4 µm membranes 17 times to form 
small or large unilamellar vesicles (SUVs or LUVs), respectively.  For use in nanodisc 
preparations, lipid was reconstituted in MSP buffer (20 mM Tris-HCl [pH 7.4], 100 mM NaCl, 
0.5 mM EDTA) with 59 mM sodium cholate and bath sonicated until all lipid was completely in 
solution. 
2.2.3. In vitro Translation System 
Wheat germ system master mixes utilized for in vitro translations of Complex II 
membrane subunits were assembled as in [242].  Co-translational incorporation of the membrane 
subunits into liposomes (100 nm, SUVs) was completed by adding 0.25 mg SUVs with and 
without CL to the wheat germ translation mixes.  Briefly, translation buffer (20 mM HEPES [pH 
7.5], 100 mM potassium acetate, 3 mM magnesium acetate), 1 mM DTT, 200 mM spermidine, 8 
mM S-adenosyl-methionine, protease inhibitor cocktail, RNase inhibitor, amino acid mixtures, 
wheat germ, and appropriate mRNA were incubated at RT for 40 min.  To radioactively label the 
membrane subunits, 35S-Methionine (0.0788 µCi) was added to the master mix and an amino 
acid mixture lacking methionine was used. 
2.2.4. Nanodisc Assembly 
Membrane Scaffolding Protein (MSP1E3D1) was synthesized and purified as described 
[223]. Lipid, MSP1E3D1 (in lipid: MSP1E3D1 ratios of 122:1 [DMPC], 108:1 [POPC], 140:1 
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[POPC/POPE], 143:1 [POPC/POPE/POPG], and 143:1 [biomimetic]), DDM-solubilized 
mitochondria, and MSP buffer ([cholate]=14.8 mM) were incubated at RT for 30 min. Pre-
hydrated Bio-Beads SM Hydrophobic Interaction Adsorbent (Bio-Rad Laboratories, Inc., 
Hercules, CA) were added and rotated for 2 hrs at RT to remove detergent and allow ND self-
assembly to proceed. Following bead removal and incubation with Ni-NTA agarose, samples 
were subjected to step gradients of MSP buffer and imidazole (up to 400 mM) to isolate NDs 
with His-tagged MSP. The first two elution samples were combined (E*), dialyzed into MSP 
buffer to remove imidazole and concentrated in Centricon 3000 MWCO tubes in an Eppendorf 
Centrifuge 5804R. 
2.2.5. SDS-PAGE and Immunoblot Analysis 
12.5% or 15% SDS-PAGE gels in a Bio-Rad Mini-PROTEAN® system were run at 150 
V for approximately 1 hour.  To detect the presence of FAD, NBD, or BODIPY, gels were 
scanned on a Bio-Rad Pharos FX Plus Molecular Imager with External Lasers using Quantity 
One software (version 4.6.9) under the FITC fluorescent setting (488 nm laser, 530 nm emission 
filter). For these gels, the high MW band represents Sdh1p-FAD and the lower-migrating bands 
represent unrelated mitochondrial flavoproteins [104].  The presence of FAD was considered an 
indicator for the presence of the catalytic dimer [157].  The same gel was subsequently stained 
with Coomassie blue.  
Immunoblots were conducted with primary antibodies against Sdh1p (αSdh1p, a 
generous gift of Dr. Bernard Lemire) and Sdh3p (αSdh3p, custom made, Pacific Immunology) 
with Amersham ECL Plex Cy5-conjugated secondary antibody. Blots were scanned on the Bio-
Rad Imager under the Cy5 fluorescent setting (635 nm laser, 695 nm emission filter).  To detect 
radioactively-labeled Complex II membrane subunits, the gels were first incubated in destain 
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(50% (v/v) methanol and 10% (v/v) acetic acid) twice for 5 min each, incubated once in dH2O 
for 10 min, and dried onto filter paper in a Bio-Rad Model 583 Gel Dryer for 40 min.  The dried 
gel was placed in a Bio-Rad Exposure Cassette-K under a General Purpose Kodak Storage 
Phosphor Screen overnight and scanned on the Bio-Rad Imager under the Radioisotopes- K-
screen setting (532 nm laser, 390 nm emission filter, low sample intensity). 
2.2.6. Fluorescence Specifications 
Steady-state fluorescence measurements were completed in a Spex Fluorolog 3-22 
photon counting spectrofluorometer (HORIBA Jobin Yvon) equipped with photon-counting 
electronics, double-grating excitation and emission monochromators, and a 450-W xenon lamp 
using the FluorEssence software program.  All measurements were completed at RT in quartz 
microcuvettes.  In all cases, fluorescent samples were measured in parallel with blank samples 
(lacking the dye but otherwise identical to the fluorescent sample) used to obtain the emission 
originating from the probe by subtraction. 
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Chapter 3 
 
The Stability and Activity of Respiratory Complex II is Cardiolipin-
Dependent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derived from: Schwall C.T., Greenwood V.L., and Alder N.N.,  The stability and activity of 
respiratory Complex II is cardiolipin-dependent, Biochimica et Biophysica Acta: Bioenergetics, 
1817 (2012), 1588-1596. 
58 
 
3.1. Abstract 
 Respiratory Complex II of the mitochondrial inner membrane serves as a link between 
the tricarboxylic acid (TCA) cycle and the electron transport chain (ETC). Complex II 
dysfunction has been implicated in a wide range of heritable mitochondrial diseases, including 
cancer, by a mechanism that likely involves the production of reactive oxygen species (ROS). 
Many studies have focused on the effects of individual SDH mutations; however, the potential 
role that lipids may play in Complex II activity is unknown. To address this issue, we have 
reconstituted Complex II into nanoscale model membrane particles, termed nanodiscs (NDs), 
with defined lipid compositions.  In the present report, we demonstrate for the first time that a 
native-like IM lipid composition, specifically the presence of cardiolipin, is critical for the 
optimal stability and enzymatic activity of the complex, as well as in the curtailment of ROS 
production. 
 
3.2. Materials and Methods 
For Materials, Mitochondria Solubilization, Lipid Preparation, Nanodisc Assembly, and 
SDS-PAGE and Immunoblot Analysis details, please see Chapter 2.  
3.2.1. Size Exclusion Chromatography 
A GE Healthcare ÄKTApurifier system with a Superdex 200 10/300 GL column was 
used for gel filtration chromatography, monitoring absorbance at 280 nm. The following 
standards with previously reported Stokes diameters [243] were used to calibrate the column: 
blue dextran (8.3 mL), β-amylase (12.2 mL, 7.4 nm), alcohol dehydrogenase (13.5 mL), BSA 
(14.3 mL, 6.58 nm), carbonic anhydrase (16.7 mL, 4.0 nm) and cytochrome c (18.1 mL, 3.76 
nm).  
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3.2.2. Electron Microscopy 
ND samples containing a biomimetic blend of lipids only (empty) and those containing 
mitochondrial membrane proteins (loaded) were imaged by negative staining (uranyl acetate) 
transmission electron microscopy after 100X dilution in ddH2O. Images were collected at 
180,000X magnification on a Tecnai Biotwin G2 Spirit transmission electron microscope.  
3.2.3. Complex II Activity Assays (Figure 3.1) 
Assays were conducted as previously described [66] on an Amersham Biosciences 
Ultrospec 2100 pro UV/Vis Spectrophotometer in 1 cm quartz cuvettes following the extinction 
of DCPIP absorbance (ε600 = 20.7 mM
-1cm-1).  Intact mitochondria were isolated as described 
[241] from S. cerevisiae wild type strain (D273-10B) or from S. cerevisiae deletion mutant YKO 
strain Δcrd1 (Open Biosystems), which lacks the cardiolipin synthase gene CRD1. 
3.2.3.1. Succinate Dehydrogenase (SDH) Activity (PMS-mediated) 
Master mix (50 mM Tris [pH 7.5], 5 mM Succinate [pH 7.5], 0.5 mM 
dichlorophenolindophenol [DCPIP], 0.1 mM phenazine methosulfate [PMS]) was added to the 
sample and incubated for 10 min prior to measurements. 
3.2.3.2. Succinate: Quinone Oxidoreductase (SQR) Activity (DB-mediated) 
Samples were pre-incubated with 10 µM decylubiquinone (DB) before adding master 
mix (50 mM KPO4 [pH 7.5], 1 mM EDTA, 62 µM DCPIP) and 0 to 20 mM K-Succinate [pH 
7.5] prior to measurements.  Where indicated, samples were pre-incubated with 2.5 mM 
thenoyltrifluoroacetone (TTFA) inhibitor for 5 min prior to DB incubation.  DCPIP reduction 
was monitored over the linear range (30 s for all ND and Table 3.1 values; 20 s for temperature-
sensitivity experiments with intact mitochondria). 
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3.2.4. FAD Quantification 
Analyses were performed with commercially available kits (BioVision, Inc.) following 
manufacturer’s instructions. Briefly, isolated mitochondria and ND samples from each lipid type 
were resuspended in Assay Buffer containing NP-40 detergent (BioVision FAD Assay Kit) and 
centrifuged to remove insoluble material. Samples were then deproteinized by perchloric acid 
precipitation (BioVision Deproteinizing Sample Prep Kit) and the resulting sample was used to 
determine the quantity of FAD. A colorimetric assay was used to determine amount of FAD by 
adding FAD standards or the sample to a mixture of Assay Buffer, the OxiRed Probe, and 
Enzyme Mix from the FAD Assay Kit. Absorbance was read at 570 nm and the reaction was 
linear with time to an absorbance of 1.8. These values were used to determine the FAD content 
of samples utilized for SQR activity assay analysis (represented as µmol DCPIP reduced min-1 
µmol FAD-1). Specific SQR activities for intact mitochondria (Table 3.1) were consistent with 
published values [e.g. 244]. 
3.2.5. ROS Production Assay 
Analyses were performed using the MitoSOX assay kit (Invitrogen Molecular Probes) 
following manufacturer’s instructions. Briefly, ND samples from each lipid type were pre-
incubated with 10 µM DB, mixed with 16 mM K-Succinate and 10 µM MitoSOX reagent and 
incubated for 10 min at RT and added to 10 µg salmon testes DNA. Where indicated, samples 
were pre-incubated with 2.5 mM TTFA for 5 min.  Fluorescence emission spectra were 
measured for each sample pre- and post-DNA addition (λex = 510 nm, λem = 530-630 nm, 1 sec 
integration time, 4 nm slit widths). 
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3.2.6. Data Representation and Statistical Analysis 
SDS-PAGE gels, immunoblot gels, SEC elution profiles, and kinetic analyses are 
representative of at least three independent experiments.  SQR activity is represented as % 
change (compared to Biomimetic ND elution (E*) fractions) in DCPIP absorbance over the 
initial 30 sec time period divided by the initial absorbance.  SDH activity is represented as total 
% change in DCPIP absorbance compared to Biomimetic ND elution (E*) fractions, as with 
SQR activity. Fluorescence values for ROS production are represented as background corrected 
(empty ND samples) intensities that are normalized according to the highest emission intensity 
for that data set and summed to determine the total area under each curve, which were then 
relativized according to the lipid-type of maximum value, POPC. The results presented for the 
cytochrome spectra, kinetic analysis, activity assays, and ROS production assay are shown as 
means ± standard errors of the means (s.e.m.) of at least three independent experiments.  A two-
tailed student T-test (equal variance) was used to determine statistical significance (p ≤ 0.1 or p ≤ 
0.01) for activity assay and ROS production assay measurements.   
 
3.3. Results and Discussion 
3.3.1. Reconstitution of Complex II from Isolated Mitochondria into NDs 
Traditional means of ND reconstitution originate with a single overexpressed membrane 
protein or biomembrane whose protein content consists mostly of a single protein or complex.  In 
this report, we have optimized the procedure for reconstituting the entire complement of 
membrane proteins solubilized from mitochondria into NDs, showing that: (i) a single complex 
(Complex II in this case) could be reconstituted in an active state with sufficient yield to 
accurately measure enzymatic activity among the population of reconstituted proteins, and (ii) 
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the effect of lipids on the assembly and activity of Complex II could be assayed by synthesizing 
NDs with different lipid combinations. 
By this process, detergent-solubilized membrane proteins from mitochondria isolated 
from yeast (S. cerevisiae) were reconstituted into NDs of a defined lipid composition and the 
preparations were isolated by affinity chromatography and exchanged into a buffer compatible 
with our analyses (Figure 3.2A). To recapitulate the native IM, we assembled NDs with a 
biomimetic blend of lipids that included POPC (16:0/18:1), POPE (16:0/18:1) and 18:1 CL in 
molar ratios of 40:40:20, respectively. Based on size exclusion chromatography, empty NDs 
prepared without mitochondrial proteins (Figure 3.2B, black trace) had a Stokes diameter 
consistent with the published value of ~12nm for this MSP [217]. By comparison, NDs 
assembled with mitochondrial membrane proteins were larger and had a broader hydrodynamic 
size distribution (Figure 3.2B, red trace). The reconstitution of membrane proteins into affinity 
column-purified NDs was further confirmed by gel analysis of total protein content (Figure 
3.3A) and characteristic cytochrome absorbance spectra (Figure 3.3B). Transmission electron 
micrographs showed that both empty NDs and those containing membrane proteins yielded 
particles with homogeneous MSP-limited diameters (Figure 3.2C), confirming proper ND 
assembly. 
 To assay for the successful reconstitution of intact Complex II within NDs specifically, 
we conducted gel analysis of all affinity chromatography fractions and found that Complex II 
subunits co-eluted with the scaffolding protein at high imidazole concentrations (Figure 3.2D). 
To confirm that Complex II retention on the column was indeed ND-dependent, we performed 
mock assembly reactions in the absence of MSP and found that Complex II subunits eluted in the 
flow through (Figure 3.4). To confirm that Complex II reconstituted into NDs retained SQR 
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enzymatic activity, we measured the succinate-dependent, decylubiquinone (DB)-mediated 
reduction of dichlorophenolindophenol (DCPIP) for both detergent-solubilized mitochondrial 
membranes and ND preparations (Figure 3.2E). While both preparations showed saturation 
kinetics with comparable Km values, we found that Complex II in NDs had a maximal reaction 
velocity that was ~30 times that of complexes in detergent. We conclude that we have 
reconstituted fully-assembled and catalytically competent Complex II holoenzymes directly from 
mitochondrial membranes into NDs. 
  
3.3.2. CL Promotes Complex II Stability 
 Having optimized the procedures for reconstituting mitochondrial complexes into NDs, 
we had an excellent experimental platform for testing the influence of lipid composition on the 
stability and activity of Complex II. Hence, we performed ND assembly reactions with the 
following phospholipid compositions (Figure 3.5): (i) DMPC (14:0/14:0) only, (ii) POPC 
(16:0/18:1) only, (iii) POPC (16:0/18:1) and POPE (16:0/18:1) in a 50:50 molar ratio and (iv) 
POPC, POPE and CL in a 40:40:20 molar ratio (“biomimetic,” described above). 
To assay the effects of these lipid compositions on Complex II stability, we adapted our 
affinity column purification strategy to test for the association of the Sdh1p/Sdh2p soluble 
catalytic dimer with the Sdh3p/Sdh4p membrane-bound subunits (Figure 3.6). With each of the 
four different lipid compositions, most of the Complex II membrane subunits (based on αSdh3p 
immunoblots) were stably incorporated into NDs (i.e. appearing in the elution fractions, Figure 
3.6, lanes 9-10), and very little appeared free in earlier fractions. In contrast, whereas the soluble 
dimer (based on FAD fluorescence) was stably associated with NDs containing a biomimetic 
lipid composition (Figure 3.6, lanes 9-10), a large percentage of the flavoprotein remained 
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unbound (i.e. appeared in wash steps, Figure 3.6, lanes 3-7) for all other preparations. We 
therefore conclude that the biomimetic lipid composition stabilized the interaction between the 
membrane and soluble subunits. The destabilizing effect was observed when NDs were prepared 
with short chain lipids (DMPC only), with longer chain, monounsaturated lipids (POPC only) 
and with lipid combinations that included non-bilayer (HII phase) preferring lipids in amounts 
consistent with the mitochondrial IM (POPC and POPE). Among our four lipid combinations, 
the ternary biomimetic composition uniquely contained CL; we thus conclude that the presence 
of CL in the bilayer stabilized the interaction between membrane bound subunits and the 
catalytic dimer. 
 
3.3.3. CL is Essential for Optimal Complex II Enzymatic Activity 
 We then measured the catalytic activity of Complex II reconstituted into NDs with the 
same four lipid compositions as above (Figure 3.7). As described, SQR activity, assayed by 
electron transfer from succinate to DCPIP via the ubiquinone (Q) analog DB, requires an intact 
holocomplex; SDH activity, assayed by electron transfer from succinate to DCPIP via the redox 
mediator PMS, requires only a stable catalytic dimer (Figure 3.1). SQR activity time course 
measurements revealed that complexes reconstituted with biomimetic lipids had robust electron 
transport rates from succinate to the membrane-bound electron carrier, whereas the transport 
rates of complexes reconstituted with all other lipid compositions were extremely low (Figure 
3.7A, compare solid blue trace with all other traces). As expected, the negative control sample 
(mock assembly in the absence of MSP) showed no SQR activity (Figure 3.7A, blue dashed 
line).  Notably, the potent inhibitor TTFA, which blocks electron flow by binding at the Q site, 
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reduced our measured rates of catalysis by ~83% (Figure 3.7A, blue dotted line), confirming 
that we were monitoring genuine Complex II SQR activity. 
In addition, we performed a comprehensive analysis of SDH and SQR activities of all 
fractions from the affinity chromatography steps. The relative SQR activities were clearly 
highest in the elution fractions of NDs with the biomimetic lipid composition (Figure 3.7B), 
consistent with our observed requirement of CL to form a stable holocomplex (Figure 3.6). The 
relative SDH activities were highest in the elution fraction for biomimetic samples, but relatively 
higher in earlier fractions for other lipid combinations (Figure 3.7C), consistent with the 
observed dissociation of the catalytic dimer from membrane subunits when CL is lacking 
(Figure 3.6). 
Taken together, the results from Figure 3.6 and Figure 3.7 demonstrate that CL is 
required to stabilize the interaction between the membrane-bound heterodimer and catalytic 
heterodimer of Complex II.  It has been previously shown that the soluble SdhA/B dimer, fully 
active in SDH activity, dissociates from the membrane in the presence of chaotropes and organic 
solvents and more recently that it dissociates during matrix acidification, as would occur during 
apoptosis [131 & references therein]. Our results strongly suggest that CL is required for the 
proper folding and/or interactions of the membrane subunits, which, in turn, may be required to 
form an interactive surface with the Fe-S protein and hence stabilize the complex. These results 
also indicate that the loss of SQR activity that likely occurs with Complex II delipidation during 
mitochondrial solubilization is reversible upon reconstitution with biomimetic lipids. Notably, a 
CL molecule was shown to co-crystallize with the membrane subunits of the homologous 
complex in E. coli [30]. CL was not observed in a homologous structure from porcine [36]; 
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however, the structure did contain two PE molecules, which share non-bilayer propensity with 
CL. 
To further confirm that CL is required to maintain SQR activity, we measured the 
specific activities of ND preparations made with different lipids and isolated by our affinity 
purification procedure (normalized with respect to the concentration of catalytic dimer FAD, 
Table 3.1). Complex II reconstituted into NDs with CL had an approximately 9-fold higher 
specific activity than complexes reconstituted with lipids containing similar acyl chain lengths 
(POPC and POPC/POPE), and an approximately 85-fold higher activity than those in the 
presence of short chain phospholipids (DMPC).  Hence, even when measured on a catalytic 
dimer-specific basis, CL enhances the catalytic efficiency of Complex II.  CL may therefore not 
only stabilize the complex, as described above (Section 3.3.2), but also promote catalysis by 
other mechanisms (see Section 3.4 and Chapter 7).   
We further tested the effects of CL on Complex II activity in organello.  It has been 
reported that although CL is not absolutely required for OXPHOS activity, this lipid does 
enhance OXPHOS efficiency, particularly under unfavorable conditions [164, 177, 245].  For 
example, S. cerevisiae Δcrd1 mutants (lacking the gene encoding cardiolipin synthase, CRD1), 
which have no CL in their mitochondrial membranes, can grow in non-fermentable medium 
[178, 186].  Yet mitochondria from S. cerevisiae Δcrd1 strains show lower OXPHOS activity at 
elevated temperatures [179] and have significant uncoupling (lower ADP/O ratio and higher state 
4 respiration) at high respiration rates [181].  To test for possible effects of CL on Complex II 
catalysis within intact mitochondria, we compared SQR activity for mitochondria isolated from 
wild type and Δcrd1 S. cerevisiae strains at 26°C and at 40°C.  At the lower temperature, wild 
type and Δcrd1 strains had similar rates (0.098 ± 0.0062 and 0.079 ± 0.0069 µmol DCPIP 
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reduced min-1 mg mitochondrial protein-1, respectively).  But at higher temperature, whereas 
SQR activity from the wild type strain did not change appreciably (~2% increase), that of the 
Δcrd1 strain was reduced (~17% decrease).  While these results support a role for CL in the 
maintenance of Complex II stability and/or activity, they also suggest that the absence of CL in 
intact mitochondria has less of an effect on Complex II activity than it does in our reconstituted 
system.  This is likely due to a compensatory increase in the synthesis of other phospholipids 
(phosphatidylglycerol and PE) in Δcrd1 strains, which may partially replace the function of CL 
[158, 159, 180, 186 and see Section 3.3.4]. 
 
3.3.4. Phosphatidylglycerol Partially Assumes the Role of CL in Complex II Activity 
 CL has several properties that may contribute to its role in energy conserving 
membranes: its unique dimeric structure with four acyl chains, its propensity to form non-bilayer 
structures in the presence of divalent cations, and its anionic phosphodiester headgroup.  
Phosphatidylglycerol (PG), like CL, is an anionic phospholipid.  As an immediate biosynthetic 
precursor to CL, PG does not accumulate to a significant extent in the mitochondrial IM.  
However, in S. cerevisiae Δcrd1 null strains, the amount of PG increases to levels similar to that 
of CL in wild type strains [159, 180, 186].  The notion that PG may partially compensate for the 
lack of CL is underscored by inability of strains lacking both PG and CL (with a null mutation in 
PGS1 which encodes PG phosphate synthase) to grow on nonfermentable carbon sources [186, 
246]. 
 Our experimental system allowed us to directly test whether PG could functionally 
replace the role of CL in Complex II structure and function; more specifically, whether the 
anionic headgroup was responsible for maintaining holocomplex stability and/or redox activity.  
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Hence, we prepared samples with lipid mixtures of POPC, POPE, and POPG in molar ratios of 
40:40:20, respectively.  When POPG-containing NDs were subjected to our complex stability 
assay, a large fraction of the Sdh1p was released early in the affinity purification (Figure 3.8A, 
lanes 3-7).  We therefore conclude that, like the other CL-lacking DMPC, POPC, and 
POPC/POPE preparations (Figure 3.6), POPG-containing NDs had a weak interaction between 
the membrane-bound and catalytic subunits.  On the other hand, POPG-containing NDs with 
holocomplexes that remained after purification displayed SQR activity that approached that of 
CL-containing preparations, assayed by time course measurements (Figure 3.8B) and by FAD-
normalized specific activity (Table 3.1).  Hence, while PG does not promote stability of 
Complex II, it does appear to enhance catalysis.  By extension, these results suggest that that 
hydrophobic domain of CL is important for mediating complex subunit interactions, whereas the 
anionic headgroup plays a role in promoting redox activity. 
 
3.3.5. The Phospholipid-Dependence of Complex II ROS Production Rates 
 The production of ROS (primarily O2-) by Complex II can result from a block in the 
redox chain from succinate to Q [131]. Our observation that Complex II reconstituted with 
particular lipid combinations in the absence of CL had negligible SQR activity (Figure 3.7B, E* 
fraction) but robust SDH activity (Figure 3.7C, E* fraction) suggested that in these cases, 
electrons from succinate oxidation may not be efficiently transferred to the Q-binding site and 
may therefore react with O2 to produce O2-. To test this, we measured the succinate-dependent 
production of O2- by Complex II with all lipid combinations in the presence of DB using the 
superoxide-specific reporter MitoSOX Red (Figure 3.9). In the presence of DMPC or POPC 
alone (Figure 3.9, red and yellow bars), Complex II had significantly higher O2- production rates 
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than when reconstituted with biomimetic lipids (Figure 3.9, blue bar), consistent with the 
predicted block of electron flux to the Q-binding site in the former samples. As a control, 
Complex II in biomimetic NDs that were pre-treated with TTFA had 44% higher O2- production 
rates than mock-treated (ethanol only) samples, demonstrating that our monitored ROS 
production was in fact from Complex II.  Interestingly, Complex II in the presence of POPG, 
having measured SQR activities intermediate between biomimetic samples and those lacking CL 
(Figure 3.8B, Table 3.1), appeared to also have intermediate rates of ROS production (Figure 
3.9, orange bar).  Taken together, these results are consistent with the prediction that a reduced 
efficiency of electron transfer from the catalytic dimer to the Q-site may result in excess electron 
leakage.  Notably, however, this inverse relationship between SQR catalytic efficiency and ROS 
production does not hold for Complex II reconstituted with POPC/POPE.  Whereas PE does not 
markedly stabilize the holocomplex (Figure 3.6) or promote SQR activity (Figure 3.7), it does 
appear to lower ROS production rates to levels comparable to CL-containing samples (Figure 
3.9, green bar).  We speculate that this may be related to the non-bilayer (HII) propensity of PE, 
which could be a contributing factor in curtailing Complex II ROS production.  
 
3.4. Brief Conclusions 
 We have presented evidence that CL is essential for the structure and function of 
mitochondrial Complex II by: (i) maintaining the interaction between the catalytic dimer and 
membrane subunits (Figure 3.6), (ii) promoting electron flux from succinate to the Q reduction 
site in the bilayer (Figure 3.7), and (iii) reducing ROS production (Figure 3.9). Our results and 
working model are summarized in Figure 3.10.  We propose that CL may stabilize the 
holocomplex by promoting the proper folding and/or helical packing interactions of the 
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membrane subunits, which may in turn present an interactive site for the Fe-S subunit 
(Sdh2p/SdhB).  Our observation that CL also enhances Complex II catalysis per se (FAD-
normalized SQR activity, Table 3.1) indicates that it may assume a more direct catalytic function 
as it does for other respiratory complexes.  The catalytic Q site of Complex II is formed at the 
interface of the Fe-S subunit and the two membrane subunits, wherein amino acids from each 
subunit contribute to an extensive hydrogen bonding network with the bound ubiquinone [30, 35, 
36, 38, 247].  The results from our analysis suggest that CL may be involved in stabilizing these 
interactions, allowing conformational dynamics required for movement of the ubiquinone into 
the catalytic site, and/or facilitating the proton transfer pathway to the Q-site.  CL forms a 
resonance-stabilized bicyclic structure that is protonated at physiological pH, and may therefore 
act as a proton sink that recruits protons to specific sites within enzymes of energy-transducing 
membranes [40, 146].  In the yeast cytochrome bc1 complex, for example, a single peripheral CL 
molecule is bound between monomers in proximity to the quinone binding site, and this lipid has 
been implicated in the conduction of protons from the bulk solvent to the ubiquinone [149, 160].  
A similar proton antenna function may also concentrate protons at the interfacial region near the 
quinone binding pocket of Complex II, thereby promoting Q protonation.  In this regard, it is 
noteworthy that our POPG-containing preparations showed enhanced SQR activity (Figure 3.8, 
Table 3.1), consistent with the notion that this acidic phospholipid may also serve as an anionic 
proton antenna as it might in the cytochrome b6f complex of thylakoid membranes [139].  More 
recently, the activity of the respiratory complex NarGHI in E. coli was shown to be enhanced by 
a CL molecule that binds in the vicinity of the Q site, likely promoting the correct interaction 
with the menaquinol substrate [145].  
 
71 
 
3.5. Figures and Tables 
 
 
Figure 3.1.  Schematic of Complex II illustrating SDH and SQR activities. In the Complex II 
catalytic cycle in vivo, the metabolite succinate is oxidized to fumarate by the SdhA (Sdh1p) 
flavoprotein. Electrons are then transferred singly through the Fe-S redox centers of SdhB 
(Sdh2p) to the coenzyme Q binding cavity (QP) at the interface of the SdhC/D (Sdh3p/4p) 
membrane subunits and the Fe-S subunit.  At this site, the reduction of ubiquinone (Q) to 
ubiquinol (QH2) via the ubisemiquinone intermediate requires two protons and two electrons 
from the oxidation of succinate. A second distal ubiquinone binding site (QD) may exist on the 
opposing side of the bilayer toward the intermembrane space (not shown).  Note that the heme-b 
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coordinated by the membrane subunits is not depicted in this figure.  Complex II therefore links 
the TCA cycle and the ETC. The catalytic cycle of Complex II can be conceptually divided into 
two experimentally separable stages. The first, succinate dehydrogenase (SDH) activity, occurs 
as the SdhA/B catalytic dimer oxidizes succinate to fumarate and under experimental conditions, 
electrons are transferred to the final acceptor dichlorophenolindophenol (DCPIP) via the redox 
mediator phenazine methosulfate (PMS). Hence, this assay measures succinate oxidase activity 
independently of electron transfer to Q. The second, succinate: ubiquinone oxidoreductase 
(SQR) activity, involves the transfer of electrons that result from succinate oxidation along a 
linear path of redox centers to the Q binding pocket where electrons are transferred to DCPIP via 
the supplied Q analog decylubiquinone (DB). Electron flow of the physiological cycle is 
depicted in black text and arrows. Electron flow under experimental conditions using added 
redox mediators is depicted in red text and dotted arrows. 
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Table 3.1. Specific SQR activity of Complex II. 
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Figure 3.2.  Reconstitution of active Complex II into NDs. (A) Schematic of assembly process 
to produce NDs containing mitochondrial membrane complexes.  Following detergent 
solubilization of mitochondria, membrane complexes are added to a reaction containing 
scaffolding protein (MSP1E3D1) and cholate-solubilized lipids. ND self-assembly occurs 
following the selective removal of detergent with hydrophobic adsorbents, and elution of the 
reaction over a nickel affinity column allows for purification of assembled NDs (which possess 
an N-terminal His tag on MSP1E3D1). (B) Size exclusion fractionation of NDs containing lipid 
only (empty, black trace) and NDs assembled with mitochondrial membrane complexes (loaded, 
dashed red trace). Chromatograms display absorbance at 280 nm (total protein content), and 
were calibrated by molecular mass standards (above). (C) Electron micrographs of empty NDs 
(left panel) and NDs assembled with mitochondrial membrane proteins (right panel) at 180,000X 
magnification. (scale bar = 100 nm). (D) Fractions from Ni-NTA column purification of NDs 
resolved by SDS-PAGE and analyzed as indicated by: (i) Coomassie stain, (ii) in-gel fluorometry 
(to visualize the FAD moiety covalently bound to Sdh1p), and immunoblots with antibodies 
against (iii) Sdh1p (αSdh1p) and (iv) Sdh3p (αSdh3p). Abbreviations are S: supernatant and P: 
pellet from mitochondrial solubilization; FT: column flow through; W1A-W3B: column wash 
steps; E1-E3: column elution steps. Note relative imidazole concentrations depicted above.  (E) 
Michaelis-Menten plots and Eadie-Hofstee diagrams (inset) of SQR activity for (i) DDM-
solubilized mitochondria (Km = 0.10 mM and Vmax = 51.9 µmol DCPIP min-1 µmol FAD-1) and 
(ii) ND-bound Complex II (Km = 0.37 mM and Vmax = 1432.3 µmol DCPIP min-1 µmol FAD-1). 
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Figure 3.3.  Reconstitution of mitochondrial membrane proteins into affinity-purified NDs. 
(A) Coomassie-stained SDS-PAGE gels of purified NDs assembled in the absence (“Empty”) 
and in the presence (“Loaded”) of solubilized mitochondrial membrane proteins.  Both samples 
contained MSP1E3D1 (dominant band at ~32 kDa). The successful encapsulation of 
mitochondrial membrane proteins and complexes is shown by the appearance of many additional 
proteins in the “loaded” samples that are not present in the empty NDs. (B) Visible absorbance 
spectra of loaded NDs to support assembly with heme-rich mitochondrial proteins in the air-
oxidized (black line) and dithionite-reduced (dashed red line) states. Upon reduction, there is a 
characteristic red shift in the absorbance maximum of the Soret region (γ band) from ~412 nm to 
~430 nm. The dithionite-dependent appearances of β and α bands were not easily resolvable in 
these ND preparations. 
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Figure 3.4.  Negative control assembly reaction performed in the absence of scaffolding 
protein MSP1E3D1. Samples were prepared with solubilized mitochondrial complexes but in 
the absence of scaffolding protein and nickel affinity column fractions were analyzed exactly as 
described (see Figure 3.2D) by FAD fluorescence and immunoblot against Sdh3p (αSdh3p).   
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Figure 3.5.  Different phospholipids used for ND assembly in this study to test the 
dependence of Complex II stability and activity on lipid composition. Images were derived 
from the structure database from the LIPID MAPS Consortium website 
(http://www.lipidmaps.org). 
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Figure 3.6.  The stability of Complex II is dependent on lipid composition.  Membrane 
proteins from DDM-solubilized mitochondria were reconstituted into NDs with the indicated 
lipid compositions and subjected to affinity chromatography to isolate the NDs. Subunits co-
eluting with MSP1E3D1 (fractions E1 and E2) were considered to be stably associated with the 
NDs; those eluting at the earlier fractions were not stably associated. The fluorescent FAD signal 
was used as the marker for the soluble dimer and immunodetection with antiserum against Sdh3p 
(αSdh3p) was used as the marker for the membrane dimer. Column fraction designations are 
identical to those in Figure 3.2D, except supernatant and pellet lanes are not present. 
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Figure 3.7.  Enzymatic activity of Complex II reconstituted into NDs of different lipid 
composition.  Assays were designed to monitor SQR activity (mediated by DB) or SDH activity 
(mediated by PMS), in both cases quantified colorimetrically as the extinction of DCPIP 
absorbance. (A) Signal-averaged time course traces of SQR activity for Complex II reconstituted 
in NDs containing DMPC only (red), POPC only (yellow), POPC with POPE (green), 
biomimetic lipids (blue), biomimetic lipids treated with TTFA (blue dotted), and prepared with 
biomimetic lipids but without MSP1E3D1 (blue dashed). (B) Relative SQR activity of column 
fractions for ND samples with the indicated lipid composition, determined from the initial 
reaction velocity (30 s following succinate addition). (C) Relative SDH activity of column 
fractions for ND samples with the indicated lipid compositions.  For both panels B and C, E* 
represents fractions E1 and E2, which were pooled, and statistical differences are represented in 
relation to biomimetic NDs (* = p ≤ 0.1; ** = p ≤ 0.01).   
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Figure 3.8.  Stability and enzymatic activity of Complex II reconstituted into NDs with 
POPG.  (A) Elution profiles of NDs assembled with POPG replacing the CL present in 
biomimetic samples.  Preparation of samples and column fraction designations are identical to 
those in Figure 3.6.  (B) Signal-averaged time course traces of SQR activity for Complex II 
reconstituted in NDs containing either biomimetic lipids with CL (blue) or biomimetic-like lipids 
with POPG replacing the CL (dashed orange). 
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Figure 3.9.  ROS formation as determined by MitoSOX fluorescence analysis. Statistical 
significance identical to Figure 3.7C, but statistics are represented in relation to biomimetic and 
POPC/POPE NDs. 
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Figure 3.10.  Working model for the role of CL in the stability and catalytic activity of 
Complex II.  In the presence of CL (left panel), the holocomplex is fully assembled and efficient 
in SQR activity. In the absence of CL (right panel), the soluble catalytic heterodimer is not as 
stably associated with the membrane heterodimer, promoting the transfer of succinate-derived 
electrons to O2 to form O2-. 
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Chapter 4 
 
Divalent Cation-Dependent Structural Alterations in Cardiolipin-
Containing Biomembranes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derived from Schwall C.T. and Alder N.N., Divalent cation-dependent structural alterations in 
cardiolipin-containing biomembranes, Manuscript in preparation. 
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4.1. Abstract 
 Cardiolipin (CL), a unique phospholipid of the mitochondrial inner membrane (IM), will 
preferentially form curved hexagonal (HII) structures, rather than a linear bilayer, when in 
aqueous dispersions in the presence of divalent cations. It is important to understand the 
implications that this behavior of CL in solution has on that of CL within native membranes in 
order to determine if induction of localized highly curved structures has implications in the 
disease states to which CL deletion and dysfunction have been linked.  The goal of the present 
work is to study the behavior of CL-containing membranes at the levels of both headgroup and 
acyl chains in the presence of the divalent cations magnesium (Mg2+) and calcium (Ca2+).  Here, 
we use fluorescent probes, Laurdan and DPH, which localize to different bilayer regions in order 
to gain a better understanding of the interaction between CL and divalent cations within IM-
mimicking liposomes (large unilamellar vesicles, LUVs).  We show that divalent cations induce 
more ordered packing in the interfacial region when interacting with CL, whereas headgroup 
variants of this lipid show no such interaction. 
 
4.2. Materials and Methods 
For Materials, Lipid Preparation, and Fluorescence Specifications, please see Chapter 2. 
4.2.1. Large Unilamellar Vesicle (LUV) Preparation 
LUVs were synthesized as described in Chapter 2.  For fluorescence measurements, the 
fluorescent probes were added to the initial lipid mixes at a ratio of 200:1 (lipid: fluorophore).  
LUVs were subjected to size-exclusion chromatography on a Sephadex G-50 column to separate 
LUVs from excess unincorporated fluorescent probe.  Fractions with assembled LUVs were 
identified by detecting a peak absorbance due to light scattering of the LUVs at approximately 
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260 nm [248, 249] on an Amersham Bioscience Ultrospec 2100 pro UV/Vis Spectrophotometer 
and subsequently pooled and stored at 4°C until utilized in further analyses. 
4.2.2. Fluorescence Measurements 
Measurements were completed as described in Chapter 2 with a final lipid concentration 
of approximately 500 µM.  Divalent cations were titrated from stock solutions of either MgCl2 or 
CaCl2 (in ddH2O) to the final concentrations specified (between 0 and 20 mM; 0:1 and 10:1 
cation: lipid ratio). 
4.2.2.1. Laurdan Generalized Polarization 
Laurdan, 6-dodecanoyl-2-dimethylaminonaphthalene, is an environment-sensitive probe 
whose fluorescent naphthalene moiety embeds within the interfacial region of the membrane 
near the glycerol base of the phospholipid headgroups; it has been shown to incorporate into the 
membrane without perturbing the native lipid packing [250-253].  It has previously been used to 
study thermotropic phase transitions and the impacts of cholesterol and membrane-interacting 
proteins on phospholipid bilayers [254-256].  
Excitation wavelength was set at 340 nm and emission was monitored from 410 to 510 
nm (2 nm slit widths).  As Laurdan is an environment sensitive probe whose fluorescent moiety 
localizes to the interfacial region of the bilayer, shifts in the emission spectrum of Laurdan are 
indicative of polarity (or hydration) changes in the bilayer near the headgroup.  The generalized 
polarization (GP) of Laurdan, GP = (I440-I490)/(I440+I490), quantifies these shifts wherein a GP 
value closer to 1.0 (or closer to 0.2, the highest value determined during the current experiments) 
indicates a lower polarity and less hydration of the probe (I440 and I490 are the emission intensities 
at 440 and 490 nm, respectively).  In these experiments, GP measurements reflect at minimum 
two separate liposome preparations of at least four sets of measurements each. 
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4.2.2.2. DPH Anisotropy 
DPH, 1,6-diphenyl-1,3,5-hexatriene, is a rod-shaped molecule that inserts into the bilayer 
parallel to the phospholipid acyl chains [257, 258].  By monitoring its anisotropy or polarization, 
it is possible to gain an understanding of membrane packing at the level of acyl chains within the 
bilayer [259, 260]. 
Excitation wavelength was set at 360 nm and emission wavelength was set at 430 nm (2 
nm excitation and emission slit widths).  DPH localizes to the hydrophobic core region of the 
bilayer and changes in its rotational movement (measured as fluorescence anisotropy) within the 
bilayer are indicative of the packing or lateral diffusion of the phospholipid acyl chains.  The 
anisotropy (r) of DPH was determined as r = (IVV-GIVH)/(IVV+2GIVH), where subscripts denote 
orientation of the polarizers (i.e. VV indicates that both the excitation and emission polarizers are 
oriented vertically to the incident light), I is the intensity of emission, and G is the correction 
factor for the fluorometer determined as G = IHV/IHH.  In these experiments, anisotropy 
measurements reflect at minimum two separate liposome preparations of at least six sets of 
measurements each with individual sample data collected three sequential times to account for 
minor variation in anisotropy readings due to instrument variability. 
4.2.3. Zeta Potential 
 Measurements of zeta potential represent the surface charge density slightly above the 
membrane interface [169]. Here, zeta potential values were calculated from electrophoretic 
mobilities based on the Smoluchowski relationship using a ZetaPlus Zeta Potential Analyzer 
(Brookhaven Instruments Corp., Holtsville, NY).  LUVs at 1 mg/ mL (approximately 1 mM) and 
pH 7.5 were titrated with MgCl2 or CaCl2 (Hydration Buffer [pH 7.5]) at 25°C to obtain identical 
cation: lipid molar ratios identical to the fluorescence-based experiments, which ranged from 0:1 
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to 10:1 cation: lipid.  Each value is an average of six runs of at least three cycles each from two 
separate liposome preparations. 
4.2.4. Turbidity Measurements 
 Solution turbidity measurements were completed on an Amersham Biosciences Ultrospec 
2100 pro UV/Vis Spectrophotometer in 1 cm quartz cuvettes.  Wavelength scans were conducted 
to determine wavelength at which the maximum absorbance of LUVs occurred.  Absorbance 
measurements were then made at a near-maximal wavelength to confirm that addition of calcium 
up to 5 mM did not induce a shift from lamellar to hexagonal phase for LUVs containing CL, 
which was monitored by an increase in absorbance (i.e. turbidity) at 300 nm [172, 261].  Note 
that parallel measurements with the addition of water were completed to account for dilution 
effects. 
4.2.5. Transmission Electron Microscopy 
 Samples of each LUV type were imaged by negative staining (uranyl acetate) 
transmission electron microscopy after 20x or 40x dilution in Hydration Buffer.  Images were 
collected at 23,000x magnification on a Tecnai Biotwin G2 Spirit electron microscope at the 
University of Connecticut Electron Microscopy Facility. 
4.2.6. Data Representation and Statistical Analysis 
 All generalized polarizations and anisotropy measurements are representative of at least 
two independent samples, each measured at least four separate times.  Zeta potential values and 
absorbance measurements are representative of two independent samples, each measured at least 
three separate times.  Values displayed for Mg2+ and Ca2+ additions are corrected for effects due 
to buffer addition/dilution.  All values are displayed as means ± standard errors of the means 
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(s.e.m.).  A two-tailed student T-test (equal variance) was used to determine statistical 
significance (p ≤ 0.05). 
 
4.3. Results and Discussion 
4.3.1. Ordering of LUVs in the Absence of Divalent Cations 
As CL is uniquely found in energy-conserving membranes, we modeled our bilayer 
LUVs on the mitochondrial IM; any changes to the lipid mixtures were made as substitutions for 
TOCL (CL with four 18:1 acyl chains).  For example, our IM mimetic LUVs consisted of 
phosphatidylcholine (POPC), phosphatidylethanolamine (POPE), and tetraoleoylcardiolipin 
(TOCL) in a 40:40:20 mol% ratio and the addition of deoxy-CL (dTOCL), monolyso-CL 
(MLCL), or phosphatidylglycerol (POPG) to the membrane occurred as a replacement of TOCL 
(note that dTOCL and MLCL also contain only 18:1 acyl chains).  Deoxy-TOCL, MLCL, and 
POPG were used to investigate the effects of the cations on different physiochemical features of 
CL.  Deoxy-TOCL lacks the hydroxyl group on the central glycerol moiety of the headgroup, 
breaking the proposed resonance between headgroups within a CL molecule, which would 
effectively cause the molecule to have two separate negative charges at physiological pH, as 
compared to TOCL, which is hypothesized to contain a single negative charge at neutral pH due 
to the resonance-stabilized headgroup structure (Figure 4.1, [146]).  MLCL lacks a single acyl 
chain, leaving only three acyl chains attached to the CL double headgroup.  It has been theorized 
that the missing acyl chain causes a shift in the headgroup structure of CL, breaking the 
resonance between the two phosphates as well (Figure 4.1, [150]).  POPG is the native 
biosynthetic precursor of CL that also contains a mono-anionic headgroup, but only two acyl 
chains.  In addition, we confirmed that these lipid combinations formed LUVs (as compared to 
92 
 
micelles or other non-bilayer structures) by conducting transmission electron microscopy 
imaging of all LUV samples (Figure 4.2). 
 While previous studies concerning the large-scale effect of cations on CL have revealed 
that cations can induce CL to take on a highly curved reverse-micellar structure that can induce 
membrane fusion [172, 173], we were interested in dissecting the effect of increasing 
concentrations of different divalent cations within the headgroup and hydrophobic core regions 
of stable CL-containing membranes.  In order to do this we utilized the fluorescent probes 
Laurdan and DPH, which have been used extensively to study membrane packing and interfacial 
hydration in various membrane types and under different environmental conditions [252, 254, 
257, 259].  When used in parallel, the probes yield a comprehensive readout of the physical state 
of a bilayer because Laurdan is sensitive to the presence of water in the interfacial region of the 
bilayer and reports on lipid headgroup hydration, whereas DPH is used to monitor the rigidity of 
the hydrophobic acyl chain region at the core of the membrane [169].  As an example, a previous 
study utilized both probes to look at the influence of pH on the ordering of CL-containing 
membranes, finding that low pH decreased membrane surface charge and that addition of CL to 
the membrane was necessary to form IM cristae-like morphology [169]. 
 Upon beginning our studies, we observed that among all of the LUV types, those 
containing the anionic phospholipids TOCL, dTOCL, MLCL, or POPG had lower GP values 
than the LUVs containing the zwitterionic POPC and POPE only (Table 4.1).  The results may 
be interpreted as the charge repulsion between the anionic phospholipids forcing more space 
between headgroups of the membrane, allowing more water molecules into the interfacial region.  
As explained earlier, this was reflected in the observed lowering of GP values of Laurdan for 
these LUVs as compared to the POPC/POPE LUVs without anionic phospholipids present.  
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These results are further supported by measurements of the zeta potential for each LUV sample 
in the absence of cations (Table 4.1): all LUVs containing anionic phospholipids have a more 
negative zeta potential value as compared to POPC/POPE only LUVs.  The larger negative 
values support that liposomes containing anionic phospholipids are more stable particles and less 
likely to aggregate as compared to those containing only the zwitterionic POPC/POPE lipids.  
These results are also in line with previous molecular dynamics work that showed that as the 
amount of CL within a membrane increased, there was an increase in the hydration level of the 
interfacial region, probably due to the larger spaces maintained between the smaller, repulsive 
anionic CL headgroups [262]. 
 In addition, MLCL-containing LUVs have significantly lower DPH anisotropy values as 
compared to all other LUVs when divalent cations are not present (Table 4.2).  This supports 
that when MLCL is the only anionic lipid in the membrane, there is a higher rotational mobility 
of DPH due to an increase in the lateral mobility of the bilayer hydrophobic core.  This makes 
sense because with only three acyl chains, instead of the typical four, there may be a higher 
degree of thermal disorder within the nonpolar core, allowing DPH more rotational mobility.  On 
the other hand, POPG- and dTOCL-containing LUVs displayed higher anisotropy values 
comparable to POPC/POPE only LUVs, whereas TOCL-containing LUVs displayed anisotropy 
values midway between these two extremes.  The higher DPH anisotropy values of POPG-
containing LUVs may be explained by the fact that POPG has only two acyl chains per 
headgroup that may be able to pack closely with the identical acyl chains of POPC and POPE, as 
compared to the four unsaturated acyl chains of TOCL.  The higher anisotropy values for 
dTOCL-containing LUVs may be explained when one considers that dTOCL theoretically 
cannot form the resonance-stabilized bicyclic headgroup structure that TOCL maintains at 
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physiological pH and contains two anionic charges (one on each phosphate of the headgroup).  
Without this rigidifying structure, which could otherwise hold the CL acyl chains in register, the 
acyl chains of dTOCL may be “off-balance,” thereby shifting the placement of the unsaturation 
point of the acyl chains in the depth of the bilayer allowing closer packing of the acyl chains of 
dTOCL with those of POPC and POPE [150].  Alternatively, electrostatic repulsion between the 
two anionic phosphates may widen the diameter of the headgroup causing dTOCL to adapt a 
cylindrical, rather than wedge-shaped (as for TOCL), molecular geometry.  In this way, its acyl 
chains may be more aligned with the cylindrical POPC within the lamellar bilayer. 
 
4.3.2. Effect of Divalent Cations on LUVs- Interfacial Region 
 After considering native (in the absence of divalent cations) hydration and packing levels 
of the IM-mimicking LUVs, we treated these LUVs with increasing concentrations of Mg2+ or 
Ca2+ to determine the effect of divalent cations on Laurdan GP values.  Note that turbidity 
measurements (Absorbance at 300 nm) were made to confirm that titration of cations was not 
inducing lamellar to hexagonal-like phase shifts (Figure 4.3).  Titration of Mg2+ or Ca2+ into 
POPC/POPE LUVs did not cause any noticeable or significant change in GP values, which is not 
unexpected as there are no anionic phospholipids with which the cations could interact (Figures 
4.4 and 4.5, red line). 
On the other hand, addition of either cation to TOCL-, dTOCL-, MLCL-, or POPG-
containing LUVs caused an increase in the GP of Laurdan (Figures 4.4 and 4.5, yellow line, blue 
line, purple line, or green line, respectively).  Interestingly, the decrease in headgroup hydration, 
which was reflected in the increase in GP, occurred at the 1.0 mM addition of Mg2+ or Ca2+ (2:1 
cation: lipid molar ratio) for TOCL-containing LUVs, but occurred later in the titration at higher 
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cation: lipid ratios for dTOCL- and MLCL-containing LUVs.  Also, the seeming increase in 
POPG-containing LUVs was not statistically significant, indicating that the slight divalent 
cation-induced increase in packing at the interfacial region was not as pronounced as compared 
to the CL-containing LUVs.   Further, a previous study using submicrosecond molecular 
dynamics simulations of POPG bilayers supported that increases in ordering and tightening of 
these bilayers can occur only when an excess of Ca2+ ions were added to the bilayers and not 
when a 1:1 ratio, which they term “counterions,” of lipid-to-cation was present [263].  This may 
give an indication as to why POPG-containing LUVs did not display larger changes in response 
to divalent cations even though a phospholipid with an anionic headgroup that can interact with 
cations was present. 
The zeta potential analysis of divalent cation titrations is consistent with the Laurdan-
based approach.  POPC/POPE LUVs did not display any detectable change in the zeta potential 
values as either Mg2+ or Ca2+ was titrated into the solution (Figures 4.6 and 4.7).  In addition, 
any bilayer containing anionic phospholipids showed a cation-dependent increase in the zeta 
potential values from strongly negative to almost neutral.  Titrations with both cations induced 
very strong increases in zeta potential values at the 1:1 cation: lipid ratio, but as the titration 
continued this effect seemed to decrease.  This was especially true for titrations with Mg2+, as it 
seemed that there was still a slight increase as Ca2+ was titrated in at higher cation: lipid ratios.  
While there was no distinct effect of cations on individual LUV types containing various anionic 
phospholipids, the lack of distinct differences could indicate that the packing changes occurring 
in the interfacial region of the bilayers were not due to localized changes in charge surrounding 
the anionic LUVs.  There may be a more specific interaction occurring, such as the displacement 
of water ions for cations or differences in the number of cations binding per anionic headgroup 
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(1 Ca2+ per 2 TOCL as compared to 1 Ca2+ per 1 dTOCL), that varies according to the charge 
localization across the headgroup. 
In order to probe the mechanism behind the specific packing differences among anionic 
LUVs, TOCL-containing LUVs were formed and purified in Glycine Hydration Buffer (pH 9.0).  
As explained previously, it is theorized that CL has two pKas due to the resonance effect across 
the hydroxyl moiety in the glycerol headgroup, one below pH 4.0 and one above pH 8.0.  When 
the pH is raised to 9.0, there should be two negative charges on the TOCL headgroup, mimicking 
the hypothesized state of the headgroup of dTOCL.  When the cations were titrated into TOCL-
containing LUVs at pH 9.0, the trend effectively matched that seen with the dTOCL-containing 
LUVs (Figure 4.8, compare light green and blue lines, respectively), supporting that the higher 
cation concentrations needed to induce changes within the dTOCL-containing membranes may 
be linked with having two formal charges on each phosphate of the CL headgroup, rather than 
one resonating charge.  This can be explained by the idea that a single Ca2+ ion can interact with 
two TOCL molecules at physiological pH because each has a single negative charge; however, 
dTOCL and TOCL at pH 9.0 have two negative charges that would only allow a single Ca2+ ion 
to interact with one TOCL molecule.  At the same concentration of Ca2+, TOCL lipids would 
become more closely packed than dTOCL or TOCL lipids at pH 9.0.  In addition, even though 
the titration of TOCL-containing LUVs at pH 9.0 closely mimics that of dTOCL-containing 
LUVs, it is not identical, leading us to propose that some TOCL headgroups at pH 9.0 may be 
singly charged (rather than both phosphates being deprotonated), which is possible when 
considering the shifting pKa2 of the TOCL headgroup can extend upwards of pH 9.5 [151]. 
In addition, TOCL-containing LUVs were also assembled and purified in Glycine 
Hydration Buffer (pH 3.0), at a pH below the first pKa of TOCL.  At low pH, the headgroup of 
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TOCL should be neutral and we would expect the TOCL-containing LUVs to behave as those 
containing POPC and POPE only.  The results supported this hypothesis in that TOCL at pH 3.0 
not only had a higher GP as compared to TOCL at pH 7.4 when cations were not present 
(indicating closer packing of the headgroups), but also did not display a change in GP as divalent 
cations were titrated into the sample (Figure 4.8, pink line). 
To investigate the effects of divalent cations on TOCL further, as LUVs containing this 
lipid displayed the most extreme packing alterations as they were added, we titrated divalent 
cations up to 20 mM (40:1 cation: lipid ratio).  Surprisingly, it appeared that there were two 
phase changes of TOCL-containing LUVs when Ca2+ (not Mg2+) was added to the samples: one 
that occurred at lower Ca2+ concentrations that were close to a 2:1 ratio of lipid-to-cation, and 
one of which occurred at higher concentrations, where a large excess of cation as compared to 
lipid was present (Figure 4.9).  The first phase change most likely represents an initial 
dehydration of the interfacial region of the bilayer, as addition of cations to phospholipid bilayers 
has previously been seen to mimic a dehydration event [174].  The lipid headgroups would then 
be able to pack more closely due to the removal of water coupled with a decrease in the charge 
repulsion between TOCL anionic headgroups, which would be shielded by the divalent cations.  
The second phase change is more extreme and could be attributed to a strain within the LUVs as 
TOCL attempts to induce negative curvature into the bilayer.  This would push the headgroups of 
all phospholipids within the membrane closer together, effectively dehydrating the interfacial 
region and greatly increasing the GP of the Laurdan probe.  
In addition, note that this large change in GP of the TOCL-containing LUVs occurred 
when Ca2+ was titrated, but not Mg2+, which runs counter to what we saw at the lower 
concentrations of cations in that both cations had similar effects on GP values.  Using molecular 
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dynamics simulations it has previously been shown that Ca2+ holds onto the water molecules in 
its first solvation shell for only a few picoseconds, as compared to hundreds of picoseconds for 
Mg2+ [264].  It may be that as the Mg2+ ions were more tightly shielded by waters, they were 
unable to induce as strong a change in the ordering of the TOCL bilayer as Ca2+, whose charges 
were not shielded as tightly by its solvation shell.  Once a higher concentration of the less 
shielded Ca2+ cations was introduced into the system, Ca2+ was able to disrupt the bilayer of 
TOCL-containing LUVs and induce HII formation.  In addition, it has previously been shown in 
solutions of pure CL that while both Mg2+ and Ca2+ can induce HII CL structures, at lower 
concentrations of Mg2+  (3 mM) it is more likely that there will be a mix of lamellar and 
hexagonal phases as compared to the induction of a purely hexagonal phase in the presence of 
Ca2+ [174].  All of these results are consistent with previous work supporting that CL has a 
higher affinity for Ca2+ than for Mg2+ [143]. 
Taken together, at the interfacial region of a bilayer, divalent cations are able to induce 
ordering or structural changes in TOCL-, dTOCL-, MLCL-, and POPG-containing LUVs, but 
not in POPC/POPE-containing bilayers.  The increase in GP values, indicative of a more 
dehydrated headgroup region of the bilayer, when Ca2+ was titrated into TOCL-containing LUVs 
most likely reflect induction of large levels of strain into the bilayer, with the lipid headgroups 
becoming much more closely packed.   
 
4.3.3. Effect of Divalent Cations on LUVs- Acyl Chains 
 In addition to looking at the effects of divalent cations at the interfacial region of the 
membrane, which is in direct contact with the cations, we were also interested in any effects on 
packing among the acyl chains composing the hydrophobic core of the membrane.  Unlike our 
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observations in the interfacial region, titration of Mg2+ or Ca2+ to LUVs containing DPH did not 
induce significant effects on any of the bilayers (Table 4.2).  When POPC/POPE LUVs were 
studied, there was no effect of adding in Mg2+ or Ca2+ on the anisotropy of DPH within the 
hydrophobic core of the membrane, which is not unexpected as the headgroup region of these 
LUVs was unaffected as well (Table 4.2).  On the other hand, TOCL-, dTOCL- MLCL-, and 
POPG-containing LUVs also did not display a significant change in anisotropy values as either 
cation was titrated, which was in contrast to what was observed in the interfacial region with 
both the Laurdan and zeta potential measurements (Table 4.2).  
 
4.4. Brief Conclusions 
Overall, these studies have utilized fluorescent probes complemented by other techniques 
to investigate the packing interactions of bilayer lipids, namely those containing CL, in the 
presence of divalent cations, which has implications for the mitochondrial IM and its role in 
apoptosis as Ca2+ is an important signaling molecule in this process.  Monitoring the behavior of 
these probes allowed us to propose that divalent cations were able to induce a stronger structural 
change in ordering and lipid packing in the interfacial region of the membrane as compared to 
the acyl-chain region.  This was due to the cations alleviating charge repulsion between adjacent 
anionic CL headgroups and also forming crosslinks between separate CL molecules, which 
allowed them to move closer together; however, these spatial alterations did not appear to be 
translated further to the acyl chain region of the bilayer.  A previous study focusing on the effects 
of acyl chain unsaturation and lipid type on bilayer ordering also found that changes in packing 
at the headgroup and acyl chain regions of the bilayer may not be consistent and may in fact be 
“structurally uncoupled” [259].  In addition, it has been shown that Ca2+ tends to interact with the 
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bilayer in the interfacial region, the same region that the fluorescent moiety of Laurdan 
intercalates and the region in which we saw the most significant changes in bilayer hydration and 
ordering [265].  Further, the variation in behavior between TOCL and dTOCL, as well as the 
investigation of TOCL-containing LUVs at various pH, supports the hypothesis that at neutral 
pH the TOCL headgroup exists as a singly-charged resonance-stabilized acid anion [148]. 
Further, the variation in behavior of TOCL-, MLCL-, and dTOCL-containing bilayers in 
the presence of divalent cations has implications for the pathogenic mechanisms underlying 
Barth Syndrome (Figure 4.10).  Until very recently, it was believed that the CL remodeling 
pathway, which produces mature CL with symmetric, unsaturated acyl chains from asymmetric 
immature CL with fully saturated acyl chains, was necessary for the proper functioning of 
mitochondria because CL acyl chain specificity was integral to function. However, it has newly 
been shown that it may in fact be the decreased levels of CL and increased levels of MLCL that 
are contributing to mitochondrial dysfunction, rather than the particular acyl chain composition 
of the CL molecules [266].  The results here support that the pathogenesis of Barth Syndrome, 
which is linked to malfunction in CL remodeling, may be related to the decrease in packing 
between phospholipid headgroups and the decrease in lateral mobility of the acyl chains for 
MLCL-containing, as compared to TOCL-containing, bilayers.  This lower packing and 
increased hydration of the bilayer may have detrimental implications for various processes 
occurring at, or within, the mitochondrial IM, leading to the development of the Barth Syndrome 
phenotype. 
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4.5. Figures and Tables 
 
 
Figure 4.1.  Different CL variants used for LUV assembly in this study.  Images were 
derived from the structure database from the LIPID MAPS Consortium website 
(http://www.lipidmaps.org). 
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Figure 4.2. TEM Images of LUVs.  Negative staining transmission electron microscopy images 
were taken of all LUV samples at 23,000X magnification (scale bars = 500 nm). (A) 
POPC/POPE only; (B) TOCL-Containing; (C) POPG-Containing; (D) dTOCL-Containing; (E) 
MLCL-Containing. 
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Table 4.1. Ordering of LUVs in the Absence of Divalent Cations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
 
Table 4.2. Divalent Cations are Unable to Induce Ordering in LUV Acyl Chain Region. 
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Figure 4.3. Turbidity measurements to confirm lamellar LUVs.  Calcium chloride solution 
was added to LUVs of varying lipid composition in order to confirm that addition of the cation 
did not induce a lamellar-to-hexagonal phase transition within our titrations.  Note that a large, 
rapid increase in absorbance at 300 nm (turbidity) indicates a phase transition and this does not 
occur prior to 10:1 calcium: phospholipid molar ratios.  POPC/POPE (red line), TOCL-
containing (yellow line), POPG-containing (green line), dTOCL-containing (blue line), or 
MLCL-containing (purple line). Turbidity measurements were completed as in Section 4.2.4.  
Traces are represented as averages of at minimum two independent experiments of at least three 
measurements each with standard errors of the mean (s.e.m.).  
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Figure 4.4. Calcium induces order of the interfacial region of the bilayer in TOCL-
containing LUVs.  Calcium chloride solution was added to LUVs of varying lipid composition.  
POPC/POPE (red line), TOCL-containing (yellow line), POPG-containing (green line), dTOCL-
containing (blue line), or MLCL-containing (purple line). Generalized polarization values were 
determined as in Section 4.2.2.1.  Traces are represented as averages of at minimum two 
independent experiments of at least four measurements each with standard errors of the mean 
(s.e.m.).  Statistical differences are represented in relation to 0 mM calcium addition (* = p ≤ 
0.05). 
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Figure 4.5.  Magnesium induces order of the interfacial region of the bilayer in TOCL-
containing LUVs.  Magnesium chloride solution was added to LUVs of varying lipid 
composition.  POPC/POPE (red line), TOCL-containing (yellow line), POPG-containing (green 
line), dTOCL-containing (blue line), and MLCL-containing (purple line). Generalized 
polarization values were determined as in Section 4.2.2.1.  Traces are represented as averages of 
at minimum two independent experiments of at least four measurements each with s.e.m.  
Statistical differences are represented in relation to 0 mM magnesium addition (* = p ≤ 0.05). 
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Figure 4.6.  Calcium neutralizes the surface charge of anionic phospholipid-containing 
LUVs.  Calcium chloride solution was added to LUVs of varying lipid composition.  
POPC/POPE (red line), TOCL-containing (yellow line), POPG-containing (green line), dTOCL-
containing (blue line), or MLCL-containing (purple line).  Zeta potential was measured as 
described in Section 4.2.3.  Traces are represented as averages of at minimum two independent 
experiments of at least three measurements each with s.e.m.  Statistical differences are 
represented in relation to 0 mM calcium addition (* = p ≤ 0.05). 
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Figure 4.7. Magnesium neutralizes the surface charge of anionic phospholipid-containing 
LUVs.  Magnesium chloride solution was added to LUVs of varying lipid composition.  
POPC/POPE (red line), TOCL-containing (yellow line), POPG-containing (green line), dTOCL-
containing (blue line), or MLCL-containing (purple line).  Zeta potential was measured as 
described in Section 4.2.3.  Traces are represented as averages of at minimum two independent 
experiments of at least three measurements each with s.e.m.  Statistical differences are 
represented in relation to 0 mM magnesium addition (* = p ≤ 0.05). 
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Figure 4.8.  Analysis of effect of divalent cations on TOCL-containing LUVs at various pH. 
Calcium (A) and magnesium (B) were titrated into the following LUVs: TOCL (pH 3.0) (pink 
line), TOCL (pH 7.4) (yellow line), TOCL (pH 9.0) (light green line), and dTOCL (blue line) for 
comparison.  Generalized polarization values were determined as in Section 4.2.2.1.  Traces are 
represented as averages of at minimum two independent experiments of at least four 
measurements each with s.e.m.  Statistical differences are represented in relation to 0 mM cation 
addition (* = p ≤ 0.05). 
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Figure 4.9. Titration of calcium up to 20 mM (40:1 calcium to lipid ratio).  There is evidence 
for a biphasic effect that may indicate that Ca2+ is able to enhance ordering of membranes 
containing TOCL until there is too much strain on the bilayer and the LUVs burst (as supported 
by turbidity measurements, data not shown), allowing TOCL in solution to enter HII (hexagonal, 
inverted micellar) phase.  Generalized polarization values were determined as in Section 4.2.2.1.  
Traces are represented as averages of at minimum two independent experiments of at least four 
measurements each with s.e.m.  Statistical differences are represented in relation to 0 mM cation 
addition (* = p ≤ 0.05). 
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Figure 4.10. Hypothesized effects of divalent cations on various CL-containing bilayers 
based on present results.  While there is no effect of titrating cations into solutions of 
zwitterionic lipid-containing LUVs (POPC/POPE only), titrating the cations into solutions of 
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LUVs with anionic phospholipids (POPG, TOCL, dTOCL, MLCL) results in dehydration of the 
interfacial region of the bilayers and phospholipids packing more closely together.  In addition, 
LUVs containing different forms of CL (TOCL, dTOCL, MLCL) do not behave identically: 
bilayers containing TOCL- and MLCL-containing LUVs display a more marked effect of cations 
as compared to dTOCL-containing LUVs. 
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Chapter 5 
 
Complex II Membrane Subunit Assembly:  
A Crosslinking-Based Analysis 
 
 
 
 
 
 
 
 
 
 
 
Other authors who have contributed to the studies presented in this chapter are Victoria L. 
Greenwood and Nathan N. Alder.  All coauthors are from the University of Connecticut (Storrs, 
CT 06269, USA). 
115 
 
5.1. Abstract 
 The assembly process of holoenzyme Complex II within the mitochondrial inner 
membrane (IM) is largely unknown and made more complicated by the numerous homologs of 
the Complex II membrane subunits that exist within the membrane.  In bacteria, the flagellar 
switch complex needs to associate with Complex II (SDH) and fumarate reductase (FRD) in 
order for the correct assembly and switching function of the flagella to occur [98].  There are 
also two homologs to Sdh4p found in yeast, Tim18p, an integral IM protein that is part of the 
TIM22 import complex, and YLR164w, a protein with a currently unknown function.  It has 
recently been shown that Sdh3p is able to interact with Tim18p in a way that regulates the 
assembly of the TIM22 complex, supporting the possibility that these proteins may have a larger 
regulatory role within the mitochondrial IM than previously believed [96].  The functions of 
heme and cardiolipin (CL), the signature phospholipid of the IM, in the context of Complex II 
assembly have also been relatively elusive [46, 47, 51, 157, 267].  Further, while mutants of 
Complex II that lead to disease states have been identified, the mechanism underlying their 
pathogenicity is poorly understood.  
 Therefore, it is necessary to investigate the assembly process of Complex II membrane 
subunits and the factors that influence dimer formation.  In order to evaluate the assembly of the 
membrane subunits in isolation, we investigated the interaction among Sdh3p, Sdh4p, Tim18p, 
and YLR164w from S. cerevisiae and SdhC and SdhD from the mammalian Sus scrofa using a 
novel cell-free translation system in the presence of IM-mimicking liposomes (large unilamellar 
vesicles, LUVs).  We explored the influence of homologous partner proteins on the unexpected 
homodimerization of Sdh3p and SdhC and we showed that CL was necessary for membrane 
protein incorporation into liposomes and homodimer formation.  In addition, we found that the 
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presence of heme enhanced the ability of Sdh3p to form a homodimer and that the presence of 
partner proteins Sdh4p and SdhD, as well as their homologs, interrupted homodimer formation, 
likely due to formation of a dynamic heterodimer species.  Lastly, we found evidence that the 
possible mechanism of pathogenicity in a mutant construct of SdhD, Asp 57 Tyr, which has 
previously been identified as leading to dysfunction of Complex II, may be through inhibition of 
native Complex II membrane dimer formation. 
 
5.2. Materials and Methods 
 For Materials, Lipid Preparation, In vitro Translation System, and SDS-PAGE and 
Immunoblot Analysis please see Chapter 2. 
5.2.1. Mutagenesis of SDH3, SDHC, SDHD 
Site-directed mutagenesis by PCR of mature (lacking a pre-sequence) wild type 
constructs of SDH3, SDHC, and SDHD was performed as previously described [51].  For the 
mutagenesis of the heme coordination site in SDH3, complimentary mutagenic primers that flank 
amino acid 106 were designed to change the His residue at this position to an Ala residue, in 
order to remove the heme coordination site (Table 5.1).  Pathogenic mutants of SDHC and 
SDHD were generated by designing complimentary mutagenic primers that flank the following 
amino acid residues (with mutations in parentheses): SDHC Leu 130 (Pro), SDHD Arg 35 (Gly), 
SDHD Pro 46 (Leu), SDHD Asp 57 (Tyr), SDHD Leu 60 (Pro), SDHD His 67 (Leu), SDHD Tyr 
79 (Cys), and SDHD Leu 104 (Pro) (Table 5.1, [36]). 
5.2.2. Sucrose-Floatation Purification  
Translation reactions were brought to 150 µL with hydration buffer, layered on top of a 
15% sucrose cushion (15% w/w sucrose in hydration buffer), and subjected to centrifugation at 
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55K RPM in a Beckman Coulter Optima™ TLX Ultracentrifuge in a TLS-55 swinging bucket 
rotor for 2 hrs at 15°C.  The top (“floated”) 150 µL fractions were removed and used for cofactor 
and crosslinker incubations as the top fraction contains proteins incorporated within floated 
LUVs [203].   
5.2.3. Heme Reconstitution and Incubation  
It has previously been shown that heme can be added to proteins externally and the b-
type cytochrome will be able to form through incorporation and coordination of the heme [268, 
269].  Heme was dissolved in 50% EtOH and 100 µL aliquots of 1 M NaOH were added until 
heme was fully solubilized.  This was diluted 4 times in Dilution Buffer (50 mM Tris-HCl, 50 
mM NaCl, 5 mM TX-100) and absorbance readings were taken at 385 nm on an Amersham 
Biosciences Ultrospec 2100 pro UV/Vis Spectrophotometer in 1 cm quartz cuvettes (ε = 56 mM-
1cm-1 at 385 nm for heme).  Proteoliposome samples were split in half and incubated with 3 µM 
heme or a mock heme solution (that consisted of the same chemical and buffer components as 
heme without the heme cytochrome) at RT for 20 min after sucrose gradient purification. 
5.2.4. Crosslinker Incubation 
Heme- and mock-treated proteoliposomes were split in half and diluted to 200 µL in 
crosslinking buffer (20 mM HEPES pH 7.5, 80 mM KCl, 3 mM MgCl2, 250 mM Sucrose, 2 mM 
KPO4, 3 mM Malate, 3 mM Pyruvate).  Appropriate crosslinker (disuccinimidyl suberate (DSS) 
for primary amino group conjugation or bis(maleimido)hexane (BMH) for sulfhydryl group 
conjugation reconstituted in dimethylsulfoxide (DMSO)) was added to 50 µM or an equivalent 
volume of DMSO was added for control samples and incubated at RT for 30 min.  Samples were 
treated with quencher (40 mM Tris-HCl and 40 mM DTT final concentrations) for 15 min at RT 
to stop the reaction. 
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5.2.5. Data Representation and Statistical Analysis 
 SDS-PAGE gels are representative of at least three independent experiments and 
crosslinking efficiencies are averages of at least three separate SDS-PAGE gels.  Band 
quantification for crosslinking efficiency analysis was completed using Quantity One software.  
Crosslinking efficiency data is represented as a percentage of the band intensity (calculated as a 
relative quantity compared to the intensities of all bands on the gel) of the crosslinked (dimer) 
species (background corrected) compared to the total band intensity of the crosslinked species 
and the non-crosslinked (monomer) translation combined, unless otherwise noted.  A two-tailed 
student T-test (unequal variance) was used to determine statistical significance (p ≤ 0.05). 
 
5.3. Results and Discussion 
The holoenzyme of Complex II is assembled in vivo as a heterodimer of Sdh3p/SdhC and 
Sdh4p/SdhD within the membrane that forms a base with which the soluble catalytic dimer 
Sdh1p/SdhA and Sdh2p/SdhB can then interact (numerals and letters correspond to yeast and 
mammalian nomenclature, respectively).  By utilizing our developed in vitro translation system, 
various constructs of the membrane-bound Complex II subunits were produced and incorporated 
into proteoliposomes in order to study this first stage of holoenzyme formation: membrane 
heterodimer assembly.  In our crosslinking-based approach, proteoliposomes were purified via 
floatation on a sucrose cushion and then treated with appropriate crosslinker.  Two types of 
homobifunctional crosslinkers were applied in this study, disuccinimidyl suberate (DSS), which 
reacts with primary amino groups to link Lys residues, and bis(maleimido)hexane (BMH) that 
crosslinks the sulfhydryl groups of Cys residues.  The reason for using two crosslinkers was that 
Sdh3p does not natively contain Cys residues, therefore DSS was used for studies involving 
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Sdh3p while BMH proved to be more potent crosslinker for SdhC, which does contain multiple 
Cys residues, as do Sdh4p and SdhD.  
 
5.3.1. Sdh3p and SdhC Homodimerize; Sdh4p and SdhD are Unable to Homodimerize 
Unexpectedly, we first found that in the presence of IM-mimicking lipid environments, 
Sdh3p and SdhC favor homodimerization (Figure 5.1A).  The darker bands (open arrows) near 
the bottom of the gel represent the monomeric species of each protein (Sdh3p is 16.7 kDa; SdhC 
is 15 kDa) [36, 46].  It was clear that with crosslinker present, a homodimer species of Sdh3p or 
SdhC was assembled and sustained within the nonpolar environment provided by the liposomes, 
but SdhC seemed to crosslink to a greater extent than Sdh3p (filled arrows).  While at first these 
results were surprising, the homodimerization of Sdh3p and SdhC may act as a regulatory system 
within the mitochondria.  A regulatory role for Sdh3p and SdhC homodimerization is further 
supported by evidence that Sdh4p and SdhD do not form detectable crosslink-stabilized 
homodimers (Figure 5.1B).  However, it is important to note that Sdh4p and SdhD may form 
more dynamic, transient homodimers allowing them to sample the surrounding membrane for a 
heterodimer binding partner.  Unless Sdh3p encounters an Sdh4p native partner protein, 
potentially also requiring the presence of the catalytic dimer subunits Sdh1p and Sdh2p, it will 
homodimerize until the appropriate signals or proteins for holoenzyme Complex II assembly are 
present within the local environment as well. 
 
5.3.2. Sdh3p and SdhC homodimerization is dependent on the presence of lipid 
The homodimerization of Sdh3p and SdhC was a novel and intriguing finding that we 
investigated further to determine the external factors that may influence such dimerization.  First, 
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we wanted to determine the necessity of the lipid environment for this newfound 
homodimerization.  After completing a cell-free translation in the presence of LUVs, which 
provide a mitochondrial IM-mimicking (CL-containing) environment, the reaction was floated 
on a sucrose cushion for purification and the floated fraction was removed and treated with 
appropriate crosslinker (Figure 5.2, “Float.”).  In parallel, an in vitro translation was also 
completed in the absence of LUVs and was then treated with crosslinker (Figure 5.2, “Trans.”).  
It was found that only protein that was incorporated into the liposomes, which is represented by 
the “Floated” lanes, and treated with crosslinker could form homodimers.   
There was evidence of higher molecular weight species in the lanes representing 
translations in the absence of LUVs that were similar in molecular weight to the dimer formed by 
Sdh3p.  It has previously been shown that SDS can have stabilizing effects on the assembly of 
heme-binding transmembrane b-type cytochromes [270], even without the presence of 
crosslinker, and we briefly speculated that these species may represent SDS-stabilized Sdh3p or 
SdhC homodimers that survived electrophoresis.  This hypothesis could be discounted because 
identical higher molecular weight species were present in both Sdh3p and SdhC translations and 
Sdh3p and SdhC are of different molecular weights (16.7 and 15 kDa, respectively).  In addition, 
these species were not of exactly the same mobility as the crosslinked species seen in the floated 
lanes.  Instead, it is likely that the species we observed in the translation-only (in the absence of 
LUVs; Figure 5.2, “Trans.”) lanes are wheat germ proteins from the cell-free translation system 
that were common between the two constructs and were not actually dimers of Sdh3p or SdhC.   
These proteins would not be present in the samples translated in the presence of LUVs and then 
floated on sucrose because excess unincorporated protein aggregates and pellets to the bottom of 
the sucrose gradients (i.e. is removed from the floated fractions).  These results provide evidence 
121 
 
that a native-like lipid environment is necessary in order for the membrane subunits of Complex 
II to interact and form crosslink-stabilized homodimers.   
 
5.3.3. Cardiolipin-dependent homodimerization of Sdh3p and SdhC 
 Next, we wanted to determine if dimerization was dependent on lipid type or if a general 
lipid environment (as represented by the LUVs) was the only requirement.  To study this, we 
made two preparations of liposomes mimicking the IM of the mitochondrion: one containing 
cardiolipin (CL), the signature phospholipid of the energy conserving mitochondrial IM, and the 
other devoid of CL, containing only POPC and POPE, the predominant phospholipids of the IM.  
As shown by us and several other groups, CL is necessary for the correct assembly, activity, and 
stability of mitochondrial IM complexes, such as the ADP/ATP Carrier and Complex II itself 
[163, 189, 271, 272].  Interestingly we found a stark contrast between translations completed in 
the presence and absence of CL (Figure 5.3A).  Whereas Sdh3p and SdhC were able to form 
homodimers when translated in the presence of CL-containing LUVs, remarkably, there was no 
homodimerization detected when these same constructs were translated in the presence of LUVs 
without CL.  The results clearly indicated the need for CL in the homodimerization process of 
Sdh3p and SdhC; without CL, homodimers were unable to be stabilized by crosslinker and likely 
unable to form at all. 
 After establishing that CL is necessary for assembly of the membrane subunits, we 
wanted to determine whether CL enhances insertion of the proteins into the liposome membrane, 
facilitates dimerization once the proteins are already inserted into the membrane, or influences 
both processes.  We compared the intensity of translated protein (either Sdh3p or SdhC) found in 
the top-most floated (incorporated into LUVs, Figure 5.3B “F”) and bottom-most pelleted (non-
122 
 
incorporated protein, Figure 5.3B “P”) fractions of a sucrose cushion when translations were 
completed in both the presence and absence of CL.  We reasoned that if there was an increase in 
intensity of the protein found in the top (floated) fraction with CL present as compared to when it 
was absent and/or a decrease in the intensity of the pelleted fraction with CL-containing LUVs, 
then this would support that CL increases the ability of Sdh3p and SdhC to insert into the 
liposome membranes. As indicated in Figure 5.3B, when comparing the intensity of protein 
contained within the floated fractions (“F”) when CL was present and when it was absent from 
the LUVs, it was clear that CL was required for insertion of Sdh3p and SdhC.   
Also of note was that the translation efficiency in CL-containing and CL-lacking LUVs 
seemed to be consistent (Figure 5.3B, Compare “T” translation lane with and without CL).  
Therefore, the increase in insertion into the liposome membrane was not solely a reflection of 
increased translation efficiency in the presence of CL leading to a higher protein concentration so 
that more protein was inserted, but was instead caused by an increased liposome insertion 
efficiency. 
 
5.3.4. Heme-dependent homodimerization of Sdh3p and SdhC 
In addition to studying the influence of lipid on the homodimerization of Sdh3p and 
SdhC, we studied the impact of heme on dimerization.  Heme is coordinated between the 
heterodimer of the Complex II membrane subunits (Sdh3p and Sdh4p or SdhC and SdhD), but 
the function of the heme is up for debate within the Complex II field (See Chapter 1).  Based on 
a homology model of yeast Complex II, the heme coordination site is comprised of a typical His 
residue on Sdh3p, whereas the proximal His position of Sdh4p is replaced by a Tyr residue [37].  
Therefore, it has been postulated that Sdh4p coordinates the heme with a nearby Cys residue, 
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which has not been observed for any other b-type cytochrome, of which Complex II is part [47, 
50, 51]. On the other hand, both SdhC and SdhD contain the requisite and traditional His residue 
to coordinate heme [36].  In our cell-free system, heme appeared to promote the 
homodimerization of Sdh3p even without crosslinker present, which was remarkable because no 
other condition seemed to stabilize dimerization in a crosslinker-independent manner (Figure 
5.4A).  On the other hand, the influence of heme was not as apparent with SdhC.  Heme did not 
seem to enhance dimerization when crosslinker was present and it did not sustain a non-covalent 
interaction (when crosslinker was not present) between SdhC subunits as it did for Sdh3p.    
In order to study the effect of heme further, we used site-directed mutagenesis of SDH3 
to alter the native heme axial ligand His106 to an Ala residue [51].  As before, an in vitro 
translation was conducted in the presence of LUVs, the proteoliposomes were purified via 
sucrose floatation, and the samples were treated with both heme and crosslinker.  As seen in 
Figure 5.4B, when crosslinker was present we found that heme did not increase the dimerization 
efficiency of the mutant as it did for the wild type Sdh3p and may have even decreased the 
ability of the mutant Sdh3p to homodimerize.  Even more interesting, heme did not stabilize a 
dimer of the mutant species without crosslinker, as it did with native Sdh3p, further supporting 
that heme has a strong influence on the homodimerization and assembly of wild type Sdh3p.  
Previous studies have shown that when this mutagenesis was conducted in yeast and Escherichia 
coli, the presence of heme did not have a critical role in assembly or activity of Complex II [47, 
55].  By contrast, our results indicate that whereas heme may not be an absolute requirement for 
homodimerization of Sdh3p, it promotes the stability of this interaction. 
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5.3.5. Sdh4p-, SdhD-, Tim18p-, and YLR164w-dependent destabilization of Sdh3p and SdhC 
homodimerization 
 Having investigated the lipid- and heme-dependent dimerization of Sdh3p and SdhC, we 
next investigated the influence that the native complementary binding partners, Sdh4p and SdhD, 
have on homodimerization of Sdh3p and SdhC.  We co-translated the proteins in the presence of 
LUVs and floated them on sucrose cushions as above.  We found that Sdh4p slightly disrupted 
the Sdh3p homodimer and SdhD disrupted the SdhC homodimer, which was expected because 
Sdh3p and Sdh4p are the complementary S. cerevisiae constructs and SdhC and SdhD are the 
partner mammalian porcine constructs (Figure 5.5). However, it was remarkable to find that 
whereas SdhD could also disrupt the Sdh3p homodimerization, Sdh4p was not able to disrupt the 
SdhC homodimers and could potentially even cause a strengthening of homodimerization. 
Further, as mentioned above, Sdh4p contains two homologous proteins in yeast, Tim18p, 
which is part of the TIM22 import complex of the mitochondrial IM and YLR164w, a protein of 
unknown function, that is also found in the mitochondria [46].  We wanted to investigate the 
influence that these proteins may have on Sdh3p and SdhC homodimerization because Tim18p 
contains a Tyr in the heme-coordination position similar to Sdh4p, but YLR164w contains a His 
in this position similar to SdhD [47]. As displayed in Figure 5.5, both Tim18p and YLR164w 
disrupted both the Sdh3p and SdhC homodimers.  Interestingly, Tim18p seemed to interrupt the 
homodimers of Sdh3p and SdhC to a slightly greater extent than YLR164w, but both seemed to 
disrupt the Sdh3p homodimer more strongly than the native complementary protein Sdh4p.  
However, neither was more effective than mammalian SdhD at disrupting SdhC, and even 
Sdh3p, homodimers indicating that SdhD is most efficient at interrupting the formation of 
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homodimers regardless of the species from which its complementary membrane subunit was 
derived. 
These findings are even more intriguing when considering that Tim18p mimics Sdh4p in 
that both contain Tyr residues in the position expected to coordinate heme, which may assist in 
explaining why Tim18p seemed to interact with Sdh3p to a greater extent than YLR164w.  On 
the other hand, YLR164w more closely resembles SdhD in that the His is in the putative position 
to coordinate a heme; however, YLR164w is unable to disrupt Sdh3p or SdhC homodimerization 
as effectively as SdhD.  While these divergent heme coordination residues may influence the 
interaction between binding partners, they do not seem to definitively determine how strongly 
two partner proteins are going to interact.  Taken together, these novel results implicate yeast-
derived homologs of Sdh4p in not only influencing the homodimerization of Sdh3p, but also that 
of SdhC, the homologous porcine construct.  These results provide further support for the 
hypothesis that the membrane subunits of Complex II are dynamically interacting proteins and 
may even have a deeper regulatory role in the mitochondria than previously thought. 
 
5.3.6. The Asp 57 Tyr Pathogenic Mutant of SdhD Homodimerizes 
 After obtaining the surprising and interesting result that Sdh3p and SdhC form 
homodimers, whereas Sdh4p and SdhD do not form homodimers, we looked further into the 
implications that homodimerization may have in the molecular etiology of Complex II-
associated diseases.  We produced a panel of SdhC and SdhD point mutants that have previously 
been implicated in tumorigenic disease progression and tested them for the ability to alter 
homodimerization patterns.  The majority of mutant constructs behaved in an identical manner to 
the wild type proteins: SdhC Leu 130 Pro was able to homodimerize similar to wild type SdhC 
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and seven of the eight SdhD mutants were unable to homodimerize, just as with wild type SdhD 
(Figure 5.6A and B).  In addition, the homodimers of SdhC Leu 130 Pro were disrupted by 
SdhD and the SdhD mutants were able to disrupt SdhC homodimerization (data not shown).   
However, unlike wild type SdhD, the pathogenic SdhD Asp 57 Tyr mutant showed strong 
potential for homodimerization (Figure 5.6B).  This surprising result indicated that this 
particular mutant of SdhD may contribute to pathogenesis by allowing strong SdhD homodimers 
to form, perhaps preventing SdhD from interacting with SdhC, breaking up the SdhC 
homodimers, and forming a stable membrane heterodimer for the assembly of holoenzyme 
Complex II.  In this way, equivalent amounts of membrane protein subunits may be produced in 
an individual carrying the mutant SdhD, but the inability to disrupt SdhC homodimers and set up 
native membrane heterodimer interacting sites for Complex II catalytic dimers may contribute to 
the development of tumorigenesis. 
 
5.4. Brief Conclusions 
The membrane subunits of respiratory Complex II, Sdh3p/C and Sdh4p/D, were the focus 
of the current study and we have used native mitochondrial IM-mimicking (i.e. CL-containing) 
liposome environments to study the assembly of these proteins.  It is a completely novel finding 
that Sdh3p and SdhC homodimerize when translated in an in vitro wheat germ system in the 
presence of LUVs (Figure 5.7).  This interaction required a CL-containing lipid environment 
and was stable enough to be captured through the use of chemical crosslinking agents.  In 
addition, homodimer formation was promoted by heme.  On the other hand, when Sdh4p or 
SdhD (or their homologs) were added to their complementary partner protein of the same 
species, the homodimerization of Sdh3p and SdhC was disrupted.  However, we found no 
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evidence of a stabilized heterodimer likely due to the lack of proximal side chains with reactivity 
suitable for the chemical crosslinkers used.  These results may also suggest that the heterodimer 
species may exist in a very dynamic state, constantly sampling the surrounding environment and 
interacting with other proteins, and may only be stabilized by the presence of the soluble 
Complex II catalytic dimer.  In the future, it will be interesting to investigate the influence that 
the presence of the soluble catalytic dimer or other TIM22 subunits have on the 
homodimerization and assembly of the Complex II membrane dimer.  In addition, these results 
shed light on the pathogenicity of certain characterized mutations of Complex II membrane 
subunits and further consideration is necessary to determine if newly recognized mutations of 
Complex II may also have implications in the development of disease states by their formation of 
non-native homodimers. 
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5.5. Figures and Tables  
 
 
Table 5.1.  Sdh3, SdhC, and SdhD Mutagenic Primers. 
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Figure 5.1.  Complex II Sdh3p/C membrane subunits form homodimers.  In vitro 
translations of (A) Sdh3p and SdhC or (B) Sdh4p and SdhD were conducted separately in the 
presence of [35S]Methionine and IM-mimicking liposomes, purified via a 15% sucrose cushion, 
and treated with crosslinker (Sdh3p/Sdh4p were treated with DSS and SdhC/SdhD were treated 
with BMH) or buffer.  The dark bands at approximately 15 kDa represent the monomeric species 
of the proteins (open arrows, with the higher arrow pointing to Sdh3p/Sdh4p and the lower arrow 
pointing to SdhC/SdhD); the lighter bands running at approximately 30 kDa represent the 
crosslinked homodimer species (filled arrows).  The small molecular weight species present at 
the bottom of the gel below the monomeric Complex II membrane subunits are most likely 
protease-digested proteins.  Percent Band Intensity was determined as in Section 5.2.5. 
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Figure 5.2.  Lipid environment is necessary for homodimerization of Sdh3p and SdhC.  In 
vitro translations of Sdh3p and SdhC and proteoliposome purifications were conducted as in 
Figure 5.1 with and without liposomes.  The dark bands at 15 kDa represent the monomeric 
species of each protein (open arrows).  When liposomes are present (labeled “Float.” lanes) the 
species at approximately 30 kDa represents the dimeric species (filled arrows).  The bands 
present at approximately equivalent molecular weights in lanes of the translation without 
liposomes (labeled “Trans.”) represent contaminating accessory wheat germ proteins.  Percent 
Band Intensity was determined as in Section 5.2.5. 
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Figure 5.3.  CL is necessary for homodimerization of Sdh3p and SdhC.  In vitro translations 
of Sdh3p and SdhC were conducted as in Figure 5.1 in the presence of liposomes with and 
without cardiolipin.  Part of the translation was removed to run immediately on a separate SDS-
PAGE gel (B) and the remaining translation was purified via a 15% sucrose cushion and samples 
from the floated fraction as well as the pelleted fraction were removed. (A) The floated fraction 
was treated with crosslinker or buffer.  Dimers were only present when protein was translated in 
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the presence of CL-containing liposomes.  (B) The translation (“T”) efficiency, and the pellet 
(“P”) and the floated (“F”) fractions incorporation efficiency were compared for the monomeric 
translated species.  Note that the gel was left on the screen for only a couple of hours, compared 
to the overnight exposure of for the other SDS-PAGE gels.  For both (A) and (B) monomers and 
dimers are labeled as in Figure 5.1.  Percent Band Intensity was determined as in Section 5.2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
 
Figure 5.4.  Heme enhances the homodimerization of Sdh3p, but not SdhC.  Protein was 
translated and proteoliposomes purified as in Figure 5.1 and incubated with heme or buffer prior 
to crosslinker or buffer treatment.  Monomer and dimer species are labeled as in Figure 5.1. 
Sdh3p homodimerization was enhanced and stabilized by heme, whereas SdhC 
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homodimerization was not (A).  When the heme coordination site was mutagenized (His 106 
Ala), the influence of heme was removed and the profile of homodimerization resembled that of 
SdhC, which was unaffected by heme (B).  Percent Band Intensity was determined as in Section 
5.2.5. 
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Figure 5.5.  Sdh4p, SdhD, and their homologs affect the homodimerization of Sdh3p and 
SdhC.  In vitro translations of Sdh3p or SdhC alone or co-translated with Sdh4p, SdhD, Tim18p, 
and YLR164w were completed, purified, and treated with crosslinker as in Figure 5.1.  The dark 
bands between 15-10 kDa represent the monomeric species (indicated by the open arrow; Sdh4p 
is 16.6 kDa, SdhD is 11 kDa, Tim18p is 18 kDa, and YLR164w is approximately 18 kDa [36, 
46, 94]) of the translated proteins and the lighter bands at 30 kDa represent the homodimers 
(filled arrows) of either Sdh3p or SdhC.  If no homodimer band is present, the complementary 
protein subunit disrupted the homodimerization of Sdh3p or SdhC.  Percent Band Intensity was 
determined as in Section 5.2.5. 
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Figure 5.6. SdhD D57Y pathogenic mutant is able to homodimerize, unique among eight 
SdhC and SdhD pathogenic mutants studied.  In vitro translations of (A) SdhD D57Y or (B) 
SdhC L130P and various SdhD pathogenic mutants were completed and proteoliposomes 
purified as in Figure 5.1. The dark bands between 15-10 kDa represent the monomeric species 
of the proteins translated (open arrows) and the lighter bands at 30 kDa represent the 
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homodimers of SdhC and SdhD pathogenic mutants (filled arrows), which only formed in the 
case of SdhC L158P and SdhD D57Y.  Percent Band Intensity was determined as in Section 
5.2.5. 
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Figure 5.7. Schematic of potential interactions of Sdh3p and SdhC with complementary 
partner subunits.  The growing interactome of Complex II membrane subunits may influence 
the assembly of holoenzyme Complex II and other mitochondrial IM protein complexes. 
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Chapter 6 
 
Sdh3 Helix I and its Involvement in Complex II  
Holoenzyme Assembly 
 
 
 
 
 
 
 
 
 
 
 
 
Other colleagues who have contributed to the studies presented in this chapter are Victoria L. 
Greenwood, Matthew Greenwood, and Nathan N. Alder, all from the University of Connecticut 
(Storrs, CT 06269, USA). 
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6.1. Abstract 
Despite the fact that respiratory Complex II is the linkage point between the 
Tricarboxylic Acid (TCA) cycle and the electron transport chain (ETC), marking it as a critical 
control point central to cellular energy metabolism, little is understood regarding how its four 
protein subunits and associated cofactors assemble into the holoenzyme.  The porcine structure 
of the complex pointed to particular structural features of SdhC that could interact with SdhB 
and mediate catalytic and membrane dimer interactions [36].  A soluble helix, termed Helix I, of 
approximately 15 amino acids at the N-terminus of SdhC (residues 6 to 20) is located in the 
matrix near the SdhB subunit.  This helix accounts for forty percent of the contact area between 
SdhB and the membrane dimer.  Further, Helix I is attached to the main transmembrane 
segments of SdhC through a flexible linker region and may therefore be important in mediating 
and recognizing the interaction between the membrane subunits and SdhB depending on local 
environmental conditions.   
Although the crystal structures implicate Helix I as a tremendously important piece in the 
assembly of holoenzyme Complex II, the helix has not yet been studied in any particular detail.  
Therefore, the present study utilized nanodisc (ND) reconstitutions of the holoenzyme Complex 
II  to investigate the general assembly of the yeast Complex II and the specific role that Helix I 
plays in this assembly.  The holoenzyme was reconstituted by incubating catalytic dimer 
resolved directly from solubilized mitochondria with membrane dimer translated in a cell-free 
system and incorporated into NDs.  In order to probe assembly even further, we have engineered 
mutant constructs of the Complex II Sdh3p membrane subunit in order to use IASD chemical 
labeling and NBD fluorescence quenching to investigate the dynamics of Helix I.  We found 
preliminary evidence to support that Helix I can sample different conformations depending on 
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the local environment in order to allow, or inhibit, catalytic dimer attachment and holoenzyme 
assembly. 
 
6.2. Materials and Methods 
 For Materials, Lipid Preparation, Mitochondria Solubilization, In vitro Translation 
System, and SDS-PAGE Analysis details, please see Chapter 2.  
6.2.1. Catalytic Dimer Isolation 
We have previously shown that when NDs lacking cardiolipin (CL) are utilized to isolate 
Complex II from solubilized membranes, there was a high level of instability between the 
catalytic and membrane dimers (Chapter 3, [157]).  We have exploited these conditions by 
utilizing DMPC NDs to capture catalytic dimer that has broken free of membrane dimer 
reconstituted within NDs after metal affinity purification.  Membrane Scaffolding Protein (MSP, 
specifically MSP1E3D1) was synthesized and purified as described [223].  DMPC, MSP1E3D1 
(in lipid: MSP1E3D1 ratio of 122:1), DDM-solubilized mitochondria, and MSP buffer ([cholate] 
= 14.8 mM) were incubated at RT for 30 min.  Pre-hydrated Bio-Beads SM Hydrophobic 
Interaction Adsorbent (Bio-Rad Laboratories, Inc., Hercules, CA) were added and rotated at RT 
for 2 h to remove detergent and initiate ND self-assembly.  After Bio-Bead removal, NDs were 
incubated with Ni-NTA agarose at RT for 40 min.  They were then subject to step gradients of 
MSP buffer and imidazole (up to 400 mM) to isolate NDs via the His-tagged MSP1E3D1.  The 
middle wash fractions (Washes 2A-3B) containing free catalytic dimer were combined, dialyzed 
into MSP buffer with 100 mM ammonium sulfate to improve catalytic dimer stability, and 
concentrated in Centricon 3000 MWCO tubes in an Eppendorf Centrifuge 5804R.  Ammonium 
sulfate has previously been shown to enhance reconstitution of Complex II due to 
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“antichaotropic” activity: the sulfate ion has a structuring effect on water molecules, slowing 
their diffusion [273].  Catalytic dimer was then prepared for addition to NDs containing 
Complex II membrane subunits. 
6.2.2. Complex II Holoenzyme Reconstitution 
Biomimetic lipid mix, MSP1E3D1 (in lipid: MSP1E3D1 ratio of 143:1), in vitro 
translation product, and MSP buffer ([cholate] = 14.8 mM) were incubated at RT for 30 min.  
Pre-hydrated Bio-Beads SM Hydrophobic Interaction Adsorbent (Bio-Rad Laboratories, Inc., 
Hercules, CA) were added and rotated at RT for 2 h to remove detergent and initiate ND self-
assembly.  After Bio-Bead removal, NDs were incubated with isolated catalytic dimer, 3 µM 
heme, and 0.23 M ammonium sulfate while rotating at RT for 1 h.  ND samples were then 
incubated with Ni-NTA agarose at RT for 40 min and subject to step gradients of MSP buffer 
and imidazole (up to 400 mM) to isolate NDs via the His-tagged MSP1E3D1.  The first two 
elution fractions containing NDs assembled with holoenzyme Complex II were combined, 
dialyzed into MSP buffer to remove imidazole and concentrated in Centricon 3000 MWCO tubes 
in an Eppendorf Centrifuge 5804R. 
6.2.3. Site-Directed Mutagenesis 
Site-directed mutagenesis of Sdh3p Helix I was conducted by PCR of a mature (pre-
sequence removed) wild type construct of SDH3 as previously described [51].  Complimentary 
mutagenic primers that flanked each of the desired sites (Thr8, Ala13, and Leu18) were designed 
to change each of the residues at those positions to Cys.  The forward primer sequences for Thr8, 
Ala13, and Leu18 were: 5’- GGCCAGTGAAATGAACTGCAAAGCGGCAATTG-3’; 5’-
GAAATGAACACCAAAGCGGCAATTTGTGAAGAACAAATATTAAAC-3’; and 5’-
GCGGCAATTGCTGAAGAACAAATATGTAACAAGCAAAGAGC-3’, respectively.  The 
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mutagenized constructs were sequenced at the Biotechnology and Bioservices Center in the 
DNA Biotechnology Facility at the University of Connecticut (Storrs, Connecticut) in order to 
confirm that mutagenesis occurred. 
6.2.4. IASD Labeling 
In vitro translations were completed as in Chapter 2 with the addition of 35S-Met and 
Sdh3p mRNA constructs mutated at various positions along Helix I to contain Cys residues.  
Translations were halted via cycloheximide incubation for 20 min at RT, combined as 
appropriate (i.e. 35S-Sdh3p and Sdh4p) and added directly to ND reactions.  ND assembly 
reactions were completed as in Section 6.2.2, except after Ni-NTA purification samples were 
treated with IASD (4-acetamido-4’-((iodoacetyl)amino)stilbene-2-2’-disulfonic acid) for 1, 5, or 
10 min at RT.  IASD will covalently label only exposed Cys residues and the reaction is 
quenched upon addition of DTT.  Reactions were analyzed via SDS-PAGE (Chapter 2): a 
mobility shift indicates IASD labeling has occurred. 
6.2.5. NBD Fluorescence Analysis 
In vitro translations (Chapter 2) were completed in the presence of the Sdh3p Helix I Cys 
mutant construct mRNA and the non-natural NBD-Cys-tRNACys analog in order to label Sdh3p 
at these particular Cys residues with the environmentally-sensitive fluor 7-nitrobenz-2-oxa-1,3-
diazolyl (NBD).  Translations were halted via cycloheximide incubation for 20 min at RT, 
combined as appropriate (i.e. NBD-Sdh3p with Sdh4p), and added directly to biomimetic ND 
reactions, assembled as above, without catalytic dimer or heme addition (Section 6.2.2).  ND 
samples were then added to microcell cuvettes and treated with increasing concentrations of 
either KCl or KI (0 to 0.08 M).  NBD emission scans were completed after each addition with 
the following parameters: λEx = 470 nm, λEm = 510 – 550 nm, 2 sec integration time, 4 nm slit 
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widths.  Samples were corrected as explained below (Section 6.2.6) and Stern Volmer plot 
analyses were completed to determine extent of quenching at various sites. 
6.2.6. Data Representation and Statistical Analysis 
SDS-PAGE gels are representative of at least three independent experiments.  Band 
quantification of IASD-labeling of 35S-Sdh3p was completed using Quantity One software and 
band intensities are represented as the ratio of the Relative Quantity of the labeled band 
compared to the Relative Quantity of the total (labeled and unlabeled bands combined).  Ksv 
values for NBD-labeled Sdh3p were calculated from background subtracted (NDs with unlabeled 
Sdh3p) and potassium chloride-corrected potassium iodide quenched- NBD emission spectra.  
The results of IASD labeling band quantification and Ksv values resulting from iodide quenching 
of NBD are shown as means ± standard errors of the means (s.e.m.) of at least three independent 
experiments.  A two-tailed student T-Test (equal variance) was used to determine statistical 
significance (p ≤ 0.05) for these measurements (no significance was found). 
 
6.3. Results and Discussion 
6.3.1. Cell-free Reconstitution of Complex II within Biomimetic Nanodiscs 
 In order to begin probing the assembly of Complex II, we used our previously established 
nanodisc (ND) reconstitution system (Chapter 3, [157]).  Briefly, while reconstituting Complex 
II directly from solubilized mitochondrial membranes, we recognized that the holoenzyme only 
remained intact when CL was present.  When NDs assembled with only DMPC lipids were used 
to reconstitute the complex, the holoenzyme was not stable and the catalytic dimer broke away 
from the membrane subunits encapsulated within the NDs.  We exploited this event by making 
DMPC NDs with solubilized mitochondrial membranes, purifying them over a Ni-NTA column, 
and removing the wash fractions that contained only the catalytic dimer.  In parallel, biomimetic 
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NDs were assembled with membrane dimer that had been translated using a cell-free wheat 
germ-based system. These NDs were also purified over a Ni-NTA column, but the elution 
fractions containing NDs with in vitro translated membrane dimer were removed.  These NDs 
were then incubated with the purified catalytic dimer, allowing the holoenzyme to assemble.  
Holoenzyme assembly was qualified by completing a second Ni-NTA purification analysis on 
the samples: if catalytic dimer appeared in the washes then it was not stably associated into a 
holoenzyme within NDs, but if it appeared in the ND elution fractions, we had successfully 
assembled the holoenzyme.  Figure 6.1 shows that when complementary subunits Sdh3p and 
Sdh4p were assembled within discs, successful holoenzyme Complex II was reconstituted 
(compare “Sdh3p+Sdh4p” with “Mock”).  On the other hand, when only one of the membrane 
subunits was used for the reconstitution (“Sdh3p” or “Sdh4p”), holoenzyme assembly did not 
occur and the Ni-NTA elution profiles most closely mimicked that of the “Mock” assembly.  
With these results, we wondered what is unique about the Sdh3p-Sdh4p dimer, compared to each 
of the subunits alone, that allowed holoenzyme assembly to occur only in that situation?  In order 
to probe this question more deeply, we decided to take a look at Helix I of Sdh3p, which is 
hypothesized to be important in modulating attachment of the catalytic dimer to the membrane 
dimer as it composes forty percent of the contact area between SdhB (Sdh2p in yeast) and the 
membrane dimer in the porcine crystal structure. 
 
6.3.2. Identification of Helix I in Sdh3p 
 Our first step was to confirm where α-helical structure was predicted to occur in the 
amino terminus of the Sdh3p/SdhC subunit of Complex II.  The crystal structure of porcine 
Complex II first indicated that a soluble amino-terminal helix may exist in SdhC and this is 
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supported by secondary structure prediction sites, JPred3 and PSIPRED [274, 275].  These same 
prediction sites, as well as the homology model of yeast Complex II, support that a helical 
segment is also present in the yeast Sdh3p, although this segment may be shorter than that found 
in SdhC (Figure 6.2A).  Once we had confirmed the presence of a helical segment in Sdh3p (and 
SdhC), we designed mutant Sdh3p constructs with single Cys sites at various locations within (or 
near) Helix I.  As the helical wheel plots in Figure 6.2B indicate, the three residues chosen 
occupy different sides of the helix in order to capture the environment surrounding all faces of 
Helix I.  The mutated residues shown here are referred to as Sdh3p Thr8, Ala13, and Leu18 for 
the remainder of this study.  While Sdh3p Thr8 was not predicted to be within the Helix I 
segment, it is homologous to a residue at the amino-terminal edge of the helix in SdhC, which is 
why this residue of Sdh3p Helix I was included as well.  Note that mutant constructs were also 
designed for SdhC (Thr7, Met12, Asn17), but these were not utilized in the present studies. 
 
6.3.3. Helix I Potentially Opens Complex II Membrane Dimer to Catalytic Dimer Interaction 
 In order to begin looking at the role of Helix I in Complex II assembly, we examined the 
exposure of the helix to Cys-reactive 4-acetamido-4’-((iodoacetyl)amino)stilbene-2-2’-disulfonic 
acid (IASD).  IASD reacts with any solvent-exposed Cys residues, forming a covalent bond.  
When samples treated with IASD are analyzed using SDS-PAGE, the labeled protein will 
migrate more slowly through the gel due to the larger molecular weight and this mobility shift in 
the migration of the protein is monitorable.  By comparing the amount of protein that is labeled 
to the amount that is unlabeled over a certain period of time, the exposure of particular Cys sites 
can be determined.  For the present study, the different Sdh3p mono-Cys mutants were translated 
in a cell-free wheat germ-based system and assembled into NDs alone or with a wild type partner 
subunit, Sdh4p.  These NDs were subjected to IASD labeling and the results are presented in 
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Figure 6.3.  It is apparent that at position 14, the helix was not very dynamic over time (there 
was consistent IASD labeling) regardless of whether Sdh3p was alone or in the presence of 
Sdh4p, but it may have been slightly more shielded overall as compared to the surrounding sites.  
At position Leu18, there was not a significant change when Sdh3p was alone or with Sdh4p, 
again supporting that the most C-terminal end of the helix was not very dynamic.  At position 
Thr8, however, there was an increase in site exposure over time when Sdh4p was present as 
compared to Sdh3p alone.  This may indicate that this flexible region before Helix I and/or the 
amino-terminus of Helix I directed the helix to sample its environment for the presence of the 
catalytic dimer only when the membrane dimer is appropriately assembled (i.e. Sdh3p interacting 
with Sdh4p).   
 In addition, there exist two known homologs of Sdh4p: a membrane protein that is part of 
the TIM22 protein import complex, Tim18p, and a protein of unknown function, YLR164w.  It 
has previously been shown that Sdh3p is able to interact with Tim18p and is important in the 
assembly of the TIM22 complex.  It is therefore important to understand how Sdh3p 
differentiates between interactions with Sdh4p and Tim18p and to then determine which 
holocomplex should be formed [96].  In this way, we wanted to look at the dynamics of Helix I 
in the presence of Tim18p to determine if the environment sampling, presumably for the 
catalytic dimer, that occurs in the presence of Sdh4p would also occur in the presence of 
Tim18p.  Interestingly, when Tim18p was added to Sdh3p, there was no change at Thr8 (it 
behaved similarly to when Sdh3p is alone), but there was a large increase in exposure at Leu18 
(Figure 6.3).  The lack of change at the amino-terminus of Helix I supports that both native 
Complex II membrane subunits must be present in order for the solvent sampling and catalytic 
dimer attachment to occur; this will not occur when Tim18p is present.  The increase in exposure 
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at the carboxy-terminal residue Leu18 could support a shift in the conformation of Helix I that 
may expose residues necessary for interaction with other TIM22 complex proteins to form the 
holocomplex of TIM22. 
 In order to investigate the dynamics of Helix I and its conformational changes with a 
complementary technique, we labeled Sdh3p Helix I with an NBD (fluor 7-nitrobenz-2-oxa-1,3-
diazolyl) fluorophore.  NBD is a small, environmentally-sensitive probe that when incorporated 
within a protein allows site-specific environment-sensitive (i.e. conformational) data to be 
obtained.  NDs were formed exactly as with IASD labeling, except Sdh3p was translated in the 
presence of an amino-acyl tRNA analog that would incorporate Cys residues labeled with NBD 
at specific mono-cysteine sites within Helix I.  We used a soluble iodide molecule to quench 
fluorescence of NBD, which would only occur if the NBD probe was solvent-exposed, as iodide 
cannot cross the ND bilayers or enter hydrophobic pockets.  It was apparent that when Sdh4p 
was present, as compared to when Sdh3p was alone or when Tim18p was present, Thr8 was 
more solvent-exposed, which was indicated by the higher quenching by iodide at this position 
(Figure 6.4).  This was consistent with the IASD labeling results that indicated that the amino-
terminal Thr8 residue underwent an increase in labeling when Sdh4p was present.   
At the carboxy-terminal Leu18, there was a decrease in quenching when Sdh4p was 
present, as compared to when Sdh3p was alone (Figure 6.4).  The decrease in exposure supports 
that in this region of Helix I, there was a shift toward the bilayer or toward the transmembrane 
segments of Sdh3p, which may be important in setting up the membrane dimer for catalytic 
dimer attachment.  This shift was most likely very slight as the IASD labeling results do not 
show much change when Sdh4p was introduced into the system.  When Thr8 shifted outward to 
sample the environment, the helix may have twisted so that Leu18 was more likely to be buried 
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near the membrane.  Further, the exposure levels for each of the residues were similar when 
Sdh3p was alone, supporting the existence of a possible resting state of Helix I along the bilayer.  
This resting state may be slightly exposed while not actively searching the surrounding 
environment or may become buried and protected within a region of the bilayer.  It appeared that 
in the presence of Sdh4p, the amino-terminal edge of Helix I (or potential flexible region prior to 
the helix) flipped to sample the surrounding environment, while the more carboxy-terminal edge 
seemed to bury itself, possibly anchoring the helix so that it may better sample the environment 
and bind the catalytic dimer, forming a Complex II holoenzyme. 
 
6.4. Brief Conclusions 
 Complex II subunit assembly is a very intricate process whose realized complexity is 
only increasing over time.  We study here, for the first time, the dynamics of membrane subunit 
Sdh3p Helix I through IASD labeling and NBD fluorescence quenching.  First, we established 
that Complex II can be reconstituted in a cell-free system whose membrane environment is 
recapitulated in ND model membrane systems with an inner membrane (biomimetic)-mimicking 
lipid composition.  Both membrane subunits must be present for catalytic dimer attachment: it 
appears that Sdh3p alone is not sufficient, but is required for catalytic dimer attachment.  Next, 
we looked in more detail at three separate residues along Sdh3p Helix I that each sample a 
different helical face, providing information on all sides of the helix.  The most amino-terminal 
Thr8 is most dynamic and may actively sample the local environment for the catalytic dimer 
(Figure 6.5).  The middle residue Ala13 and the carboxy-terminal Leu18 seem to be more stable 
when Sdh4p is present, with Leu18 potentially anchoring itself near the membrane to support 
catalytic dimer attachment.  When Tim18p is present, Leu18 may shift in position allowing the 
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TIM22 complex to assemble and preventing Complex II catalytic dimer attachment. Overall, 
while these results shed an initial light on the process of Complex II assembly, much work 
remains to be done.  In particular, more detailed experiments looking at Helix I dynamics when 
Sdh3p (and SdhC) are paired with each of their binding partners in the presence and absence of 
the catalytic dimer would further develop our understanding of Complex II holoenzyme 
assembly. 
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6.5. Figures 
 
 
 
 
Figure 6.1. The assembly and stability of Complex II holoenzyme is dependent on the 
presence of both membrane subunits.  Complex II reconstitution was attempted by adding 
purified catalytic dimer to NDs with the indicated membrane subunits.  The NDs were then 
subjected to affinity chromatography for isolation of holoenzyme Complex II encapsulated 
within NDs.  Catalytic dimer co-eluting with MSP1E3D1 (fractions E1 and E2) was considered 
to be stably associated with the NDs (and therefore the membrane subunits); those eluting at the 
earlier fractions were not stably associated (free catalytic dimer).  The fluorescent FAD signal 
was used as the marker for the soluble catalytic dimer.  Column fractions are FT: flow through; 
W1A-W3B: column wash steps; E1-E3: column elution steps.  Note relative imidazole 
concentrations depicted above. 
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Figure 6.2. Secondary structure prediction of Sdh3p/SdhC amino-terminus.  (A) Secondary 
structure prediction programs, Jpred3 [274] and PSIPRED [275], along with the porcine crystal 
structure [36] and yeast homology model [37], were used to determine the residues comprising 
Helix I in both yeast and pig.  (B) Helical wheel plot of the eighteen residues surrounding and 
comprising Helix I in both yeast and pig.  In both (A) and (B) the residues marked in bold red are 
those that were mutated to Cys for conformational analyses. 
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Figure 6.3. IASD labeling supports sampling of environment by Helix I in the presence of 
Sdh4p.  Each of the residues, Thr8 (A), Ala13 (B), and Leu18 (C), mutated along Helix I 
samples different faces of the helix, allowing the exposure along different sides and at different 
points in the helix to be studied.  Labeling by Cys-reactive IASD indicated that the amino-
terminal Thr8 seemed to increase in exposure upon Sdh3p reconstitution with Sdh4p, while the 
carboxy-terminal Leu18 increased in exposure in the presence of Tim18p.  Data is displayed as 
the change in the ratio of the intensity of IASD-labeled bands to IASD-labeled and unlabeled 
bands (total Sdh3p present) over time.  Sdh3p was reconstituted alone (solid line), in the 
presence of Sdh4p (dashed line), or in the presence of Tim18p (short dashed line).  Based on a 
student T-test, no statistical significance was found. 
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Figure 6.4. NBD fluorescence quenching supports conformational changes of Helix I.  The 
most amino- and carboxy-terminal residues mutated in Helix I (Thr8 (A) and Leu18 (B), 
respectively) were labeled with the environmentally-sensitive NBD fluor and treated with 
increasing concentrations of iodide, which would quench fluorescence if the fluorescent probe 
was exposed to solvent.  In the presence of Sdh4p, fluorescence was quenched at the amino 
terminal Thr8 of Helix I to a higher degree as compared to when Sdh3p was alone.  In contrast, 
in the presence of Tim18p, the carboxy-terminal Leu18 NBD fluorescence was quenched to a 
higher degree.  Sdh3p was reconstituted alone, in the presence of Sdh4p, or in the presence of 
Tim18p.  Based on a student T-test, no statistically significant differences were found. 
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Figure 6.5.  Schematic of proposed Helix I conformational dynamics in the presence of 
Sdh3p binding partners.  Sdh3p has the potential to form a homodimer with other Sdh3p 
proteins, keeping Helix I in a position that leaves all sides relatively similarly exposed.  When 
Sdh4p was present, Helix I tilted so that the more carboxy-terminal Leu18 was partly shielded by 
the membrane or Sdh3p itself, while the amino-terminal Thr8 was able to sample the 
environment for the presence of the catalytic dimer to form holoenzyme Complex II.  When 
Tim18p was present, the helix adopted a third conformation in which the more carboxy-terminal 
Leu18 may become more exposed than the amino-terminal, possibly opening a different binding 
site and allowing assembly of the TIM22 complex. 
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Chapter 7 
 
Conclusions 
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7.1. Overall Conclusions 
As the linkage point between the tricarboxylic acid (TCA) cycle and the electron 
transport chain (ETC), Complex II is critical to mitochondrial, and therefore cellular, energy 
generation.  Mutations in its subunits have been linked to a variety of disease states, including 
the tumorigenic diseases paraganglioma and pheochromocytoma, as well as early-onset 
neurodegenerative disorders and the aging process.  Complex II is the least studied of the 
respiratory chain complexes; with its powerful involvement in energy generation and the 
detrimental implications of its dysfunction, it is imperative to learn more about the mechanisms 
underlying the assembly and activity of this complex. 
My current work has two main novel findings that have extended the overall 
understanding of Complex II within the field (Figure 7.1): 1) Cardiolipin (CL) is necessary for 
assembly of Complex II membrane subunits as well as in holoenzyme stability and activity, most 
likely due to its effects on membrane hydration and inter-lipid packing; and 2) Sdh3p/C 
membrane subunits are able to form homodimers that are stabilized by both heme and CL, but 
disrupted by partner subunits, Sdh4p/SdhD, and their homologs, Tim18p/YLR164w.  In addition 
to these innovative findings, my work has furthered other recent studies implicating Complex II 
as a significant contributor to reactive oxygen species (ROS) formed by the respiratory chain.  
Further, my preliminary work on Helix I of Complex II membrane subunit, Sdh3p/C, supports 
that this helix may undergo dynamic structural rearrangements depending on the partner proteins 
that are present within the membrane and may regulate the ability of the Complex II holoenzyme 
to assemble correctly. 
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7.2. Complex II and Cardiolipin 
 While CL has never previously been clearly linked with yeast or mammalian Complex II, 
I have presented ample evidence that CL is essential for the structure and function of 
mitochondrial Complex II by: 1) maintaining the interaction between the catalytic dimer and 
membrane subunits; 2) promoting electron flux from succinate to the ubiquinone reduction site 
within the bilayer; and 3) reducing ROS production.  My results add Complex II to the list of 
respiratory complexes that require CL for optimal function and assembly. It is of note, however, 
that during the largely uncharacterized assembly process of Complex II in vivo (membrane 
subunit integration via the TIM23 Complex, lateral interaction and heme coordination of 
Sdh3p/C and Sdh4p/D, and assembly with the catalytic dimer), of which other aspects of my 
research partly address, the specific roles of CL may differ from its functions in our reconstituted 
system.   
Within the mitochondria, CL is found in regions of high curvature of the IM, such as the 
cristae invaginations or contact sites between the OM and IM.  It has even recently been shown 
that alterations in the curvature and shape of the cristae affect the stability and efficiency of the 
overall respiratory chain and that the localization of CL within the membrane has widespread 
effects in mitochondrial signaling processes [276, 277]. Further, addition of divalent cations to 
aqueous dispersions of CL induces an inverted micellar phase of the lipid molecules, which 
allows long hexagonal phase tubules with a high degree of curvature to form.  The ability of the 
divalent cation calcium to alter the curvature and hydration of bilayers that contain CL has 
implications for how CL is able to affect the stability and activity of Complex II, which is 
located within the cristae membranes (of the mitochondrial IM). 
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Using fluorescent probes that intercalate into the bilayer at particular regions (i.e. 
interfacial vs. acyl chain regions) my work has also supported that when CL is present within a 
bilayer, that bilayer is more hydrated and the lipid molecules are less closely packed as compared 
to bilayers lacking CL.  When magnesium or calcium are added to the bilayers, those containing 
CL become increasingly dehydrated and the lipid molecules pack more tightly together as the 
electrostatic repulsion from anionic CL headgroups is relaxed.  My present results, set within the 
larger field of CL dynamics, suggest that when calcium is present in a bilayer containing 
Complex II, lipids within the bilayer become more tightly packed and CL may be prevented from 
directly interacting with the complex, dually inhibiting holoenzyme Complex II stability and 
activity.  Further, as I showed with my crosslinking studies, CL is necessary for assembly of 
Complex II membrane subunits; therefore, the presence of CL and its hydrating effect on the 
bilayer in the absence of cations may allow the membrane subunits to move laterally within the 
bilayer and interact to form heterodimers. 
 The link between CL and Complex II should be studied further to identify: 1) Which 
region of CL (i.e. the double headgroup, the quadruple acyl chains, or a combination of both) is 
most important in supporting holoenzyme stability and activity of Complex II?; 2) Is CL able to 
bind Complex II directly and/or able to alter bilayer dynamics in a way that may indirectly cause 
CL to have a supportive effect on the stability and activity of the complex?; and 3) What (if any) 
is the detailed mechanistic link between rapid increases of calcium within the mitochondria, 
leading to altered CL structure and function and Complex II dysfunction during apoptotic cell 
death? 
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7.3. Assembly of Complex II 
Complex II subunit assembly is a very intricate process whose realized complexity is 
only increasing over time.  Little is known regarding how the holoenzyme Complex II assembles 
and the interaction between the membrane subunits, Sdh3p/C and Sdh4p/D, is especially 
mysterious.  How do they interact once they have been imported into the mitochondria and 
individually assembled within the IM?  What regulates this assembly?  Recent work supports 
that Sdh3p is necessary not only for the interaction with Sdh4p to form Complex II, but that an 
interaction of Sdh3p with Tim18p is also necessary to assemble the TIM22 protein import 
complex of the mitochondrial IM [96].  These interactions support that not only are the subunits 
of Complex II important for energy generation processes within the mitochondria, but also in the 
regulation and assembly of an IM protein import complex. 
My work investigating the factors influencing Complex II membrane subunit assembly 
and the implications this may have for the surrounding IM environment has led to some 
surprising results.  First, this work has unexpectedly (and for the first time) revealed that 
Sdh3p/SdhC favor the formation of a homodimer that is able to be captured by chemical 
crosslinking reagents.  Not only this, but CL is required for this homodimerization and heme 
enhances the homodimer formation of Sdh3p as well.  In addition, when Sdh4p/SdhD and their 
homologs, Tim18p and YLR164w, are present the homodimer is broken, most likely due to the 
formation of dynamic (i.e. unable to be captured via crosslinking agents) heterodimers between 
partner proteins.  These results have far-reaching implications in the Complex II field as this 
homodimer assembly may expose a novel regulatory process within the IM of mitochondria: 
when Sdh3p/C does not have a native binding partner with which to interact, it will 
homodimerize to prevent spurious contacts with other proteins within the protein-rich IM 
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environment.  When an appropriate partner is present, Sdh3p/C will preferentially interact with 
that protein forming the interactive surface on which a larger complex can assemble. 
To take this a step further, while previous crystallographic evidence supports that the 
soluble Helix I of Sdh3p/C may be involved in Complex II holoenzyme assembly, as it makes up 
forty percent of the contact area between the membrane subunits and soluble SdhB [36], my 
preliminary work is the first to provide evidence to support that Helix I is involved in the overall 
assembly process of the holoenzyme.  The position of this helix may be altered depending on 
which of Sdh3p’s partner subunits are present and available within the membrane (e.g. 
Sdh4p/SdhD or Tim18p). This in turn would alter which holocomplexes would be assembled 
(e.g. Complex II or TIM22) and could have implications on the energetic state of the membrane 
and implicate Complex II subunits as key proteins in multiple processes within the mitochondria, 
not simply energy metabolism.  
Multiple questions remain regarding the details of these interactive processes: 1) Does the 
presence of CL, or other alterations in the lipid environment, influence the dynamics between 
membrane subunits Sdh3p/C and Sdh4p/D and/or the conformational dynamics of Sdh3p/C 
Helix I?; 2) Would removal of Helix I from Sdh3p prevent catalytic dimer attachment when 
Sdh4p is present?; and 3) Which particular residues of Helix I are mediating the attachment of 
the catalytic and membrane dimers?  Further work with site-specifically labeling each residue 
along the helix and probing the local environment would provide a more significant, detailed 
picture of the behavior of Helix I. 
Overall, the present work supports that CL is an important supporting factor in the 
stability and assembly not only of the membrane subunits of Complex II, but also of the 
holoenzyme, as well as in holoenzyme SQR activity.  As CL proves to be an influential force in 
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the overall functionality of Complex II, the link between CL and Complex II should be studied 
more extensively to determine the mechanistic details governing this interaction.  These results 
could have implications not only for Complex II, but also for other respiratory chain complexes 
and may even shed light on why Sdh3p is necessary for the assembly of Tim18p into the TIM22 
import complex.  Finally, from a technical standpoint, many of my studies on the CL-Complex II 
interaction have required that I develop a novel approach for studying membrane complexes.  In 
the present work, I have solubilized these complexes directly from a native biomembrane and 
reconstituted them into a model bilayer platform, the nanodisc, whose lipid composition can be 
precisely defined. This experimental approach can be applied to future studies of Complex II and 
CL within the laboratory and will also be of particular use in analyzing possible connections 
between lipid composition, membrane protein assembly, and the molecular basis of diseases 
(e.g., CL deficiency associated with Barth syndrome). 
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7.4. Figures 
 
 
Figure 7.1. Schematic of the overall implications of the present studies on our 
understanding of respiratory Complex II.  Complex II membrane subunit Sdh3p/C is able to 
form homodimers within the membrane in the presence of heme and CL (left); when Sdh3p/C is 
alone, Helix I appears to fold into the protein and become more shielded.  When an appropriate 
binding partner is present, such as Sdh4p/SdhD, holoenzyme Complex II assembles and remains 
stably associated only when CL is present (middle).  When CL is not present or prevented from 
interacting with Complex II due to the presence of divalent cations (right), the following may 
occur: 1) During assembly, the membrane subunits may not be able to interact appropriately and 
an interactive face for the attachment of the catalytic dimer is not presented, and/or 2) After 
Complex II assembly, the catalytic dimer may detach from the membrane dimer and contribute 
to the formation of ROS if electrons from succinate can no longer be passed to the ubiquinone 
within the membrane. 
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Appendix A. Complex II Membrane Subunit Mutant Construct Library 
Saccharomyces cerevisiae (yeast) 
 Sdh3p Sdh4p 
Heme Coordination Sites (green) H106A C78A 
Amber Suppressor Mutations 
for Assembly Analysis (red) S80 S133 
Mono-Cysteine Mutations for 
NBD-Probe Incorporation 
(yellow) 
S80C (131)* 
N81C (132)* 
S98C (149)* 
F137C (188)* 
T138C (189)* 
 
Tetra-Cysteine Mutations for 
FlAsH-Probe Incorporation 
(black box) 
SNWYHQ  
(80-85) 
CCPGCC 
 
Mono-Cysteine Mutations for 
Helix I Analysis (blue) 
T9C 
A14C 
L19C 
 
Homolog Constructs  Tim18 (full-length and mature) 
YLR164w (full-length and mature) 
    * Numbers in parentheses are residue number in full-length protein (mRNA tube label) 
Sus scrofa (porcine) 
 SdhC SdhD 
Amber Suppressor Mutations 
for Assembly Analysis 
 (red) 
S72 M132 
Tetra-Cysteine Mutations for 
FlAsH-Probe Incorporation 
(black box) 
CLGPTL (81-86) 
CCPGCC 
CCPGCC (135)  
C-Terminal Insertion 
Amber Suppressor Mutations 
for Helix I Analysis  
 (blue) 
T4 
M9 
N14 
 
Pathogenic Mutations  
(orange) L130P 
R35G 
P46L 
D57Y 
L60P 
H67L 
Y79C 
L104P 
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Appendix B: Complex II Membrane Subunit Purification and Labeling Protocol 
B.1. Cell Growth and Autoinduction 
B.1.1. Summary 
 IPTG-based inductions of Sdh3p mature WT and Sdh3p S80C were conducted first (with 
both denaturing and native purifications), but the resulting protein yield was inconsistent and 
poor.  While the protocol described in this section, which involves an autoinduction procedure, 
yields small amounts of protein (~ 20 µM), it results in consistent protein yields (protocol is 
derived from [278]).  Note that the autoinduction process is based on the premise that bacteria 
will consume any glucose in the media first, preventing induction of the protein encoded on a 
transformed plasmid, but after the limited amount of glucose is consumed, will begin to consume 
lactose, which will allow induction to occur more naturally and ease the bacteria into the 
induction process. 
 
B.1.2. Media and Solutions  
 1. 20X NPS Stock Solution (150 mL) 
  135 mL Double Distilled Water    
  8.01 g  Ammonium Chloride   NH4Cl  1 M 
  10.2 g  Potassium Phosphate Monobasic KH2PO4 0.5 M 
  10.65 g Sodium Phosphate Dibasic  Na2HPO4 0.5 M 
 
 2. 50X 5052 Stock Solution (150 mL) 
  12.5 g  Glycerol      0.5% (w/v) 
  36.5 mL Double Distilled Water 
  1.25 g  Glucose      0.05% (w/v) 
  5.0 g  α-Lactose      0.2% (w/v) 
 Weigh glycerol directly in glass beaker. 
Heat final solution to dissolve lactose. 
 
 3. 40% Glucose (w/v) 
  4 g  Glucose      40% (w/v) 
  7.4 mL  Double Distilled Water (stirring)   
 Heat final solution to dissolve glucose. 
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 4. 200 mM Glucose 
  0.18 g  Glucose      200 mM 
  5 mL  Double Distilled Water 
 Filter sterilize with 0.22 µm filter.  
 
5. 25 mg/mL Kanamycin 
  250 mg Kanamycin      25 mg/mL 
  10 mL  Double Distilled Water 
 
6. SOC Media (50 mL) 
  45 mL  Double Distilled Water 
  0.25 g  Yeast Extract      0.5% (w/v) 
   1.0 g  Tryptone      2% (w/v) 
  25 mg  Sodium Chloride   NaCl  8.6 mM 
  9.3 mg  Potassium Chloride   KCl  2.5 mM 
  102 mg Magnesium Chloride   MgCl2  10 mM 
 Autoclave on 30 min Liquid Setting. 
 Glucose should be added post-autoclave. 
  5 mL  200 mM Glucose     20 mM 
 
7. MDAG-Agar (500 mL) 
  465 mL Double Distilled Water 
  5.0 g  Agar 
  120 mg Magnesium Sulfate   MgSO4 2 mM 
  355 mg Sodium Sulfate   Na2SO4 5 mM 
  6.25 mL Glucose      0.5% (w/v) 
  25 mL  20X NPS Stock Solution    1X 
 Autoclave on 30 min Liquid Setting. 
 Allow media to cool while stirring. 
Kanamycin should be added when warmer than RT (slightly warm to the touch). 
  200 µL 25 mg/mL Kanamycin    100 µg/mL 
 Pour plates immediately after Kanamycin addition. 
 
8. MDAG (50 mL) 
  46.5 mL Double Distilled Water 
  12.0 mg Magnesium Sulfate   MgSO4 2 mM 
  35.5 mg Sodium Sulfate   Na2SO4 5 mM 
  625 µL Glucose      0.5% (w/v) 
  2.5 mL  20X NPS Stock Solution    1X 
 Autoclave on 30 min Liquid Setting. 
 Kanamycin should be added post-autoclave step; immediately pre-use. 
  200 µL 25 mg/mL Kanamycin    100 µg/mL  
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9. ZYM-5052 (1.6 L) 
  1.47 L  Double Distilled Water 
  16 g  Tryptone      1% (w/v) 
  8 g  Yeast Extract      0.5% (w/v) 
  0.385 g Magnesium Sulfate  MgSO4  2 mM 
  1.136 g Sodium Sulfate  Na2SO4  5 mM 
  32 mL  50X 5052 Stock Solution    1X 
  80 mL  20X NPS Stock Solution    1X 
 Split into 4 x 400 mL in 2 L flasks. 
Autoclave on 30 min Liquid Setting. 
 Kanamycin should be added to each 400 mL flask post-autoclave; immediately pre-use. 
1.6 mL  25 mg/mL Kanamycin    100 µg/mL  
 
B.1.3. Materials 
 1.  SOC, MDAG, ZYM-5052 Media (Above) 
2. Plate incubator at 37°C 
3. Shaking incubator (at 37°C, 250 RPM) 
4. Plastic inoculating spreaders 
5. Blue plastic inoculating loops 
6. Hallway Centrifuge equipped with GSA Rotor 
 
B.1.4. Methods 
 1. Transformation of competent cells 
  a. Remove BL21(DE3) competent cells from -80°C freezer; thaw on ice ~10 min. 
  b. Pre-warm MDAG-Agar (+KAN) plates in 37°C incubator. 
  c. Add 1 µL of appropriate DNA to individual pre-chilled 1.5 µL microfuge tubes. 
1- It is advised to also do one Negative Control with 1 µL of Double 
Distilled Water. 
  d. Add 50 µL of thawed competent cells to each tube and mix well. 
  e. Incubate on ice for 30 min. 
  f. Heat shock the cells by placing them in 42°C water bath for 30 sec. 
  g. Return cells to ice for 5 min. 
  h. Add 950 µL SOC media to each tube. 
  i. Incubate cells on shaking incubator at 37°C (250 RPM) for 1 hr. 
  j. Plate cells on MDAG-Agar (+KAN) plates with plastic inoculating spreaders. 
   1- Add 25 µL of cells to 175 µL of SOC pool already on the plate. 
  k. Incubate plates at 37°C overnight. 
  
2. 1 mL Liquid MDAG (+KAN) Overnight Cultures 
  a. Inoculate 1 mL MDAG (+KAN) with a single colony from each plate. 
   1- Set up at least 4 cultures plus 1 control (media only) for 5 total. 
  b. Incubate at 37°C (250 RPM) overnight. 
172 
 
  
3. 400 mL Liquid ZYM-5052(+KAN) Overnight Cultures 
  a. Inoculate 400 mL ZYM-5052 (+KAN) with 400 µL of 1 mL Overnight Culture. 
   1- Use each 1 mL culture for each separate 400 mL culture. 
  b. Incubate at 37°C (250 RPM) overnight (for at least 12 hours). 
  c. Take Absorbance readings at 600 nm after overnight incubation. 
   1- Blank with remaining liquid MDAG (+KAN) from 1 mL Cultures. 
   2- Make sure that readings are approximately 2.000 and above. 
  d. Split each 400 mL Overnight Culture into 2x 250 mL Plastic Bottles. 
  e. Spin in GSA Rotor at 5K RPM for 20 min. 
  f. Freeze in Liquid Nitrogen and place in -80°C Freezer until needed. 
 
B.2. Protein Purification 
B.2.1. Summary 
 As mentioned in Section B.1.1., after attempting both denaturing and native purification 
protocols that are traditionally used in the Alder laboratory, I moved on to an Inclusion Body-
based purification as it seemed that no matter how the bacterial cultures were grown and 
induced, any Complex II subunit protein that was produced aggregated into inclusion bodies.  In 
this protocol, traditional resuspension and probe sonication methods are used to separate 
inclusion bodies from remaining cellular debris.  When the pellets are first collected post-
centrifugation they are washed multiple times and finally resuspended in a buffer containing 4 M 
Urea, which solubilizes the aggregated inclusion body protein pellets.  Once any unsolubilized 
contaminants are removed, the resulting solute is able to be purified and ~ 20 µM of Sdh3 
protein is obtained post- dialysis.  Note that Buffers 2-5 below should be made day-of (while 
pellets are thawing) and urea should be added to buffers day-of as well. 
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B.2.2. Buffers and Solutions 
 1. Cell Disruption Buffer 
  295 mL Double Distilled Water 
  0.414 g Sodium Phosphate Monobasic NaH2PO4 10 mM 
  60.4 mg Potassium Chloride   KCl  2.7 mM 
  2.402 g Sodium Chloride   NaCl  137 mM 
 Remove 70 mL for Inclusion Body Buffers (below) before pH.  
pH to 7.4 with 3N Sodium Hydroxide. 
 
 2. 1 M Magnesium Chloride 
  0.102 g Magnesium Chloride   MgCl2  1 M 
  500 µL Double Distilled Water 
 
 3. 100 mM Phenylmethanesulfonyl fluoride 
  17.4 mg Phenylmethanesulfonyl fluoride PMSF  100 mM 
  1 mL  Ethanol    EtOH 
 Make 2X 100 mM stocks of PMSF. 
  
4. 20 mg/mL DNase 
  5 mg  DNase       20 mg/mL 
  250 µL Double Distilled Water 
 Keep on ice until added to Cell Disruption Buffer. 
  
5. 10 mg/mL Lysozyme 
  20 mg  Lysozyme      10 mg/mL 
  2 mL  Double Distilled Water 
 Make 2X 10 mg/mL stocks of Lysozyme. 
  
6. Inclusion Body Wash Buffer 
  45 mL  Cell Disruption Buffer 
  18.6 mg Ethylenediamine Tetraacetic Acid EDTA  1 mM  
 pH to 8.0 with 3N Sodium Hydroxide before adding detergent. 
  5 mL  10% (v/v) Triton X-100    1% (v/v) 
  
7. Inclusion Body Solubilization Buffer 
  25 mL  Cell Disruption Buffer 
  68.1 mg Imidazole      20 mM 
  24.02 g Urea       8 M 
  77.1 mg Dithiothreitol    DTT  10 mM 
 Check pH and make sure ~8.0. 
 If yes, do not pH with 3 N Sodium Hydroxide as the solution pH is unstable. 
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8. Column Buffer: Wash 1 
  100 mL Double Distilled Water 
  0.414 g Sodium Phosphate Monobasic NaH2PO4 20 mM 
  4.383 g Sodium Chloride   NaCl  500 mM 
  0.204 g Imidazole      20 mM 
  36.04 g Urea       4 M 
Remove 27 mL for Column Buffer: Elution (below) before pH. 
pH to 7.4 with 3 N Sodium Hydroxide before adding detergent. 
  12 mL  10% (v/v) Triton X-100    1% (v/v) 
 
 9. Column Buffer: Elution 
  27 mL  Column Buffer: Wash 1 
  1.02 g  Imidazole      500 mM 
 pH to 7.4 with Concentrated Hydrochloric Acid before adding detergent. 
  3 mL  10% (v/v) Triton X-100    1% (v/v) 
 
 10. Column Buffer: Wash 2 
  13.5 mL Column Buffer: Wash 1 
  1.5 mL  Column Buffer: Elution 
  
11. Column Buffer: Wash 3 
  12 mL  Column Buffer: Wash 1 
  3 mL  Column Buffer: Elution 
  
12. Column Buffer: Wash 4 
  7.5 mL  Column Buffer: Wash 1 
  7.5 mL  Column Buffer: Elution 
 
B.2.3. Materials 
 1. All Buffers and Solutions (Above) 
 2. Two ice buckets filled with ice (at least one Tall) 
 3. Probe Sonicator 
 4. Hallway Centrifuge equipped with SA-600 rotor 
 5. Heating Stir Plate 
 6. Large Blue Metal Rack 
 7. Albert Lab Ultracentrifuge equipped with 50.2 Ti Rotor 
  a. Large ultracentrifuge tubes and Red Titanium Caps (with tightening device) 
 8. Pliers (to help tighten and remove ultracentrifuge caps) 
 9. Alder Lab Concentrating Centrifuge 
 10. BioRad Large PolyPrep Column and Column Rack 
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B.2.4. Methods 
 1. Preparation of Inclusion Bodies 
a. Thaw cell pellets on ice for 15 min. 
   1- Usually complete this in 2 sets of 4 bottles each. 
  b. Weigh cell pellets (also weigh empty bottle for comparison). 
   1- Determine weights of cell pellets; average for easier calculations. 
  c. For each 1 g of cell pellets add the following: 
   1- 5 mL of Cell Disruption Buffer 
   2- 5 µL of 1 M Magnesium Chloride 
   3- 50 µL of 100 mM PMSF 
   4- 5 µL of 20 mg/mL DNase 
   5- 80 µL of 10 mg/mL Lysozyme 
  d. Resuspend the pellets by swirling the bottles. 
  e. Cell Disruption by Sonication. 
   1- Prepare an Ice Bath in a 600 mL Beaker. 
   2- Parameters: 50% Amp., 30 sec On, 30 sec Off, 5 min Process Time. 
   3- Add suspensions to Glass Tubes. 
4- Note that suspensions will NOT become clear. 
  f. While first set of 4 bottles Sonicates; Thaw and Resuspend remaining bottles. 
  g. Place Sonicated Suspensions in Plastic Tubes. 
   1- Should have 4 or 6 tubes depending on total volume. 
  h. Centrifuge in Hallway Centrifuge: SA-600 rotor (4°C, 24,000 Xg) for 12 min. 
  i. Resuspend the pellets by Sonicating in 10 mL Inclusion Body Wash Buffer. 
1- Resuspend 2 tubes in 10 mL each; Sonicate; Add resuspended solution   
to next tube; Sonicate; Repeat as necessary until only 2 tubes remaining. 
   2- Use the same parameters above except shorten Process Time. 
   3- Sonicate only until pellet is in solution. 
  j. Centrifuge in SA-600 rotor  (4°C, 24,000 Xg) for 15 min. 
  k. Repeat steps i and j once more (only 2 tubes at this point). 
  l. Weigh pellets (also weigh empty tube for comparison). 
   1- Determine weight of pellets; average for easier calculations. 
  
2. Inclusion Body Solubilization 
  a. Add ~15 mL Inclusion Body Solubilization Buffer to each tube. 
   1- Should have a concentration of ~50-80 mg/mL. 
  b. Place small stir bar in each tube and place tubes in Blue Metal Rack. 
  c. Place rack on heating stir plate and set to 75°C and ~150 RPM. 
  d. Incubate for ~2-3 hrs. 
1- If after ~1.5 hrs it appears that solid is remaining attached to plastic 
tube, gently scrape off using a spatula and allow to stir. 
  e. Centrifuge in Albert Lab Ultracentrifuge: 50.2Ti rotor 
   1- Parameters: 4°C, 45,000 Xg, 15 min. 
   2- Add all 30 mL to one ultracentrifuge tube. 
   3- Fill to right below where Cap inserts with a few mL TX-100. 
   4- Note that need to use Red Titanium Caps (Albert Lab). 
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 3. Protein Purification 
  a. Prepare Ni-NTA Slurry 
   1- Remove 5 mL NEW Ni-NTA (7 mL Recharged) into Falcon Tube. 
   2- Centrifuge at 2000 RPM in Alder Lab Concentrating Centrifuge. 
   3- Aspirate Ethanol. 
  b. Add 30 mL of Protein sample to Ni-NTA; Parafilm; Rotate at 4°C for 35 min. 
  c. Add Sample to BioRad Large PolyPrep column. 
   1- Collect Flow Through. 
 2- Consecutively add 15 mL each of Column Buffer: Washes 1-4 and   
  Column Buffer: Elution. 
   3- Collect ALL fractions. 
  
 4. Analysis of Yield (Clean Protein usually emerges from column in WASH 4). 
  a. Use 2X 15% SDS-PAGE gels: 1X Coomassie Stain and 1X Western Blot. 
  b. Concentrate Wash 4 and Dialyze once with excess Column Buffer: Wash 1. 
  c. Confirm protein presence and concentration with Pierce A660 Kit. 
 
B.3. Fluorescent Labeling 
B.3.1. Summary 
 The purpose of the above cell growth and purification of Complex II membrane subunits 
is to prepare protein for fluorescence labeling and liposome incorporation. Below are the basic 
steps for labeling Sdh3 with the BODIPY-FL fluorophore.  The BODIPY probes are ideal for 
FRET-based analyses due to their high absorbance and quantum yield, absorbance and emission 
spectral overlap (homoFRET), and their relatively small size (so as not to disrupt protein folding 
and structure). 
 
B.3.2. Buffers and Solutions 
 1. BODIPY-FL Iodoacetamide Stock (Molecular Probes D-6003; 417.003 g/mol) 
  0.1 mg  BODIPY-FL      20 mM 
  11.76 µL Dimethylsulfoxide   DMSO 
 Confirm concentration spectroscopically (ε = 79,000 M-1cm-1): 
  Dilute 2 µL BODIPY-FL in 2 mL Methanol; Take Absorbance at 504 nm. 
  Calculate concentration and dilute to 200x concentration of Sdh3 protein. 
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2. 1 M DTT Stock (in -20°C Freezer) 
 
B.3.3. Materials 
 1. Purified Protein 
 2. BODIPY-FL prepared stock 
3. Rotisserie 
 4. Parafilm and Foil 
 5. BioBeads 
 
B.3.4. Methods: Labeling Reaction 
 1. Add 250 µL (per proteoliposome formation reaction) of protein to microfuge tube. 
  a. Aim for a protein concentration of 10 – 25 µM. 
  b. Add 5 µL of BODIPY-FL stock per 250 µL of protein.  This should result in a  
    4X concentration of BODIPY-FL over protein. 
  
2. Parafilm tubes and cover in foil to protect from light. 
  
3. Incubate on rotisserie at RT for 2.5 hrs. 
  
4. Quench reactions with 1 M DTT to result in a final DTT concentration of 10 mM. 
  
5. Purify the FREE dye away from labeled protein with BioBead Pre-incubation 
  a. Prehydrate 120 mg BioBeads in 800 µL Column Buffer: Wash 1. 
  b. Withdraw buffer and add labeling reaction. 
   1- Parafilm tubes and cover in foil. 
  c. Incubate on rotisserie at RT for 1 hr. 
  d. Remove from BioBeads and place in fresh microfuge tube.   
1- Note that if analyzing labeling efficiency, remove aliquot at this time. 
 
B.4. Proteoliposome Formation 
B.4.1. Summary 
 The proteoliposome formation protocol below is adapted from Nathan Alder’s previous 
protocols for forming proteoliposomes with Tim23 labeled with the NBD fluorescent probe. 
Note that one of the main changes involves initially placing the sample into the most dense 
sucrose gradient layer at the bottom so that any unincorporated, aggregated protein and dye will 
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remain pelleted and the proteoliposomes will float to the top of the gradient (as compared to 
previous protocols in which the sample is initially placed toward the top of the gradient). 
 
B.4.2. Buffers and Solutions 
 1. Hydration Buffer 
  241 mL Double Distilled Water 
  2.5 mL  1 M Tris-HCl, pH 7.4     10 mM 
  6.3 mL  4 M Sodium Chloride   NaCl  100 mM 
  500 µL 1 M Magnesium Chloride   MgCl2  2 mM 
 
2. Biomimetic Liposome Formation (LUVs) 
 170 µL 18:1; 16:0-phosphatidylcholine POPC  40 mol% 
 162 µL 18:1; 16:0-phosphatidylethanolamine POPE  40 mol% 
 168 µL Tetraoleoylcardiolipin  CL  20 mol% 
Dry lipids under nitrogen stream for ~15 min. 
Dry lipids under a vacuum in the RT desiccator (D-AL setting) overnight. 
Hydrate lipids in 500 µL Hydration Buffer and let sit at RT with intermittent vortexing 
until all lipids are in solution. 
Extrude 17X through 0.1 µm pore membrane (two filters on each side). 
Store at RT until use. 
 
3. 5% (w/v) Dodecyl-β-D-maltoside  
 10 mg  Dodecyl-β-D-maltoside  DDM  5% (w/v) 
 200 µL Double Distilled Water 
Note that this stock is 98 mM, which is much greater than the CMC of 0.16 mM. 
 
4. 10% (w/w) Sucrose Solution 
 1.0 g  Sucrose      10% (w/w) 
 9.0 g  Hydration Buffer 
Prepare scale with weigh boat and small beaker holding open 15 mL Falcon tube. 
Weigh out 1.0 g sucrose into weigh boat. 
Pipette Hydration Buffer into Falcon tube until total weight is 10.0 g. 
 
5. 20% (w/w) Sucrose Solution 
 2.0 g  Sucrose      20% (w/w) 
 8.0 g  Hydration Buffer 
Prepare scale with weigh boat and small beaker holding open 15 mL Falcon tube. 
Weigh out 2.0 g sucrose into weigh boat. 
Pipette Hydration Buffer into Falcon tube until total weight is 10.0 g. 
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6. 50% (w/w) Sucrose Solution 
 5.0 g  Sucrose      50% (w/w) 
 5.0 g  Hydration Buffer 
Prepare scale with weigh boat and small beaker holding open 15 mL Falcon tube. 
Weigh out 5.0 g sucrose into weigh boat. 
Pipette Hydration Buffer into Falcon tube until total weight is 10.0 g. 
Intermittently vortex and run sample under hot tap water to dissolve sucrose. 
 
B.4.3. Materials 
 1. Liposomes 
 2. Labeled Protein 
 3. Buffers and Stock Solutions (Above) 
 4. Rotisserie 
 5. Foil and Parafilm 
 6. Alder Lab Ultracentrifuge equipped with Swinging Bucket Rotor (TLS-55) 
  a. Buckets and appropriate centrifuge tubes 
 
B.4.4. Methods 
 1. Incubate LUVs and BODIPY-Sdh3 separately with DDM. 
  a. Add 5 µL of 5% (w/v) DDM stock to 70 µL of liposomes. 
   1- Note that this is for EACH proteoliposome reaction that is planned. 
  b. Add 16.4 µL of 5% (w/v) DDM stock to 250 µL BODIPY-Sdh3 samples. 
  c. Incubate all on rotisserie at RT for 20 min. 
  
2. Combine solubilized protein and liposome samples for a total volume of ~325 µL. 
  a. Incubate on rotisserie at RT for 1 hr. 
  
3. Proteoliposome formation with BioBeads. 
  a. Prehydrate 120 mg BioBeads in 800 µL Hydration Buffer 
1- Make sure to prepare 2x each of the BioBead samples above for EACH    
proteoliposomes formation reaction. 
   2- Incubate at RT for at least 2 hrs. 
   3- Withdraw excess Hydration Buffer from one tube for each sample. 
  b. Add samples to BioBeads. 
   1- Parafilm tubes and wrap in foil. 
   2- Incubate on rotisserie at RT for 2.5 hrs. 
   3- Withdraw excess Hydration Buffer from remaining BioBead tubes. 
c. Remove sample from rotisserie and add to second set of BioBeads. 
 1- Parafilm tubes and wrap in foil. 
2- Incubate on rotisserie at RT overnight. 
3- Remove sample from BioBeads and place in fresh microfuge tube. 
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4. Sucrose Gradient Density Centrifugation Purification. 
  a. Add equal volume (as sample) of 50% sucrose to each proteoliposome sample. 
   1- Layer into bottom of Ultracentrifuge tube. 
  b. Layer 650 µL of 20% sucrose on top, followed by 650 µL of 10% sucrose. 
  c. Centrifuge in Swinging Bucket Rotor (TLS-55) in Alder Lab Ultracentrifuge. 
   1- Parameters: 55,000 RPM, 1 hr, 15°C, Accel/Decel = 2. 
  d. Split into 9 x 200 µL Fractions. 
   1- Pool fractions 2-4 and Dilute to 750 µL total with Hydration Buffer. 
  
5. Samples are ready for Fluorescence-based analysis. 
  a. Analyze 250 µL samples in quartz microcuvettes. 
  b. Programs: BFL Em Scan; BOD Anisotropy 
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Appendix C: Investigation into the Influence of Amount and Type of Cardiolipin on 
Complex II Activity: Additional Tests 
 
Other colleagues who have contributed to the studies presented in this appendix are Matthew 
Greenwood and Nathan N. Alder.  Both are from the University of Connecticut (Storrs, CT 
06269, USA). 
 
Figures C.8 and C.9 derived from: Hwang M.-S., Schwall C.T., Pazarentzos E., Datler C., Alder 
N.N., and Grimm S., Mitochondrial Ca2+ influx targets cardiolipin to disintegrate respiratory 
chain complex II for cell death induction, Cell Death and Differentiation (2014). 
 
C.1. Abstract 
 Chapter 3 introduced how cardiolipin (CL) has a great effect on the activity, as well as 
stability, of Complex II within the nanodisc (ND) model membrane system.  The studies 
presented here further explored these findings by investigating whether the acyl chain 
composition or the anionic headgroup of CL was stabilizing the holoenzyme.  First, by titrating 
the amount of tetraoleoyl-CL (TOCL; four 18:1 Δ9 acyl chains) present in the NDs we found that 
when TOCL neared levels present in the native IM, maximal activity and stability of Complex II 
was reached.  Second, the headgroup and alkyl chains of CL were also investigated and did not 
seem to have a large effect on either the stability or activity of Complex II within NDs, under 
unstressed conditions.  Finally, the effect of each of the CL types in the presence of the divalent 
cations magnesium and calcium was examined and it was found that the presence of these 
cations can greatly inhibit Complex II activity, most likely through interactions with CL, as these 
effects were dependent on the type of CL present. 
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C.2. Methods 
C.2.1. Nanodisc (ND) Compositions 
 All materials and methods used are identical to those described in Chapters 2 and 3.  
However, the lipid compositions used to assemble the NDs differ and for this reason, they are 
outlined here.  For experiments varying the amount of TOCL, lipid stocks were mixed to form: 0 
mol% TOCL (50:50 mol% POPC:POPE); 5 mol% TOCL (47.5:47.5:5 mol% 
POPC:POPE:TOCL); 10 mol% TOCL (45:45:10 mol% POPC:POPE:TOCL); 20 mol% 
(40:40:20 mol% POPC:POPE:TOCL); 30 mol% TOCL (40:30:30 mol% POPC:POPE:TOCL).  
For experiments varying the type of CL or studying the effects of divalent cations, the overall 
lipid ratio was 40:40:20 mol% of POPC:POPE:Anionic Lipid, respectively.  The types of CL 
that were substituted include: TOCL (18:1 Δ9 acyl chains), TMCL (14:0 acyl chains), dTOCL (a 
deoxy version of TOCL lacking the hydroxyl group in the central glycerol of the headgroup), and 
POPG (the negatively charged precursor of CL).  As stated, the lipid preparation and ND 
assembly were otherwise identical to that described in Chapters 2 and 3. 
 
C.2.2. Cation Incubations and Titrations 
 For high concentrations of cations, NDs were formed and metal-affinity purification 
Elutions 1 and 2 were combined and dialyzed into MSP buffer containing 100 mM of the 
appropriate cation.  For the low concentration titrations of cations, Elutions 1 and 2 were 
combined and concentrated.  Samples were split and incubated with the appropriate 
concentration of cation (0 mM to 20 mM) prior to activity assay measurements.  Both succinate 
dehydrogenase (SDH) and succinate: ubiquinone oxidoreductase (SQR) activity assays were 
performed as described in Chapter 3.   
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C.2.3. Complex II Affinity Assay 
NDs were formed and metal-affinity purification Elutions 1 and 2 were combined and 
dialyzed into MSP buffer lacking NaCl, split into separate samples and subject to low calcium 
concentration titrations, between 0 mM and 20 mM.  Samples were rotated for 15 min at RT and 
then added to Ni-NTA agarose and further rotated for 40 min at RT.  After nanodiscs were 
subjected to a second metal-affinity chromatography purification, samples were taken from each 
fraction that emerged from the column and analyzed via 12% SDS-PAGE for the presence of 
FAD as in Chapter 2. 
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C.3. Results 
C.3.1. Amount of TOCL 
 
 
 
Figure C.1. The affinity of Complex II catalytic and membrane dimers is dependent on 
amount of TOCL present in NDs.  Membrane proteins from dodecyl-β-D-maltoside (DDM)-
solubilized mitochondria were reconstituted into NDs with the indicated mol% TOCL and 
subjected to affinity chromatography to isolate the NDs.  Subunits co-eluting with MSP1E3D1 
(fractions E1 and E2) were considered to be stably associated with the NDs; those eluting at the 
earlier fractions were not stably associated.  Monitoring the fluorescence of FAD was used as the 
marker for the soluble catalytic dimer.  Abbreviations are S: supernatant and P: pellet from 
mitochondrial solubilization; FT: column flow through; W1A-W3B: column wash steps; E1-E3: 
column elution steps.  Note relative imidazole concentrations depicted above lane labels. 
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Figure C.2. The amount of TOCL present in NDs affects Complex II catalytic dimer 
activity.  Relative succinate dehydrogenase (SDH) activity of column fractions for ND samples 
with the indicated mol% TOCL: 0 mol% (white), 5 mol% (dotted), 10 mol% (gray), 20 mol% 
(diagonal lines), and 30 mol% (black).  E* represents fractions E1 and E2, which were pooled, 
and statistical differences are represented in relation to 20 mol% TOCL NDs (* = p < 0.001). 
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Figure C.3. The amount of TOCL present in NDs affects Complex II holoenzyme activity. 
(A) Relative succinate: quinone oxidoreductase (SQR) activity of column fractions for ND 
samples with the indicated mol% TOCL, determined from the initial reaction velocity (30 s 
following succinate addition).  ND samples are labeled as in Figure C.2 and E* represents 
fractions E1 and E2, which were pooled.  Statistical differences are represented in relation to 20 
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mol% TOCL NDs (* = p < 0.05).  (B) Signal-averaged time course traces of SQR activity for 
Complex II reconstituted in NDs with varying mol% TOCL, including 0 mol% (light gray line), 
5 mol% (broken line), 10 mol% (dark gray line), 20 mol% (dashed line), and 30 mol% (black 
line).  Statistical differences are represented in relation to 20 mol% TOCL NDs (* = p < 0.01). 
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C.3.2. Type of CL 
 
 
 
Figure C.4.  The type of CL present in NDs does not affect Complex II catalytic dimer and 
membrane dimer affinities.  Elution profiles of NDs assembled with indicated CL 
compositions.  Preparation of samples and column fraction designations are identical to those in 
Figure C.1. 
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Figure C.5. The type of CL present in NDs does not affect Complex II catalytic or 
holoenzyme activities.  (A) Relative SDH activity of column fractions for ND samples with the 
indicated CL type, including TOCL (light gray), dTOCL (dotted), TMCL (black) and POPG 
(diagonal lines).  (B) Relative SQR activity of column fractions for ND samples with the 
indicated CL type, determined from the initial reaction velocity (30 s following succinate 
addition) and labeled as in (A).  For both (A) and (B), E* represents fractions E1 and E2, which 
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were pooled, and statistical differences are represented in relation to POPG-containing NDs (* = 
p < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
 
C.3.3. Addition of Divalent Cations 
 
 
 
Figure C.6. Divalent cations display little ability to affect Complex II catalytic dimer 
activity, even at high concentrations.  Relative SDH activity of column fractions for ND 
samples with the indicated CL type and treated with the indicated cations, including sodium (Na, 
light gray), magnesium (Mg, dotted), and calcium (Ca, black).  Each cation is present at 
extremely high (100 mM) concentration in order to initially determine if there was a monitorable 
effect.  Statistical differences were determined in relation to sodium-treated NDs within each CL 
type, but none were found to be significant. 
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Figure C.7. High concentrations of divalent cations are able to decrease the holoenzyme 
activity of Complex II. (A) Relative SQR activity of column fractions for ND samples with the 
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indicated CL type and cation treatments, determined from the initial reaction velocity (30 s 
following succinate addition).  Note that E* represents fractions E1 and E2, which were pooled.  
(B) Signal-averaged time course traces of SQR activity for Complex II reconstituted in NDs with 
varying CL types.  For both (A) and (B), cation concentrations are identical to and treatments are 
labeled as in Figure C.6 (gray line, Na+; dashed black line, Mg2+; solid black line, Ca2+) and 
statistical differences are represented in relation to sodium-treated NDs within each CL type (* = 
p < 0.05, ** = p < 0.01, and *** = p < 0.001). 
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Figure C.8.  The activities of Complex II are selectively Ca2+-dependent and low 
concentrations of cation can decrease holoenzyme activity.  (A) Succinate dehydrogenase 
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(SDH, PMS-mediated) activity monitoring the presence of the catalytic dimer is overall not Ca2+-
dependent.  (B) Succinate: quinone oxidoreductase (SQR, DB-mediated) activity monitoring the 
presence of the holoenzyme is Ca2+-dependent reflecting the decreased affinity between the 
catalytic and membrane dimers.  Error bars are representative of s.e.m. for at least four separate 
experiments and statistical differences are represented in relation to addition of 0 mM Ca2+ (* = p 
≤ 0.05; ** = p ≤ 0.01). 
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Figure C.9.  The stability of Complex II is Ca2+-dependent (even at low concentrations) and 
mediated by CL.  Supernatant resulting from DDM-solubilized mitochondria were reconstituted 
into nanodiscs with (IM-mimetic) and without (POPC/POPE control) cardiolipin.  Nanodiscs 
were subjected to Ni-NTA affinity chromatography and then treated with the indicated 
concentration of Ca2+.  Subunits co-eluting the MSP1E3D1 (E1 and E2) were considered to be 
stably assembled within the nanodiscs; subunits emerging from the column at earlier fractions, 
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such as in the middle wash fractions, were not.  (A) SDS-PAGE analysis of the column fractions.  
The fluorescent FAD signal was used as a marker for the soluble catalytic dimer as FAD is 
covalently bound to Sdh1p.  Abbreviations indicate the following column fractions: FT: flow 
through; W1A-W3B: wash steps; E1-E3 elution steps.   (B) Quantification of FAD band 
intensity comparing the predominant middle Wash fraction (W2B in most cases or W3A under 
some conditions) and combined selected Wash with E1 and E2 (which represents the total of the 
catalytic dimer in the predominant wash and all that remains connected to the membrane dimer 
within nanodiscs).  A larger ratio indicates a less stable complex (i.e. more catalytic dimer is not 
stably associated with nanodiscs and washes off the column prior to E1 and E2).  Error bars are 
representative of s.e.m. for at least three separate experiments and statistical differences are 
represented in relation to addition of 0 mM Ca2+ (* = p ≤ 0.05; ** = p ≤ 0.01). 
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